Document:

exv10w36

 

Exhibit 10.36

***Text Omitted and Filed Separately

Confidential Treatment Requested

Under 17 C.F.R. §§ 200.80(b)(4) and 240.24b-2

Research Cross-License Agreement 

     This Research Cross-License Agreement (“Agreement”) is made and entered into
effective as of September 3, 2003 (the “Effective Date”), by and between Micromet AG,
having its principal offices at Staffelseestrasse 2, 81477, Munich, Germany (“Micromet”), Enzon
Pharmaceuticals, Inc., having its principal offices at 20 Kingsbridge Road, Piscataway, New
Jersey (“Enzon”), and Cambridge Antibody Technology Limited, having its principal offices
at The Milstein Building, Granta Park, Cambridgeshire CB1 6GH, England (“CAT”). Micromet, Enzon
and CAT each may be referred to herein individually as a “Party,” or collectively as the “Parties.”

     Whereas, pursuant to that certain Non-Exclusive License Agreement by and between
Creative BioMolecules, Inc. and CAT dated as of September 5, 1996 (“Original Creative BioMolecules
License Agreement”), Creative BioMolecules granted certain non-exclusive license rights to CAT
under certain patents relating to Single Chain Antibodies (as defined below);

     Whereas, pursuant to that certain Non-Exclusive License Agreement by and between
Enzon and CAT dated as of September 5, 1996 (“Original Enzon License Agreement”), Enzon granted
certain non-exclusive license rights to CAT under certain patents relating to Single Chain
Antibodies;

     Whereas, Curis, Inc. was the assignee of Creative BioMolecules, Inc., with respect to
the Original Creative Bio Molecules License Agreement, and Micromet is the assignee of Curis, Inc.
with respect to same;

     Whereas, CAT is the owner of (or licensee of) certain patents and know-how in the
field of Antibody Phage Display and is authorised to grant the licenses and other rights to
Micromet and Enzon pursuant to the terms of this Agreement;

     Whereas, Micromet and Enzon have entered into a certain Collaboration Agreement, a
Cross-License Agreement and Exclusive IP Marketing Agreement (the “Micromet/Enzon IP Marketing
Agreement”) each dated as of April 9, 2002, pursuant to which Micromet and Enzon granted to each
other certain rights to intellectual property relating to Single Chain Antibody technology and
pursuant to which Micromet is authorised to grant the licenses and other rights to CAT pursuant to
the terms of this Agreement; and

     Whereas, each of CAT, Micromet and Enzon desires to terminate the Original Creative
BioMolecules Agreement and the Original Enzon License Agreement and to grant each other licenses
with respect to the intellectual property described herein to use such intellectual property for
the purposes of developing and commercializing products under the terms and conditions set forth in
this Agreement.

 

 

     Now, Therefore, in consideration of the premises and the mutual covenants and
agreements herein contained, the Parties agree as follows:

1. Definitions

     When used in this Agreement, capitalized terms will have the meanings as defined below and
throughout the Agreement.

     1.1 “Affiliate” means a legal entity that, directly or indirectly, through one or more
intermediaries, controls, is controlled by, or is under common control with a Party. For purposes
of this definition only, “control” and, with correlative meanings, the terms “controlled by” and
“under common control with” means (a) the possession, directly or indirectly, of the power to
direct the management or policies of a legal entity, whether through the ownership of voting
securities or by contract relating to voting rights or corporate governance, or (b) the ownership,
directly or indirectly, of more than 50% of the voting securities or other ownership interest of a
legal entity; provided that, if local law restricts foreign ownership, control will be established
by direct or indirect ownership of the maximum ownership percentage that may, under such local law,
be owned by foreign interests.

     1.2 “Antibody” means a molecule or gene encoding such a molecule comprising or containing more
than one immunoglobulin variable domain or parts of such domain or any existing or future
fragments, variants, modifications or derivatives thereof.

     1.3 “Antibody Product” means any composition or formulation containing or comprising one or
more Antibodies in any format for the prognosis, diagnosis, prophylaxis or treatment of human
diseases or conditions or for use as a research reagent.

     1.4 “Antigen” means any structure, including an entire protein, post-translational
modifications, lipids, or glyco-lipids, for which Antibody variable domains have binding affinity.

     1.5 “BiTE Product” means any composition or formulation containing or comprising a bi-specific
Single Chain Antibody, wherein one arm of the Single Chain Antibody binds to T-cells.

     1.6 “Business Day” means any day (other than a Saturday or Sunday) upon which major commercial
banks are open for business in the cities of London and Munich.

     1.7 “CAT Background Know-How” means the Know-How Controlled by CAT relating to the CAT
Licensed Patents described in Schedule VI, which the Parties may amend from time to time at
their sole discretion in accordance with Section 2.3.

     1.8 “CAT Collaboration Partner” means any Third Party that enters into a Collaboration
Agreement with CAT.

     1.9 “CAT Excluded Technology” has the meaning assigned to it in Schedule VIII.

     1.10 “CAT Field Limitations” means those field limitations set forth in Schedule III.

2

 

     1.11 “CAT Licensed Patents” means those Patents identified in Schedule II.

     1.12 “CAT Phage Display Improvements” means any Improvement of a Phage Display process or any
other technology, process, or methodology (each as claimed in or covered by any of the CAT Licensed
Patents, Micromet Supplemental Patents, Enzon Supplemental Patents, CAT Background Know-How,
Micromet Supplemental Know-How or Enzon Supplemental Know-How, as the case may be) that satisfies
all of the following criteria: (A) is first conceived or reduced to practice within [***] of the
Effective Date; provided, however, that upon the request of Micromet or Enzon, as
the case may be, at any time during the [***] period following the date that is [***] from the
Effective Date and upon demonstration by Micromet or Enzon, as the case may be, of good commercial,
technical, or legal reasons for extension of the foregoing [***] period, the Parties agree to
negotiate in good faith the potential extension of such period for one (1) additional [***] period,
with the consent by the Parties to such extension not to be withheld absent demonstration of good
commercial, technical, or legal reasons for opposing such extension; and (B) is developed by or on
behalf of CAT or its Affiliates; provided, however, that the foregoing will exclude
any such Improvement to the extent that CAT is not permitted to disclose, license or sublicense
such improvement, modification or adaptation to Micromet or Enzon, as applicable, as a result of an
obligation of CAT to a Third Party.

     1.13 “CAT Research Contractor” means any person or entity engaged by CAT for the purpose of
performing research and development activities on a fee-for-service basis on behalf of CAT in
accordance with the rights granted to CAT under this Agreement, but excluding any CAT Collaboration
Partner.

     1.14 “CAT Research Field” means research and development activities using Phage Display or
Ribosome Display to identify and develop Antibody Products for the prognosis, diagnosis,
prophylaxis or treatment of human diseases or conditions; but in each case excluding any research
and development activities that (A) involve administration of any SCA Product to humans, (B) use or
are directed towards developing CAT Excluded Technology, or (C) are in the CAT Field Limitations.

     1.15 “Collaboration Agreement” means any agreement executed prior to or during the term of
this Agreement between a Party and a Third Party under which: (i) (A) in the case of CAT, CAT
grants such Third Party a license under one or more CAT Licensed Patents (consistent with the
license rights granted hereunder), or (B) in the case of Micromet or Enzon, as applicable, such
Party grants such Third Party a license under one or more Patents in the Consolidated Patent
Portfolio, or any other relevant intellectual property or other rights Controlled by such Party;
and (ii) each party to such agreement performs collaborative research and development obligations
related to such licensed rights. For the avoidance of doubt, a Collaboration Agreement will not
include a naked license of the Patent rights of a Party hereto.

     1.16 “Consolidated Know-How” means the Know-How Controlled by Micromet relating to the
Consolidated Patent Portfolio and described in Schedule VII, which the Parties may amend
from time to time at their sole discretion in accordance with Section 2.3.

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

3

 

     1.17 “Consolidated Patent Portfolio” means those Patents identified in Schedule I, as
updated from time to time by Micromet pursuant to Section 5.7.1(b).

     1.18 “Consolidated Patent Portfolio Improvement” means any Improvement to the Consolidated
Patent Portfolio that satisfies all of the following criteria: (A) is first conceived or reduced to
practice within [***] of the Effective Date; provided, however, that upon the
request of CAT at any time during the [***] period following the date that is [***] from the
Effective Date and upon demonstration by CAT of good commercial, technical, or legal reasons for
extension of the foregoing [***] period, the Parties agree to negotiate in good faith the potential
extension of such period for one (1) additional [***] period, with the consent by the Parties to
such extension not to be withheld absent demonstration of good commercial, technical, or legal
reasons for opposing such extension; and (B) under the Micromet/Enzon IP Marketing Agreement,
becomes part of the “Consolidated Patent Portfolio,” as that term is defined in the Micromet/Enzon
IP Marketing Agreement; provided, however, that the foregoing will exclude any such
Improvement to the extent that Micromet or Enzon is not permitted to disclose, license or
sublicense such Improvement as a result of an obligation of such Party to a third party.

     1.19 “Controlled” or “Controls” means, with respect to any Know-How, Patent, or other
intellectual property right, possession of the right, whether directly or indirectly, and whether
by ownership, license or otherwise, to assign, or grant a license, sublicense or other right to or
under, such Know-How, Patent or right as provided for herein without violating the terms of any
agreement or other arrangements with any Third Party.

     1.20 “Diagnostic SCA Product” means any SCA Product (including a composition, formulation,
device, assay, or other product, excluding Microarrays (as defined in Schedule VIII), which
is: (a) intended for sale as an in vitro or in vivo diagnostic or prognostic for use in or in
relation to humans, or (b) intended for sale separately from but in support of a therapeutic
product for use in or in relation to humans.

     1.21 “Enzon Collaboration Partner” means Micromet or any Third Party that enters into a
Collaboration Agreement with Enzon.

     1.22 “Enzon Research Contractor” means any person or entity engaged by Enzon for the purpose
of performing research and development activities on a fee-for-service basis on behalf of Enzon in
accordance with the rights granted to Enzon under this Agreement, but excluding any Enzon
Collaboration Partner.

     1.23 “Enzon Research Field” means research and development activities directed to identify and
develop Antibody Products for the prognosis, diagnosis, prophylaxis or treatment of human diseases
or conditions and in each case excluding any research and development activities that (A) involve
administration of any Antibody Product to humans, or (B) use or are directed towards developing any
Micromet-Enzon Excluded Technology.

     1.24 “Enzon Supplemental Know-How” means any Know-How for which Enzon has exercised its option
under Section 2.3.1.

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

4

 

     1.25 “Enzon Supplemental Patents” means any Patent for which Enzon has exercised its option
under Section 5.7.1(a).

     1.26 “Excluded Field” has the meaning assigned to it in Schedule IV.

     1.27 “Excluded Target” has the meaning assigned to it in Section 3.2.4 of this Agreement.

     1.28 “Existing Product Use Agreement” means each agreement between CAT and certain Third
Parties in effect as of the date hereof as listed on Schedule XIII.

     1.29 “Exploit” or “Exploitation” means to make, have made, import, export, use, sell, offer
for sale, or otherwise dispose of a product, including all discovery, research, development,
registration, modification, enhancement, improvement, manufacture, storage, formulation,
exportation, transportation, distribution, promotion and marketing activities related thereto.

     1.30 “Gatekeeping Criteria” means the criteria set out in Schedule V, which the
relevant Notified Party will use to evaluate a Nominated Target prior to the execution of any
Product License Agreement, all as described in greater detail in Section 3.2 of this Agreement.

     1.31 “Improvement” means, as to a Patent or Know-How licensed hereunder, any improvement,
modification or adaptation of any technology, process or methodology claimed in or covered by such
Patent or Know-How, which may be developed by or on behalf of a Party, its sublicensees or its
Affiliates during the Term.

     1.32 “Insolvency Event” means, except for the event of a solvent reorganization or
amalgamation, (i) the filing by a Party in court or agency pursuant to any applicable statute or
regulation of any state or country, a petition in bankruptcy or insolvency or for reorganization or
for an arrangement or for the appointment of a receiver or trustee of a Party or of its assets, or
(ii) the filing by a Third Party against a Party of an involuntary petition in bankruptcy or
seeking reorganization, liquidation, dissolution, winding up arrangement, composition or
readjustment of such Party’s debts or any other relief under any bankruptcy, insolvency,
reorganization or other similar act or law of any jurisdiction now or hereafter in effect, or the
issuance of a warrant of attachment, execution or similar process against a Party, and, in each
case, only if the applicable petition, warrant of attachment, execution or similar process is not
dismissed within ninety (90) days after the filing thereof, or (iii) if any Party proposes or is a
Party to any dissolution or liquidation under applicable law, or makes an assignment for the
benefit of creditors.

     1.33 “Know-How” means all non-public inventions, data, information, methods, procedures,
processes and materials, including but not limited to, biological, chemical, biochemical,
toxicological, pharmacological, metabolic, formulation, clinical, analytical and stability
information and data (other than such Know-How which is or becomes the subject of a patent or of a
provisional or filed patent application or which otherwise becomes public).

5

 

     1.34 “Library” means a diverse collection of at least [***] different Antibodies for use in
connection with Phage Display, Ribosome Display, or other Platform Technology.

     1.35 “Maintenance Fee Term” means the period commencing on the Effective Date and ending upon
the earlier of (i) [***] from the Effective Date or (ii) the date this Agreement terminates or
expires pursuant to Section 8.

     1.36 “Major Market Country” means the [***].

     1.37 “Micromet Collaboration Partner” means Enzon or any Third Party that enters into a
Collaboration Agreement with Micromet.

     1.38 “Micromet-Enzon Excluded Technology” has the meaning assigned to it in Schedule
VIII.

     1.39 “Micromet Research Contractor” means any person or entity engaged by Micromet for the
purpose of performing research and development activities on a fee-for-service basis on behalf of
Micromet in accordance with the rights granted to Micromet under this Agreement, but excluding any
Micromet Collaboration Partner.

     1.40 “Micromet Research Field” means research and development activities directed to identify
and develop Antibody Products for the prognosis, diagnosis, prophylaxis or treatment of human
diseases or conditions and in each case excluding (A) any research and development activities that
involve administration of any composition or formulation to humans; (B) any research or development
activities using or directed towards developing any Micromet-Enzon Excluded Technology.

     1.41 “Micromet Supplemental Know-How” means any Know-How for which Micromet has exercised its
option under Section 2.3.1.

     1.42 “Micromet Supplemental Patents” means any Patent for which Micromet has exercised its
option under Section 5.7.1(a).

     1.43 “Micromet/Enzon Collaboration Agreement” means that certain Collaboration Agreement
between Micromet and Enzon dated as of April 9, 2002.

     1.44 “Micromet/Enzon Cross-License Agreement” means that certain Cross-License Agreement
between Micromet and Enzon dated as of April 9, 2002.

     1.45 “[***] Agreement” means that certain license agreement by and between the [***] and CAT
dated as of [***], pursuant to which CAT is the exclusive licensee of certain of the CAT Licensed
Patents and certain other Know-How related thereto.

     1.46 “Nominated Target” means a Target nominated by a Party pursuant to the terms of Section
3.1.

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

6

 

     1.47 “Non-SCA Antibody Product Field” means the prognosis, diagnosis, prophylaxis or treatment
of human diseases or conditions; provided, however, that the foregoing will exclude
the CAT Field Limitations.

     1.48 “Non-SCA Antibody Products” means any Antibody Products excluding any SCA Product, BiTE
Product, or Microarray.

     1.49 “Notified Party” has the meaning assigned to it in Section 3.2.

     1.50 “Original Creative BioMolecules License Agreement” has the meaning assigned to it in the
Recitals.

     1.51 “Original Enzon License Agreement” has the meaning assigned to it in the Recitals.

     1.52 “Patents” means (a) all patents and patent applications in any country or supranational
jurisdiction, and (b) any substitutions, divisions, continuations, continuations-in-part, reissues,
renewals, registrations, confirmations, re-examinations, extensions, supplementary protection
certificates and the like, and any provisional applications, of any such patents or patent
applications.

     1.53 “Phage Display” means the technology, process or methodology whereby Antibodies are
cloned, expressed, produced and screened on the surface of filamentous bacteriophage.

     1.54 “Platform Technology” means Know-How, technologies, processes or methodologies that are
used to clone, express, produce and screen Antibodies by methods other than Phage Display or
Ribosome Display.

     1.55 “Primary Application” means a major application of a product containing an Antibody
binding to a Target, as ascertained at the time of assessment of such Target as a Nominated Target
using objective and reasonable scientific and/or commercial criteria, data and/or information.
Primary Application does not mean any minor or incidental application.

     1.56 “Product License Agreement” means the relevant product license agreement as set out in
Schedules IX and X.

     1.57 “Requesting Party” has the meaning assigned to it in Section 3.2.

     1.58 “Ribosome Display” means the technology, process or methodology whereby Antibodies are
cloned, expressed, produced and screened in vitro involving a step where an Antibody or Antibodies
are tested for binding to Antigen when said Antibody or Antibodies are attached to its coding RNA
and to ribosomes.

     1.59 “SCA Product” means any composition or formulation containing or comprising one or more
Single Chain Antibodies in any format for the prognosis, diagnosis, prophylaxis or treatment of
human diseases or conditions, in each case excluding any BiTE Product and any Microarray.

7

 

     1.60 “Single Chain Antibody” or “SCA” means an Antibody having binding affinity for an Antigen
whereby such Antibody comprises (i) a polypeptide segment having a light chain variable region,
(ii) a polypeptide having a heavy chain variable region, and (iii) at least one peptide linker
linking those polypeptides into a single chain polypeptide.

     1.61 “Target” means (i) DNA, all post-transcriptional material encoded by such DNA, including
all naturally occurring or disease-associated truncations, mutations, variants, fragments and
post-transcriptional modifications thereof (including but not limited to splice variants) and all
material encoded by such post-transcriptional material including but not limited to proteins; (ii)
the DNA encoding a polypeptide or protein, as identified by a sequence of amino acids, and all
post-translational variants thereof including but not limited to glycosylation and phosphorylation
modifications, and any complex form thereof; and (iii) any kind of carbohydrates, lipids including
any modifications and any complex forms thereof. For the purposes of this Agreement, any [***],
including but not limited to, [***] are excluded from this definition.

     1.62 “Term” has the meaning assigned to it in Section 8.1.

     1.63 “Therapeutic SCA Product” means any SCA Product sold for therapeutic or prophylactic use
in humans.

     1.64 “Third Party” means any party other than CAT, Enzon, Micromet or their respective
Affiliates.

     1.65 “Valid Claim” means (i) any claim of an issued and unexpired patent within the CAT
Licensed Patents, Micromet Supplemental Patents, Enzon Supplemental Patents, or Consolidated Patent
Portfolio, as the case may be, which has not been held unenforceable or invalid by a court or other
governmental agency of competent jurisdiction in a decision that is not appealed or cannot be
appealed, and which has not been disclaimed or admitted to be invalid or unenforceable through
reissue or otherwise, or (ii) a pending claim in a pending patent application within the CAT
Licensed Patents, Micromet Supplemental Patents, Enzon Supplemental Patents or Consolidated Patent
Portfolio, as the case may be. Notwithstanding the foregoing clause (ii), in the event that a
pending claim in a pending patent application does not issue as a valid and enforceable claim in an
issued patent within [***] after the earliest date from which such patent application claims
priority, such a pending claim will not be a Valid Claim, unless and until such pending claim
subsequently issues as a valid and enforceable claim in an issued patent, in which case such claim
will be reinstated and be deemed to be a Valid Claim as of the date of issuance of such patent.

2. Grant Of License 

     2.1 Licenses Grant By Micromet.

          2.1.1 Research License To CAT. Subject to the terms and conditions of this Agreement and the
CAT Field Limitations, Micromet hereby grants to CAT a nonexclusive,

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

8

 

worldwide license under the Consolidated Patent Portfolio and the Consolidated Know-How to
conduct research and development activities solely within the CAT Research Field. CAT hereby
covenants and agrees not to use or sublicense any of its rights under the foregoing license except
as expressly permitted in this Agreement.

          2.1.2 No Restriction on CAT Exploitation Rights. For the avoidance of doubt, this Agreement
does not restrict CAT, its Affiliates or sublicensees from, or impose a royalty payment obligation
on CAT, its Affiliates, or sublicensees with regard to, the Exploitation of Non-SCA Antibody
Products in the Non-SCA Antibody Product Field the manufacture, importation, use, or sale of which
do not (i) infringe one or more Valid Claims within the Consolidated Patent Portfolio or (ii)
utilize the Consolidated Know-How, in each case notwithstanding that such Non-SCA Antibody Products
were discovered, researched, or developed by practice of the license rights granted in Section
2.1.1 above.

          2.1.3 Sublicenses by CAT.

               (a) Subject to the terms and conditions of this Agreement, CAT will have the right to grant
sublicenses, [***], to any of its rights under the license rights granted in Section 2.1.1 solely
in the CAT Research Field or Non-SCA Antibody Product Field, as applicable, and in any case subject
to the CAT Field Limitations, to any:

                    (i) Affiliate of CAT;

                    (ii) CAT Collaboration Partner, (including any Collaboration Partner which has entered into a
Collaboration Agreement with CAT prior to the Effective Date) only in connection with a license by
CAT to such CAT Collaboration Partner of (A) a [***], (B) technology and material relating to
[***], or (C) any Antibody or Antibodies generated by [***] or [***];

                    (iii) CAT Research Contractor, only as reasonably necessary to enable such CAT Research
Contractor to provide services to CAT, any CAT Affiliate or CAT Collaboration Partner; or

                    (iv) Third Party which is a successor to all or substantially all of CAT’s business relating
to Microarrays (in relation to the [***] additional Nominated Targets for Diagnostic SCA Products
described in Section 3.1.1 (b) below only).

               (b) CAT may grant up to [***] sublicenses (such number, the “CAT Sublicense Allowance”) under
this Section 2.1.3, [***] to CAT Collaboration Partners irrespective of whether any of
such sublicenses are subsequently terminated. For the purpose of calculating the CAT Sublicense
Allowance, each agreement in which CAT grants such a sublicense to a CAT Collaboration Partner will
count as a single sublicense, irrespective of the number of intellectual property rights
sublicensed therein. After CAT has exhausted the CAT

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

9

 

Sublicense Allowance, CAT may grant further sublicenses under this Section 2.1.3 to CAT
Collaboration Partners; provided, however, that for each such additional sublicense agreement, CAT
will pay to Micromet a sublicense fee in the amount of US$[***] within [***] days of execution of
such sublicense agreement and an annual sublicense maintenance fee of US$[***], payable within
[***] days of each anniversary of the effective date of the applicable sublicense agreement, until
the termination of such sublicense or the last to expire Valid Claim licensed under such sublicense
agreement, whichever occurs first.

               (c) Any sublicense made pursuant to this Section 2.1.3 will be consistent with the terms and
conditions of this Agreement and will impose on the sublicensee the obligations of CAT contained in
Sections 2.1.4, 5.3, 5.5, 5.7.2, and 7 of this Agreement. CAT will provide Micromet with the
identity of each Third Party licensee of CAT that receives a sublicense of the rights under this
Section 2.1.3 within [***] days of execution of the applicable agreement.

          2.1.4 Limitations; Reservation of Rights

               (a) CAT will not: (i) use or sublicense any of its rights to the Consolidated Patent Portfolio
or the Consolidated Know-How for the purpose of developing or commercializing any BiTE Product for
any use (including, without limitation, use by or a sublicense to an Affiliate); (ii) use or
sublicense any of its rights to the Consolidated Patent Portfolio or the Consolidated Know-How for
the purpose of developing or commercializing any (A) SCA Product or (B) any Antibody Product having
application in the CAT Field Limitations; or (iii) sublicense any of its rights to the Consolidated
Patent Portfolio or the Consolidated Know-How to any Third Party, except as otherwise provided
herein.

               (b) Except for the rights specifically granted herein, Micromet reserves all rights to the
Consolidated Patent Portfolio Controlled by it and the Consolidated Know-How and reserves the right
to utilize or allow Third Parties to utilize the Consolidated Patent Portfolio and the Consolidated
Know-How consistent with the terms of this Agreement and any agreement with Enzon related to such
Consolidated Patent Portfolio and the Consolidated Know-How. No implied licenses are granted under
this Agreement.

          2.1.5 Expiration of CAT Field Limitations. The Parties agree and acknowledge that a
particular product or area listed in the CAT Field Limitations may, from time to time during the
Term, become available for licensing by Micromet to CAT. In such event, Micromet will inform CAT
in writing within [***] days of such availability and, at the written request of CAT, will remove
such product or area from the list of CAT Field Limitations. At such time, such product or area
will be included in the CAT Research Field (subject to the limitations set forth in the definition
of the CAT Research Field) and CAT will be licensed to use the product or area in accordance with
this Agreement, subject to the terms and conditions of this Agreement.

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

10

 

          2.1.6 Expansion of CAT Research Field. If CAT desires to add a Platform Technology (in
addition to Phage Display and Ribosome Display) to the list of technologies included in the
definition of “CAT Research Field” in Section 1 of this Agreement, then CAT will give Micromet
written notice of such desire, which notice will specify all relevant technical and scientific
information pertaining to the applicable Platform Technology in sufficient detail to permit
Micromet reasonably to assess the effect of such inclusion. Within [***] days after delivery of
such notice to Micromet, CAT and Micromet will undertake good faith negotiations regarding the
inclusion of such Platform Technology in the CAT Research Field; provided, however, that nothing
herein will obligate to the Parties to include such Platform Technology in this Agreement.

     2.2 Research License Grant By CAT.

          2.2.1 To Micromet and Enzon.

               (a) Subject to the terms and conditions of this Agreement and the Excluded Field, CAT hereby
grants to Micromet a nonexclusive, worldwide license under the CAT Licensed Patents, the Micromet
Supplemental Patents, CAT Background Know-How and Micromet Supplemental Know-How to conduct
research and development activities solely within the Micromet Research Field. Micromet hereby
covenants and agrees not to use or sublicense any of its rights under the foregoing license except
as expressly permitted in this Agreement.

               (b) Subject to the terms and conditions of this Agreement and the Excluded Field, CAT hereby
grants to Enzon a nonexclusive, worldwide license under the CAT Licensed Patents, Enzon
Supplemental Patents, Micromet Supplemental Know-How and CAT Background Know-How to conduct
research and development activities solely within the Enzon Research Field. Enzon hereby covenants
and agrees not to use or sublicense any of its rights under the foregoing license except as
expressly permitted in this Agreement.

          2.2.2 Sublicenses by Micromet.

               (a) Subject to the terms and conditions of this Agreement, Micromet will have the right to
grant a sublicense ([***]) to any of its rights under the license granted in Section 2.2.1(a)
solely in the Micromet Research Field to any:

                    (i) Micromet Affiliate;

                    (ii) Micromet Collaboration Partner (including any Collaboration Partner which has entered
into a Collaboration Agreement with Micromet prior to the Effective Date), only in connection with
a license by Micromet to such Micromet Collaboration Partner of either (A) the Consolidated Patent
Portfolio (in whole or in part) or (B) other relevant intellectual property or other rights
Controlled by Micromet, in each case to the extent reasonably necessary for the performance by such
Micromet Collaboration Partner of any

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

11

 

activities related to the research and development of products for potential license under the
terms of a Product License Agreement; or

                    (iii) Micromet Research Contractor to enable such Micromet Research Contractor to provide
services to Micromet, or any Micromet Affiliate or Micromet Collaboration Partner.

               (b) Micromet may grant up to [***] sublicenses (such number, the “Micromet Sublicense
Allowance”) under this Section 2.2.2, [***] to Micromet Collaboration Partners
irrespective of whether any of such sublicenses are subsequently terminated. For the purpose of
calculating the Micromet Sublicense Allowance, each agreement in which Micromet grants such a
sublicense to a Micromet Collaboration Partner will count as a single sublicense, irrespective of
the number of intellectual property rights sublicensed therein. After Micromet has exhausted the
Micromet Sublicense Allowance, Micromet may grant further sublicenses under this Section 2.2.2 to
Micromet Collaboration Partners; provided, however, that for each such additional
sublicense agreement, Micromet will pay to CAT a sublicense fee in the amount of US$[***] within
[***] days of execution of such sublicense agreement and an annual sublicense maintenance fee of
US$[***], payable within [***] days of each anniversary of the effective date of the applicable
sublicense agreement, until the termination of such sublicense or the last to expire Valid Claim
licensed under such sublicense agreement, whichever occurs first.

               (c) Any sublicense made pursuant to this Section 2.2.2 will be consistent with the terms and
conditions of this Agreement and will impose on the sublicensee the obligations of Micromet
contained in Sections 5.3, 5.6, 5.7.2 and 7 of this Agreement. Micromet will provide CAT with the
identity of each Third Party licensee of Micromet that receives a sublicense of the rights under
this Section 2.2.2 within [***] days of execution of the applicable agreement.

          2.2.3 Sublicenses by Enzon.

               (a) Subject to the terms and conditions of this Agreement, Enzon will have the right to grant
a sublicense ([***]) to any of its rights under the license granted in Section 2.2.1(b) solely in
the Enzon Research Field to any:

                    (i) Enzon Affiliate;

                    (ii) Enzon Collaboration Partner (including any Collaboration Partner which has entered into a
Collaboration Agreement with Enzon prior to the Effective Date), only in connection with a license
by Enzon of either (A) the Consolidated Patent Portfolio (in whole or in part) or (B) other
relevant intellectual property or other rights Controlled by Enzon, in each case to the extent
reasonably necessary for the performance by such Enzon Collaboration Partner of any activities
related to the research and development of products for potential license under the terms of a
Product License Agreement; or

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

12

 

                    (iii) Enzon Research Contractor to enable such Enzon Research Contractor to provide services
to Enzon any Enzon Affiliate or Enzon Collaboration Partner.

               (b) Enzon
may grant up to [***] sublicenses (such number, the “Enzon Sublicense
Allowance”)
under this Section 2.2.3, [***], to Enzon Collaboration Partners irrespective of whether
any of such sublicenses are subsequently terminated. For the purpose of calculating the Enzon
Sublicense Allowance, each agreement in which Enzon grants such a sublicense to an Enzon
Collaboration Partner will count as a single sublicense, irrespective of the number of intellectual
property rights sublicensed therein. After Enzon has exhausted the Enzon Sublicense Allowance,
Enzon may grant further sublicenses under this Section 2.2.3 to Enzon Collaboration Partners;
provided, however, that for each such additional sublicense agreement, Enzon will
pay to CAT a sublicense fee in the amount of US$[***] within [***] days of execution of such
sublicense agreement and an annual sublicense maintenance fee of US$[***], payable within [***]
days of each anniversary of the effective date of the applicable sublicense agreement, until the
termination of such sublicense or the last to expire Valid Claim licensed under such sublicense
agreement, whichever occurs first.

               (c) Any sublicense made pursuant to this Section 2.2.3 will be consistent with the terms and
conditions of this Agreement and will impose on the sublicensee the obligations of Enzon and grant
CAT the rights contained in Sections 5.3, 5.6, 5.7.2 and 7 of this Agreement. Enzon will provide
CAT with the identity of each Third Party licensee of Enzon that receives a sublicense of the
rights under this Section 2.2.3 within [***] days of execution of the applicable agreement.

          2.2.4 Expiration of Field Limitations on Micromet/Enzon. CAT will notify Micromet and Enzon
promptly if:

               (a) CAT ceases to be bound by the Excluded Field restriction pursuant to its agreement with
[***] dated [***]; or

               (b) CAT no longer needs to exclude Research Products from the license granted hereunder
pursuant to its agreement with [***] (now known as [***]) dated [***] (the “[***] License
Agreement”), a copy of which has been provided to Micromet and Enzon by CAT as of the Effective
Date. CAT will promptly notify Micromet and Enzon of any modification or amendment to the [***]
License Agreement and deliver to Micromet a redacted copy of any such amended agreement.

     The restrictions set out in this Agreement relating to the Excluded Field or Research Products
set forth above (as the case may be) will, subject to any other restrictions on CAT and to the
provisions of this Agreement, cease to apply from the date of removal of such restriction pursuant
to the terms of the foregoing agreements.

          2.2.5 Limitations; Reservation of Rights. Except for the rights specifically granted herein,
CAT reserves all rights to all CAT Licensed Patents, Micromet Supplemental Patents and Enzon
Supplemental Patents (each as Controlled by it) and the CAT Background

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

13

 

Know-How, Micromet Supplemental Know-How, Enzon Supplemental Know-How and reserves the right
to utilize or allow Third Parties to utilize the CAT Licensed Patents, Micromet Supplemental
Patents, Enzon Supplemental Patents, Micromet Supplemental Know-How, Enzon Supplemental Know-How
and CAT Background Know-How consistent with the terms of this Agreement. No implied licenses are
granted under this Agreement.

     2.3 Know-How Transfer.

          2.3.1 Within ninety (90) days after the Effective Date, CAT will disclose in writing and
deliver to Micromet and Enzon all CAT Background Know-How. CAT may during the Term at its sole
discretion propose to each of Micromet and Enzon that additional CAT Background Know-How (developed
by or on behalf of CAT after the Effective Date) be disclosed to Micromet and/or Enzon. Each of
Micromet and Enzon will be entitled to accept or reject such additional Know-How at its sole
discretion. If Micromet accepts such additional Know-How, then such Know-How will be deemed
Micromet Supplemental Know-How and this Agreement will be amended to reflect such addition in
accordance with Section 11.5 (but without the need for the consent of Enzon). If Enzon accepts
such additional Know-How, then such Know-How will be deemed Enzon Supplemental Know-How and this
Agreement will be amended to reflect such addition in accordance with Section 11.5 (but without the
need for the consent of Micromet).

          2.3.2 Within ninety (90) days after the Effective Date, Micromet will disclose in writing and
deliver to CAT all Consolidated Know-How. Micromet may during the Term at its sole discretion
propose to CAT that additional Consolidated Know-How (developed by or on behalf of Micromet after
the Effective Date) be disclosed to CAT and added to Schedule VII CAT will be entitled to
accept or reject such additional Know-How at its sole discretion. If CAT accepts such additional
Know-How, then Schedule VII of this Agreement will be amended in accordance with Section
11.5.

3. Target Selection

     3.1 Identification and Allocation of Targets. During the Term, each Party will have the
right, at its discretion, to nominate one or more Targets for which it desires (or may desire) to
enter into a Product License Agreement for the commercial development of an Antibody Product, in
accordance with and subject to the terms and conditions of this Agreement. The Parties agree and
acknowledge that potential Targets to be nominated under this Agreement will be allocated among the
Parties as set forth in this Section 3.1.

          3.1.1 CAT will have the right, at its discretion, to identify by written notice to Micromet
(a) up to [***] Nominated Targets for which it intends to commercially develop SCA Products by
itself or with or through a Third Party, and (b) up to [***] additional Nominated Targets for which
it intends to commercially develop Diagnostic SCA Products by itself or with or through a Third
Party. For the avoidance of doubt, CAT may identify a Nominated Target for

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

14

 

which it intends to commercially develop Diagnostic SCA Products under either of the foregoing
clauses (a) and (b), at its discretion.

          3.1.2 Micromet, with the consent of Enzon, will have the right, at its discretion, to identify
by written notice to CAT up to [***] Nominated Targets for the commercial development of Antibody
Products with or through Enzon pursuant to the Micromet/Enzon Collaboration Agreement.

          3.1.3 Micromet will have the right, at its discretion, to identify by written notice to CAT up
to [***] Nominated Targets for which it intends to commercially develop Antibody Products by itself
or with or through a Third Party but not otherwise pursuant to the Micromet/Enzon Collaboration
Agreement.

          3.1.4 Enzon will have the right, at its discretion, to identify by written notice to CAT up to
[***] Nominated Targets for which it intends to commercially develop Antibody Products by itself or
with or through a Third Party.

     Notwithstanding anything to the contrary herein, in the event of the expiration or termination
of the Micromet/Enzon Collaboration Agreement, any Targets remaining available for selection under
Section 3.1.2 will be allocated equally between each of Enzon and Micromet, it being understood
that if the number of remaining Targets is an odd number, then such number will be reduced by one
(1) if Enzon and Micromet are unable to agree the allocation for such remaining Targets.

     3.2 Notice and Selection Procedures.

          3.2.1 General. At any time and from time to time during the Term, the Parties may request to
pursue a Nominated Target by giving written notice thereof to the applicable Party (a “Request
Notice”) in accordance with the following: (i) CAT may provide a Request Notice to Micromet that
it seeks to pursue a Nominated Target itself or with or through a Third Party by obtaining a
Product License Agreement under the Consolidated Patent Portfolio and the Consolidated Know-How;
(ii) Micromet may provide a Request Notice to CAT that it seeks to pursue a Nominated Target itself
or with or through a Third Party by obtaining a Product License Agreement under the CAT Licensed
Patents, CAT Background Know-How, Micromet Supplemental Patents, and Micromet Supplemental
Know-How; (iii) Micromet may provide a Request Notice to CAT that it seeks to pursue a Nominated
Target on behalf of Micromet and Enzon pursuant to the Micromet/Enzon Collaboration Agreement (in
which case Micromet will so indicate to CAT) by obtaining a Product License Agreement under the CAT
Licensed Patents, CAT Background Know-How, Micromet Supplemental Patents and Micromet Supplemental
Know-How; and (iv) Enzon may provide a Request Notice to CAT that it seeks to pursue a Nominated
Target itself or with or through a Third Party by obtaining a Product License Agreement under the
CAT Licensed Patents, CAT Background Know-How, Enzon Supplemental Patents and Enzon Supplemental
Know-How. In each of the foregoing cases, the Party providing such Request Notice relating to the
requested Nominated Target will be referred

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

15

 

to herein as a “Requesting Party” and the Party to whom such notification was sent will be
referred to herein as the “Notified Party.” Each Request Notice provided hereunder will contain,
at a minimum, a full description of the applicable Nominated Target (including a GenBank® accession
number, an amino acid sequence, or similar information which uniquely identifies such Nominated
Target), the proposed use by the Requesting Party of such Nominated Target, and for any Request
Notice submitted to CAT hereunder by Micromet or Enzon, a representation and warranty that the
Requesting Party believes as of the date of its request made under this Section that (a) it is not
developing and does not intend to develop an Antibody Product directed at the Nominated Target in
the Excluded Field; (b) its primary purpose in using the CAT Licensed Patents in respect of the
Nominated Target is outside the Excluded Field; (c) it has provided CAT with the information
described above to allow CAT (i) to conduct an assessment of the [***] and (ii) to subject the
Nominated Target to such [***] or other customary scientifically established techniques as may be
used to determine whether or not the [***] of the Nominated Target is [***]; and (d) it believes
that the Primary Application of the Nominated Target is [***]. Each Request Notice for a Product
License Agreement must be submitted by the Requesting Party with sufficient time to allow for the
execution of a Product License Agreement prior to the earlier of (i) the [***] of any composition
or formulation comprising the relevant Antibody Product [***] or (ii) the beginning of studies
required to [***] Antibody Product.

          3.2.2 Requests by Micromet and/or Enzon to CAT. Upon receipt by CAT of a Request Notice from
either Micromet or Enzon, CAT will review the Nominated Target in accordance with this Section
3.2.2.

               (a) CAT will evaluate the Nominated Target with respect to the Gatekeeping Criteria within
[***] Business Days of receiving the relevant Request Notice. During such [***]-Business Day
period, CAT will: (i) subject such Nominated Target to such [***] or other customary or
scientifically established techniques as CAT in its sole discretion may determine in order to
confirm that a [***] of such Nominated Target to which an Antibody Product is directed is [***];
(ii) conduct an assessment of such Nominated Target using information available to CAT to determine
the Nominated Target’s [***] and the intended or actual use of [***]; and (iii) request such other
information as it may reasonably determine is necessary to confirm that the [***] of the Nominated
Target is not in [***].

               (b) Before the expiry of the [***]-Business Day period described in Section 3.2.2(a) CAT will
either: (i) notify the Requesting Party in writing that the Nominated Target has passed the
Gatekeeping Criteria and does [***], in which case CAT will execute the applicable Product License
Agreement for the Nominated Target within such time period or such longer time period as provide in
Section 3.2.2(c) below; or (ii) notify the Requesting Party in writing that the applicable
Nominated Target has not passed the Gatekeeping Criteria or that [***] of the Nominated Target is
[***] in which case CAT will not execute a Product License Agreement for the Nominated Target, as
applicable. In the event that a Nominated Target fails to pass the Gatekeeping Criteria, CAT will
notify the Requesting Party as to the specific Gatekeeping Criteria that form the basis for such
failure.

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

16

 

               (c) Upon any determination by CAT under Section 3.2.3(b)(i) above, CAT agrees that the
Requesting Party may execute the applicable Product License Agreement for the Nominated Target at
any time during the [***] period commencing upon the receipt by the Requesting Party of notice of
such determination. During such [***] period, CAT will execute the applicable Product License
Agreement for the Nominated Target (upon execution of the Product License Agreement by the
Requesting Party) will not take any action to cause a change to the status of such Nominated
Target. If, following a determination by CAT under Section 3.2.3(b)(i), it is subsequently
discovered that the Nominated Target in question does in fact have a [***], then such discovery
will not be deemed in breach of any provision of this Agreement and CAT may not refuse to enter
into a Product License Agreement because of such subsequent discovery.

          3.2.3 Requests by CAT to Micromet. Upon receipt by Micromet of a Request Notice from CAT,
Micromet and Enzon will review the Nominated Target in accordance with this Section 3.2.3.

               (a) Micromet and Enzon will evaluate the Nominated Target with respect to the Gatekeeping
Criteria within [***] Business Days of receiving the relevant Request Notice.

               (b) Before the expiry of the [***]-Business Day period described in Section 3.2.3(a) Micromet
will either: (i) notify CAT in writing that Micromet will execute a Product License Agreement for
the Nominated Target; or (ii) notify CAT in writing that the applicable Nominated Target has not
passed the Gatekeeping Criteria, in which case Micromet will not execute a Product License
Agreement, as applicable. In the event that a Nominated Target fails to pass the Gatekeeping
Criteria, Micromet will notify CAT as to the specific Gatekeeping Criteria that form the basis for
such failure.

               (c) Upon any determination by Micromet under Section 3.2.3(b)(i) above, Micromet agrees that
CAT may execute the applicable Product License Agreement for the Nominated Target at any time
during the [***] period commencing upon the receipt by the CAT of notice of such determination.
During such [***] day-period, Micromet will execute the applicable Product License Agreement for
the Nominated Target (upon execution of the Product License Agreement by CAT) and will not take any
action to cause a change to the status of such Nominated Target.

          3.2.4 Excluded Targets. Where a Nominated Target is rejected for any reason by a Notified
Party in accordance with the terms set out above in this Section 3.2 (such rejected Target to be
known as an “Excluded Target”) the following provisions will apply.

               (a) The Requesting Party will be entitled to nominate one or more additional Nominated Targets
as potential replacements for such Excluded Target until the Notified Party accepts one replacement
Target for issuance of a Product License Agreement pursuant to the procedures described in this
Section 3.2. Any Nominated Target identified as

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

17

 

such a replacement will not count towards the Requesting Party’s limited number of Nominated
Targets under Section 3.1 above.

               (b) The Parties agree and acknowledge that a particular Target will no longer be an Excluded
Target upon the occurrence of one of the following events: (i) the expiration or termination or
amendment of a collaboration or license agreement that was the basis of an exclusion pursuant to
the Gatekeeping Criteria, (ii) abandonment by the Notified Party of its interest in such Target, or
(iii) for a Target designated an Excluded Target due to the Notified Party’s negotiations with a
Third Party, upon termination of discussions with such Third Party, or if such Notified Party does
not, within [***] months from the date of rejection of the Nominated Target, execute an agreement
under which a Third Party is granted a license to develop, co-develop with such Notified Party, or
commercialize an Antibody Product to such Excluded Target, (each, a “Status Change”). Upon any
Status Change of a Target for which the Notified Party previously had received a request from the
Requesting Party and subsequently rejected such request, the Notified Party will inform the
Requesting Party in writing within [***] of such Status Change having occurred and, at the written
request of such Requesting Party, will reconsider such Nominated Target as of such date of such
Status Change under the procedures set forth in Section 3.2.

     3.3 Product License Agreement. If a Nominated Target is cleared through the procedure set out
above and the Requesting Party wishes to enter into a Product License Agreement, then:

               (a) if Micromet or Enzon submitted such Nominated Target, then the relevant Parties will enter
into a Product License Agreement in the form attached as Schedule IX;

               (b) if CAT submitted such Nominated Target for the purpose of obtaining a license for both
Diagnostic SCA Products and Therapeutic SCA Products in respect of such Target, then Micromet and
CAT will enter into a Product License Agreement in the form attached as Schedule X; or

               (c) if CAT submitted such Nominated Target for the purpose of obtaining a license solely for
Diagnostic SCA Products in respect of such Nominated Target pursuant to clause (b) of Section
3.1.1, then Micromet and CAT will enter into a Product License Agreement in the form attached as
Schedule X with all rights and obligations in respect of Therapeutic SCA Products deleted
by the Parties prior to execution (it being understood that Micromet will not grant any rights to
develop and commercialize such Therapeutic SCA Products under the agreement).

               (d) In the cases described in clause (a) through (c) above, the Parties thereto will revise
the applicable form of Product License Agreement prior to the execution thereof to reflect the
then-existing Patents to be licensed and any modifications to any field

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

18

 

limitations imposed by Third Party agreements as described herein as of the effective date of
such Product License Agreement.

     3.4 Records Retention. Each Party will maintain complete and accurate lab books and other
records in sufficient detail to confirm the accuracy of any determination with regard to the
procedures and criteria set forth in Section 3 (including, without limitation, the Gatekeeping
Criteria), which will be retained by such Party until [***] years after the end of this Agreement.

     3.5 Financial Records, Audit. Each Party will at all times keep or cause or procure to be
kept and for at least [***] years retain accurate data, accounts and supporting documentation for
payment of the fees payable pursuant to Section 4.1, Section 4.2, and Sections 2.1.3(b), 2.2.2(b)
and 2.3.2(b), as applicable (collectively, “Records”), to the extent such Records are reasonably
required for the computation and verification of such sums payable. Each Party (to whom amounts
are payable hereunder) will give to or procure for a requesting Party’s nominated representative,
upon reasonable request in writing and no more than [***], access to its facilities during normal
business hours to inspect all Records kept in accordance with this Section 3.5 and to make copies
or to take extracts from these Records. However, a requesting Party’s nominated representative
will not disclose to any other Party or any Third Party any Confidential Information belonging to
the Party providing such information but will merely report on any under or over payment discovered
as a result of his inspection. The requesting Party will bear all costs of such audit, unless the
audit reveals an underpayment of more than [***]% from payments otherwise due and payable
hereunder, in which case the audited Party will bear the cost of the audit.

     3.6 Confidentiality. A Notified Party will treat all information provided under Section 3 by
a Requesting Party (including, without limitation, the identity of the Requesting Party, the nature
and existence of the request and the identity of the Nominated Target) in accordance with the
confidentiality provisions of Section 7. A Requesting Party will treat all information provided
under Section 3 by a Notified Party with regard to an Excluded Target in accordance with the
confidentiality provisions of Section 7; provided, however, that the foregoing
restrictions will not apply in any way to limit disclosure of information by and between Enzon and
Micromet in the event Micromet is the Requesting Party on behalf of Micromet and Enzon pursuant to
the Micromet/Enzon Collaboration Agreement or any agreement related thereto; provided,
further that nothing in this Section 3.6 or Section 7 will in any way limit a Requesting
Party’s ability to disclose that it is developing a product against a Nominated Target that has
satisfied the procedures and criteria set forth in Section 3.2. Each Requesting Party will cause
any Third Party performing a review of materials subsequent to a rejection of a Nominated Target
pursuant to Sections 3.2.2(b) or 3.2.3(b), or an enquiry pursuant to Sections 3.5 or 3.7, to enter
into a confidentiality agreement with the applicable Notified Party (including, at such Requesting
Party’s election, the option to require that the Third Party not disclose such materials to the
Requesting Party except for any summary conclusions relating thereto), to protect against improper
use or disclosure of any information disclosed in the course of such review or audit.

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

19

 

     3.7 Gatekeeping Disputes and Remedies. Any dispute arising out of or
relating to a Notified
Party’s determination that [***] will, if the
dispute resolution measures described in Section 11.3.2 of this Agreement are unsuccessful, be
resolved by the process described in this Section 3.7.

          3.7.1 Within [***] following
a notice from the Notified Party that [***], the Requesting Party may
notify the Notified Party that it wishes [***] (neither affiliated with nor engaged by any Party to the dispute) having at
least [***] to make such enquiries of the Notified Party as may be reasonably
necessary for [***] to be able to [***] had been [***] in respect of
[***]. The [***]
will be appointed by the Requesting Party and [***].

          3.7.2
Each of [***] and [***] will provide such [***] as is reasonably
requested [***]. The [***] in accordance with Section 3.7.3 below and will not [***] in respect of the
[***]. The [***] with such [***].
Notwithstanding the foregoing, the [***] if to do so [***] may have with
any other [***].

          3.7.3
The [***] within [***] days after appointment by the
[***]. Such confirmation will be made with one of the following [***] described in the preceding clause (a) or (b).
If the [***] and will be given one (1)
additional [***]-day period (beginning on the date of its determination pursuant to clause (c)) [***] and provide the [***] as set out above. If the [***] will be responsible for
the [***] and the [***], except as otherwise provided in this
Agreement. If the [***]
that the [***] did not [***] will
be [***] in relation to the

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

20

 

     [***] (provided that the [***] is not [***] in relation to [***], in which case the [***] will
be subject to those [***]) [***] will be responsible for the [***].

4. Payments; Annual Report

     4.1 Upfront License Fees.

          4.1.1 By CAT. On the Effective Date, CAT will pay to Micromet a non-refundable,
non-creditable license fee in the amount of US$[***] in consideration of the license grants set
forth herein.

          4.1.2 By Micromet. On the Effective Date, Micromet will pay to CAT a non-refundable,
non-creditable license fee in the amount of US$[***] in consideration of the license grants and
other obligations set forth herein.

          4.1.3 By Enzon. On the Effective Date, Enzon will pay to CAT a non-refundable, non-creditable
license fee in the amount of US$[***] in consideration of the license grants set forth herein.

          4.1.4 Payment Offset. The Parties agree that any payments payable by a Party in accordance
with Section 4.1 will be offset against any payments which may be due to that Party under Section
4.1.

          4.1.5 Withholdings. The Parties agree that, in all cases, the net payment made by CAT in
Section 4.1.1 will equal the aggregate payments made by Micromet and Enzon together under Section
4.1.2 and 4.1.3, respectively, which is intended to make such payments cash flow neutral. If each
of the following applies: (a) CAT is required to deduct and pay to a revenue authority any
Withholding Tax pursuant to Section 4.5.1 on account of any payment made to Micromet under Section
4.1.1, (b) Micromet is not able to claim a credit or reimbursement for such tax, and (c) Sections
4.5.3 or 4.5.4 do not apply, (such Withholding Tax, a “CAT Deduction”), then Micromet and Enzon
will be entitled to withhold on a pro rata basis from any payment due to CAT under Section 4.1.2
and Section 4.1.3, respectively, in an aggregate amount equal to the CAT Deduction until such time
as the CAT Deduction is paid by CAT to Micromet. If either Micromet or Enzon is required to deduct
and pay to a revenue authority any Withholding Tax pursuant to Section 4.5.1 on account of any
payment made to CAT under Section 4.1.2 or 4.1.3, respectively, (b) CAT is not able to claim a
credit or reimbursement for such tax, and (c) Sections 4.5.3 or 4.5.4 do not apply, (such
Withholding Tax, a “Micromet/Enzon Deduction”), then CAT will be entitled to withhold from any
payment due to Micromet under Section 4.1.1 an aggregate amount equal to the Micromet/Enzon
Deduction until such time as the Micromet/Enzon Deduction is paid by Micromet or Enzon to CAT.

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

21

 

4.2 License Maintenance Fees.

          4.2.1 By CAT. On the first Business Day following each anniversary of the Effective Date
during the Maintenance Fee Term, CAT will pay to Micromet a non-refundable, non-creditable license
fee in the amount of US$[***] in consideration of the license grants set forth herein. CAT’s
payment obligation in this Section 4.2.1 will expire upon expiration of the Maintenance Fee Term,
or upon relinquishment by CAT of its rights as set forth in Section 8.3.

          4.2.2 By Micromet. On the first Business Day following each anniversary of the Effective Date
during the Maintenance Fee Term, Micromet will pay to CAT a non-refundable, non-creditable license
fee in the amount of US$[***] in consideration of the license grants and other obligations set
forth herein. Micromet’s payment obligation in this Section 4.2.2 will expire upon expiration of
the Maintenance Fee Term, or upon relinquishment by Micromet of its rights as set forth in Section
8.3.

          4.2.3 By Enzon. On the first Business Day following each anniversary of the Effective Date
during the Maintenance Fee Term, Enzon will pay to CAT a non-refundable, non-creditable license fee
in the amount of US$[***] in consideration of the license grants set forth herein. Enzon’s payment
obligation in this Section 4.2.3 will expire upon expiration of the Maintenance Fee Term, or upon
relinquishment by CAT of its rights as set forth in Section 8.3.

          4.2.4 Payment Offset. The Parties agree that any payments payable by a Party in accordance
with Section 4.2 will be offset against any payments which may be due to that Party under Section
4.2.

          4.2.5 Withholdings. The Parties agree that, in all cases where Micromet, CAT and Enzon are
parties to this Agreement, the net payment made by CAT in Section 4.2.1 will equal the aggregate
payments made by Micromet and Enzon together under Section 4.2.2 and 4.2.3, respectively, which is
intended to make such payments cash flow neutral for so long as each of Enzon, Micromet and CAT are
parties to this Agreement. In each case (whether or not both Micromet and Enzon remain parties to
this Agreement), if CAT is required to deduct and pay to a revenue authority any Withholding Tax
pursuant to Section 4.5.1 on account of any payment made to Micromet under Section 4.2.1, (b)
Micromet is not able to claim a credit or reimbursement for such tax, and (c) Sections 4.5.3 or
4.5.4 do not apply, (such Withholding Tax, a “CAT Fee Deduction”), then Micromet and Enzon, as the
case may be, will be entitled to withhold on a pro rata basis from any payment due to CAT under
Section 4.2.2 and Section 4.2.3 (to the extent that such payments are due and payable),
respectively, in an aggregate amount equal to the CAT Fee Deduction until such time as the CAT Fee
Deduction is paid by CAT to Micromet. If either Micromet or Enzon is required to deduct and pay to
a revenue authority any Withholding Tax pursuant to Section 4.5.1 on account of any payment made to
CAT under Section 4.2.2 or 4.2.3, respectively, (b) CAT is not able to claim a credit or
reimbursement for such tax, and (c) Sections 4.5.3 or 4.5.4 do not apply, (such Withholding Tax, a
“Micromet/Enzon Fee Deduction”) on account of any payment to be made to CAT, then CAT will be
entitled to withhold from any payment due to Micromet under Section 4.2.1 an aggregate

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

22

 

amount equal to the Micromet /Enzon Fee Deduction until such time as the Micromet/Enzon Fee
Deduction is paid by Micromet or Enzon to CAT.

     4.3 Payment.

          4.3.1 Payment Method. All amounts due hereunder will be paid in Euros by wire transfer in
immediately available funds to an account designated by the receiving Party. Any payments or
portions thereof due hereunder which are not paid on the date such payments are due will bear
interest from the due date until the date of payment at the rate which is the lower of (i) [***]
percentage points above the overnight London Interbank Offering Rate in effect on the due date or
(ii) the highest rate permitted by applicable law.

          4.3.2 Currency Conversion for Payments. For any currency conversion required in connection
with any payment hereunder, such conversion will be made at the prevailing commercial rate of
exchange for purchasing the currency into which an amount is to be converted as publicly announced
by Deutsche Bank (or its successor) in Frankfurt on the day such payment is due.

     4.4 Annual Report. On the date that the license maintenance fees are due and payable by a
Party under Section 4.2, such Party will submit to each of the other Parties an annual written
report briefly summarizing the matters for which such Party is obligated to report under the terms
of this Agreement and confirming that no reportable activities took place during the preceding
twelve (12)-month period in the event that a particular report was not delivered during such
period.

     4.5 Withholdings.

          4.5.1 Each Party (the “Paying Party”) will be entitled (if required to do so) to deduct tax
from the payments it makes to any other Party (the “Receiving Party”) under this Section 4 above
(“Withholding Tax”) provided that:

               (a) The Paying Party will pay over such Withholding Tax to the relevant revenue authority and
will provide to the Receiving Party such documentary evidence as the Receiving Party may reasonably
require regarding (i) the amount so deducted, and (ii) evidence of payment to such authority; and

               (b) The Paying Party will provide to the Receiving Party such assistance as the Receiving
Party may reasonably require (including submission of documents to relevant revenue authorities) to
obtain a repayment of the Withholding Tax or (as the case may be) to obtain the benefit of such
Withholding Tax whether by credit against taxes or otherwise.

          4.5.2 If, pursuant to a relevant double taxation agreement, a Party has the right to claim
relief (whether in whole or in part) from any Withholding Tax, then:

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

23

 

               (a) The Paying Party will co-operate with the Receiving Party in seeking a written direction
from the relevant revenue authorities to the effect that either: (i) no Withholding Tax should be
operated in respect of payments under this Agreement, or (ii) the rate of Withholding Tax will be
such lower rate as specified by the relevant revenue authority, and the Paying Party will comply
with any such direction given; and

               (b) pending such written direction, the Paying Party will deduct Withholding Tax in accordance
with Section 4.5.1 above, but will, in addition to the sums otherwise payable under this Agreement,
pay to the Receiving Party such further sum as will ensure that, after operation of Withholding Tax
on all such sums, the net amount received by the Receiving Party equals the amount that the
Receiving Party would have received had the relevant revenue authority already issued the written
direction described in Section 4.5.2(a)(i) above or, as the case may be, Section 4.5.2(a)(ii)
above.

          4.5.3 If, as a result of any change in corporate status or location of the Receiving Party, or
permitted assignment of this Agreement by the Receiving Party, Withholding Tax becomes due on
payments from the Paying Party to the Receiving Party or its permitted assignee and the Receiving
Party is not able to claim a credit or reimbursement for such tax, in whole or in part, then any
amount of Withholding Tax deducted by the Paying Party on amounts payable by the Paying Party to
the Receiving Party hereunder will be treated as if the amount of Withholding Tax was paid directly
to the Receiving Party, to the extent that a credit or reimbursement could not be claimed by the
Receiving Party.

          4.5.4 If, as a result of any change in corporate status or location of the Paying Party, or
permitted assignment of this Agreement by the Paying Party, Withholding Tax becomes due on payments
from the Paying Party to the Receiving Party or its permitted assignee and the Receiving Party is
not able to claim a credit or reimbursement for such tax, in whole or in part, then the Paying
Party will deduct Withholding Tax in accordance with Section 4.5.1 above, but will, in addition to
the sums otherwise payable under this Agreement, pay to the Receiving Party such further sum as
will ensure that, after operation of Withholding Tax on all such sums, the net amount received by
the Receiving Party equals the amount that the Receiving Party would have received had the
non-creditable or non-deductible amount of such Withholding Tax not been deducted. To the extent
that any such amount deducted by Paying Party in accordance with this Section 4.5.4 is in fact
subsequently able to be claimed by the Receiving Party as a credit or reimbursement for such tax
otherwise deducted, then the Receiving Party will pay to the Paying Party the corresponding amount
of any such credit or reimbursement for such tax otherwise eligible to be deducted by the Receiving
Party.

24

 

5. Filing, Prosecution, Maintenance of Patent Rights; Improvements

     5.1 Responsibilities. CAT will be solely responsible and bear all costs for the preparation,
filing, prosecution and maintenance of the CAT Licensed Patents, Micromet Supplemental Patents and
Enzon Supplemental Patents in its sole and absolute discretion. The preparation, filing,
prosecution and maintenance of the Consolidated Patent Portfolio will be performed in accordance
with the Micromet/Enzon Cross-License Agreement or other agreement between Micromet and Enzon, as
the case may be.

     5.2 Costs. Each Party will be solely responsible and bear all costs for (and enjoy all
recovery from) any actions concerning its licensed Patents, including but not limited to
reexaminations, oppositions, interferences, and infringement actions, all in its sole and absolute
discretion.

     5.3 Notice.

          5.3.1 Micromet and Enzon will notify CAT of any successful challenge of any Patent in the
Consolidated Patent Portfolio by any Third Party and will, upon request by CAT, provide CAT with
reasonable documentation regarding any such challenge. Micromet and Enzon will notify CAT of any
infringement by a Third Party of any Patent in the CAT Licensed Patents of which Micromet or Enzon,
as the case may be, becomes aware, and will provide CAT with the available evidence, if any, of
such infringement.

          5.3.2 CAT will notify Micromet and Enzon of any successful challenge of any Patent in the CAT
Licensed Patents by any Third Party and will, upon request by Micromet or Enzon, provide to
Micromet and Enzon with reasonable documentation regarding any such challenge. CAT will notify
Micromet and Enzon of any infringement by a Third Party of any Patent in the Consolidated Patent
Portfolio of which CAT becomes aware, and will provide Micromet and Enzon with the available
evidence, if any, of such infringement.

     5.4 Enforcement.

          5.4.1 As between Micromet and CAT, Micromet will have the exclusive right and sole discretion
during the Term to stop infringement of the Consolidated Patent Portfolio, including by bringing
suit or other proceeding against the infringer in its own name. Upon request by Micromet, CAT will
provide reasonable assistance to Micromet as a party to the lawsuit or other proceeding, at
Micromet’s expense; provided, however, that Micromet will retain control of the
prosecution of such suit or proceeding. Subject to the Micromet/Enzon Cross-License Agreement or
other agreement between Micromet and Enzon, as the case may be, Micromet will bear all its costs
incurred in connection with such lawsuit or other proceeding, and, consequently, will be entitled
to collect and retain for its own account such damages and profits as may be accrued as a result of
such lawsuit or other proceeding.

          5.4.2 As between CAT, Micromet and Enzon, CAT will have the exclusive right and sole
discretion during the Term to stop infringement of the CAT Licensed Patents, including by bringing
suit or other proceeding against the infringer in its own name. Upon request by CAT, Micromet and
Enzon, as the case may be, will provide reasonable assistance to CAT as a party to the lawsuit or
other proceeding, at CAT’s expense; provided, however, that CAT will

25

 

retain control of the prosecution of such suit or proceeding. CAT will bear all its costs
incurred in connection with such lawsuit or other proceeding, and, consequently, will be entitled
to collect and retain for its own account such damages and profits as may be accrued as a result of
such lawsuit or other proceeding.

     5.5 Patent Challenges by CAT.

          5.5.1 Micromet will be permitted to terminate this Agreement if CAT or its Affiliates
challenge, or intentionally direct or intentionally assist (other than under compulsion of a legal
process) a third party to challenge, the validity or enforceability of any of the Patents within
the Consolidated Patent Portfolio; provided, however, that the foregoing
termination right will not apply in the event that such challenge to a patent within the
Consolidated Patent Portfolio is brought by CAT or its Affiliates in response to a suit or
proceeding on such patent brought by Micromet or Enzon (or their Affiliates) against CAT or its
Affiliates. If a sublicensee of CAT or its Affiliates (or an Affiliate of such sublicensee)
challenges the validity or enforceability of or otherwise opposes any such Patent under which such
sublicensee is sublicensed, then CAT upon notice by Micromet will terminate such sublicense. CAT
and its Affiliates will include provisions in all agreements that grant sublicense rights under the
Patents within the Consolidated Patent Portfolio that if the sublicensee or its Affiliates
challenge the validity or enforceability of or otherwise oppose any such Patents under which the
sublicensee is sublicensed, CAT may terminate its sublicense agreement with such sublicensee.

          5.5.2 Within [***] Business Days from the Effective Date, CAT will withdraw and cease its
participation in the opposition currently pending before the European Patent Office against [***]
[***].

     5.6 Patent Challenges by Micromet or Enzon.

          5.6.1 CAT will be permitted to terminate this Agreement if Micromet, Enzon or their respective
Affiliates challenge, or intentionally direct or intentionally assist (other than under compulsion
of a legal process) a third party to challenge, the validity or enforceability of any of the
Patents within CAT Licensed Patents, Micromet Supplemental Patents or Enzon Supplemental Patents,
as applicable; provided, however, that the foregoing termination right will not
apply in the event that such challenge to a patent within the CAT Licensed Patents, Micromet
Supplemental Patents or Enzon Supplemental Patents, as applicable, is brought by Micromet, Enzon or
their respective Affiliates in response to a suit or proceeding on such patent brought by CAT (or
its Affiliates) against Micromet, Enzon or their respective Affiliates. If a sublicensee of
Micromet, Enzon or their respective Affiliates (or an Affiliate of such sublicensee) challenges the
validity or enforceability of or otherwise opposes any such Patent under which such sublicensee is
sublicensed, then Micromet or Enzon upon notice by CAT will terminate such sublicense. Micromet,
Enzon and their respective Affiliates will include provisions in all agreements that grant
sublicense rights under the Patents within CAT Licensed Patents, Micromet Supplemental Patents,
Enzon Supplemental Patents, as the case may be, that if the sublicensee or its Affiliates challenge
the validity or enforceability of or otherwise opposes any

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

26

 

such Patents under which the sublicensee is sublicensed, Micromet may terminate its sublicense
agreement with such sublicensee.

          5.6.2 Within [***] Business Days from the Effective Date, Enzon will withdraw and terminate
its opposition appeal currently pending before the European Patent Office against [***].

     5.7 Improvements.

          5.7.1 To Own Technology.

               (a) Within [***] following conception or discovery by or on behalf of CAT or its Affiliates of
any CAT Phage Display Improvements, CAT will provide Micromet and Enzon with written notice of such
CAT Phage Display Improvements. If either of Micromet or Enzon elects to include any Patents
claiming or covering one or more of such CAT Phage Display Improvements, then either one or both of
Micromet and Enzon, as applicable, will provide CAT with written notice of such election and, upon
receipt by CAT of such notice, any such Patents will be deemed Micromet Supplemental Patents or
Enzon Supplemental Patents, as the case may be. Subject to the licenses granted in Section 2.2,
CAT will retain all right, title and interest in and to any and all CAT Phage Display Improvements.

               (b) Within [***] following conception or discovery of any Consolidated Patent Portfolio
Improvements, Micromet will (a) provide CAT with prompt written notice of such Consolidated Patent
Portfolio Improvements and (b) update Schedule I to include any Patents added to the
“Consolidated Patent Portfolio,” as defined in the Micromet/Enzon IP Marketing Agreement, since the
last such update, if any. Subject to the licenses granted in Section 2.1, Micromet and/or Enzon,
as the case may be, will retain all right, title and interest in and to any and all such
Improvements and Patents.

          5.7.2 To Another Party’s Technology.

               (a) Improvements by CAT.

                    (i) Within [***] of conception or discovery by or on behalf of CAT, its Affiliates or
sublicensees of any CAT Improvements (as hereinafter defined) relating to the Consolidated Patent
Portfolio or the Consolidated Know-How, CAT will provide Micromet and Enzon with notice of such
Improvements. Subject to the licenses granted in this Section 5.7.2(a), as between the Parties,
CAT will retain all right, title and interest in and to any and all Improvements relating to such
licensed Patents or Know-How discovered by or on behalf of CAT, its Affiliates and sublicensees.
As used in this Section 5.7.2(a), the term “CAT Improvements” means an invention or discovery that
satisfies all of the following criteria: (A) is first reduced to practice, or described in a patent
application, publication, or abstract within [***] years of the Effective Date; provided,
however, that upon the request of Micromet or Enzon, as the case may be, at any time during
the [***] period following the date that is [***] years from the Effective Date and upon
demonstration by Micromet or Enzon, as the case may be, of good

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

27

 

commercial, technical, or legal reasons for extension of the foregoing [***] period, the
Parties agree to negotiate in good faith the potential extension of such period for one (1)
additional [***] period, with the consent by the Parties to such extension not to be withheld
absent demonstration of good commercial, technical, or legal reasons for opposing such extension;
(B) may not lawfully be Exploited without a license to one or more Valid Claims within the
Consolidated Patent Portfolio; and (C) is not a human therapeutic or diagnostic product, a
manufacturing method applicable to that product, or a method of using that product.

                    (ii) Subject to the terms and conditions of this Agreement, CAT hereby grants to each of
Micromet and Enzon a perpetual, irrevocable, non-exclusive, worldwide, royalty-free, fully paid
license, with the right to grant and authorize the grant of sublicenses in accordance with Sections
2.2.2, 2.2.3 and 2.2.5 as applicable to Micromet or Enzon, as the case may be, under any CAT
Improvements as defined in Section 5.7.2(a)(i).

                    (iii) CAT will ensure that to the extent permitted by law, any Third Party, including CAT’s
sublicensees, performing work related to the Consolidated Patent Portfolio or Consolidated Know-How
is under an obligation: (a) to assign all inventions, Patents, and Know-How relating to the
Consolidated Patent Portfolio and Consolidated Know-How to CAT, or where this obligation is not
permitted, (b) to exclusively license all such inventions, Patents, and Know-How to CAT, with the
right to sublicense, or where neither of the obligations described in the preceding clause (a) or
(b) is permitted then, (c) to non-exclusively license all such inventions, Patents, and Know-How to
CAT, with the right to sublicense.

               (b) Improvements by Micromet or Enzon.

                    (i) Within [***] of conception or discovery by or on behalf of (1) Micromet, Enzon, or their
respective Affiliates and sublicensees of any E/M Improvements (as hereafter defined) relating to
the CAT Licensed Patents or CAT Background Know-How, (2) Micromet or its respective Affiliates and
sublicensees of any E/M Improvements relating to the Micromet Supplemental Patents or Micromet
Supplemental Know-How, (3) Enzon or its respective Affiliates and sublicensees of any E/M
Improvements relating to the Enzon Supplemental Patents or Enzon Supplemental Know-How, Micromet or
Enzon, as the case may be, will provide CAT with notice of such E/M Improvements. Subject to the
licenses granted in this Section 5.7.2(b), as between the Parties, Micromet or Enzon, as the case
may be, will retain all right, title and interest in and to any and all Improvements relating to
such licensed Patents or Know-How discovered by or on behalf of Micromet, Enzon, or their
respective Affiliates and sublicensees, as the case may be. As used in this Section 5.7.2(a), the
term “E/M Improvements” means an invention or discovery that satisfies all of the following
criteria: (A) is first reduced to practice, or described in a patent application, publication, or
abstract within [***] years of the Effective Date; provided, however, that upon the
request of CAT at any time during the [***] period following the date that is [***] years from the
Effective Date and upon demonstration by CAT of good commercial, technical, or legal reasons for
extension of the foregoing [***] period, the Parties agree to negotiate in good faith the potential
extension of such period for one (1) additional [***] period, with the consent by the Parties to
such extension not

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

28

 

to be withheld absent demonstration of good commercial, technical, or legal reasons for
opposing such extension; (B) may not lawfully be Exploited without a license to one or more Valid
Claims within the CAT Licensed Patents, Micromet Supplemental Patents (in the case of Micromet or
its Affiliates or sublicensees), or Enzon Supplemental Patents (in the case of Enzon or its
Affiliates or sublicensees); and (C) is not a human therapeutic or diagnostic product manufacturing
method applicable to that product, or a method of using that product.

                    (ii) Subject to the terms and conditions of this Agreement, Micromet and Enzon, as the case
may be, hereby grant to CAT a perpetual, irrevocable, non-exclusive, worldwide, royalty-free, fully
paid license, with the right to grant and authorize the grant of sublicenses in accordance with
Sections 2.1.3 and 2.1.4, under any Improvements described in Section 5.7.2(b)(i).

                    (iii) Micromet and Enzon, as the case may be, will ensure that to the extent permitted by law,
any Third Party, including Micromet’s or Enzon’s sublicensees, performing work related to the CAT
Licensed Patents, Micromet Supplemental Patents, Micromet Supplemental Know-How, Enzon Supplemental
Patents or Enzon Supplemental Know-How, as the case may be, is under an obligation: (a) to assign
all inventions, Improvements, Patents, and Know-How relating to such Patent and Know-How to
Micromet or Enzon, as applicable, or where this obligation is not permitted, (b) to exclusively
license all such inventions, Improvements, Patents, and Know-How to Micromet or Enzon, as
applicable, with the right to sublicense, or where neither of the obligations described in the
preceding clause (a) or (b) is permitted then, (c) to non-exclusively license all such inventions,
Patents, and Know-How to Micromet or Enzon, as applicable, with the right to sublicense.

          5.7.3 Further Assurances. Each Party agrees to take all necessary and proper acts, and will
cause its employees, Affiliates, contractors, sublicensees, and consultants to take such necessary
and proper acts, to effectuate the ownership provisions set forth in this Section 5.7.

6. Representation and Warranties; Covenants

     6.1 Representations of Micromet. Micromet represents to CAT that as of the Effective Date:
(a) it Controls the Consolidated Patent Portfolio licensed under this Agreement (subject to the
restrictions described in the CAT Field Limitations and application of Micromet’s Gatekeeping
Criteria under Section 3.2.3); (b) the Consolidated Patent Portfolio includes all Patents relating
to Single Chain Antibodies that both (i) are owned by Micromet or are licensed from Enzon to
Micromet under the Micromet/Enzon Cross-License Agreement, and (ii) would be infringed by CAT’s
performance of activities in the CAT Research Field, or the development, importation, manufacture,
use or sale of Antibody Products resulting from such activities; provided, however,
that it will not be a breach of the foregoing representation if Micromet has in good faith
inadvertently omitted a Patent from Schedule I and is not otherwise in breach of its
covenant under Section 6.4 regarding such Patent; (c) except as disclosed in Schedule XI,
it has not received any written communication that expressly threatens interference actions or
oppositions to any Patents within the Consolidated Patent Portfolio or other litigation before any
patent office, court, or any other governmental entity in any jurisdiction in regard to the
Consolidated Patent Portfolio; (d) except as disclosed in Schedule XI, it has not been
served with

29

 

any complaint alleging infringement of a Third Party’s patents arising from the practice of
the claims in the Patents within the Consolidated Patent Portfolio; and (e) Schedule XI
includes a complete list of all pending claims of Third Parties in regard to the entitlement,
validity or enforceability of the Consolidated Patent Portfolio.

     6.2 Representations of CAT. CAT represents to each of Enzon and Micromet that as of the
Effective Date: (a) it Controls the CAT Licensed Patents and the CAT Background Know-How licensed
under this Agreement (subject to the restrictions described in the Excluded Field and the Micromet
- Enzon Excluded Technology and application of CAT’s Gatekeeping Criteria under Section 3.2.2); (b)
the CAT Licensed Patents includes all Patents relating to Phage Display that both (i) are owned by
CAT or are licensed from the [***] to CAT, and (ii) would be infringed by Micromet’s or Enzon’s
performance, respectively, of activities in the Micromet Research Field, Enzon Research Field, or
the development, importation, manufacture, use or sale of Antibody Products resulting from such
activities; provided, however, that it will not be a breach of the foregoing
representation if CAT has in good faith inadvertently omitted a Patent from Schedule II and
is not otherwise in breach of its covenant under Section 6.4 regarding such Patent; (c) except as
disclosed in Schedules II and XII, it has not received any written
communication that expressly threatens interference actions or oppositions to any Patents within
the CAT Licensed Patents or other litigation before any patent office, court, or any other
governmental entity in any jurisdiction in regard to the CAT Licensed Patents; (d) except as
disclosed in Schedules II and XII, it has not been served with any
complaint alleging infringement of a Third Party’s patents arising from the practice of the claims
in the Patents within the CAT Licensed Patents; and (e) Schedule XII includes a complete
list of all pending claims of Third Parties in regard to the entitlement, validity or
enforceability of the CAT Licensed Patents.

     6.3 Reciprocal Representations and Warranties. Each Party represents and warrants to the other
Parties hereto that: (i) this Agreement is a legal and valid obligation binding upon its execution
and enforceable against it in accordance with its terms and conditions; and (ii) the execution,
delivery and performance of this Agreement by such Party has been duly authorized by all necessary
corporate action, and the person executing this Agreement on behalf of such Party has been duly
authorized to do so by all requisite corporate actions.

     6.4 Additional Covenants.

          6.4.1 CAT hereby covenants and agrees that it will maintain throughout the Term all agreements
with Third Parties granting CAT rights in and to the CAT Licensed Patents, Micromet Supplemental
Patents, CAT Background Know-How and CAT Supplemental Know-How that are necessary to grant Micromet
the licenses granted in Section 2 of this Agreement (including, without limitation, the [***]
Agreement). Upon termination of the [***] Agreement, and upon request by Micromet, CAT will use
commercially reasonable efforts to obtain a direct license for Micromet from the [***], its
successors or assigns to any CAT Licensed Patents licensed to CAT under such agreement;
provided, however, that CAT will have no such

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

30

 

obligation if Micromet’s acts or omissions under this Agreement caused such termination of the
[***] Agreement.

          6.4.2 CAT hereby covenants and agrees that it will maintain throughout the Term all agreements
with Third Parties granting Enzon rights in and to the CAT Licensed Patents, CAT Background
Know-How, Enzon Supplemental Patents and Enzon Supplemental Know-How that are necessary to grant
Enzon the licenses granted in Section 2 of this Agreement (including, without limitation, the [***]
Agreement). Upon termination of the [***] Agreement, and upon request by Enzon, CAT will use
commercially reasonable efforts to obtain a direct license for Enzon from the [***], its successors
or assigns to any CAT Licensed Patents licensed to CAT under such agreement; provided,
however, that CAT will have no such obligation if Enzon’s acts or omissions under this
Agreement caused such termination of the [***] Agreement.

          6.4.3 Micromet and Enzon each hereby covenants and agrees that it will maintain throughout the
Term all agreements with each other or any Third Party granting Micromet or Enzon rights in and to
the Consolidated Patent Portfolio and Consolidated Know-How that are necessary to grant CAT the
licenses granted in Section 2 of this Agreement (including, without limitation, the Micromet/Enzon
Cross-License Agreement and the Exclusive IP Marketing Agreement between Micromet and Enzon, dated
as of April 9, 2002).

          6.4.4 Micromet and Enzon each agrees and acknowledges that the licenses granted by Micromet in
Section 2.1.1 and Section 2.1.2 will survive any termination or expiration of the Micromet/Enzon
Cross-License Agreement, subject to the conditions set forth in Section 8.5.1.

     6.5 DISCLAIMER OF WARRANTY. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN THIS AGREEMENT,
EACH OF MICROMET, ENZON AND CAT MAKES NO REPRESENTATIONS AND GRANTS NO WARRANTIES, EXPRESS OR
IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND EACH OF MICROMET,
ENZON AND CAT EACH SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS
OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR
THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.

7. Confidentiality 

     7.1 Definition. During the Term and subject to the terms and conditions of this Agreement, a
Party (the “Disclosing Party”) may communicate to another Party (the “Receiving Party”)
confidential information in connection with this Agreement or the performance of its obligations
hereunder, including, without limitation, any Know-How, any information regarding Improvements, any
reports provided pursuant to this Agreement, any scientific and manufacturing information and
plans, marketing and business plans, and financial and personnel

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

31

 

matters relating to a Party or its present or future products, sales, suppliers, customers,
employees, investors or business (collectively, “Confidential Information”).

     7.2 Exclusions.

          7.2.1 Notwithstanding the foregoing, information of a Disclosing Party will not be deemed
Confidential Information with respect to a Receiving Party for purposes of this Agreement if such
information:

               (a) was already known to the Receiving Party or its Affiliates, other than under an obligation
of confidentiality or non-use, at the time of disclosure to the Receiving Party;

               (b) was generally available or known to parties reasonably skilled in the field to which such
information or Know-How pertains, or was otherwise part of the public domain, at the time of its
disclosure to the Receiving Party;

               (c) became generally available or known to parties reasonably skilled in the field to which
such information or Know-How pertains, or otherwise became part of the public domain, after its
disclosure to the Receiving Party through no fault of or breach of its obligations under Section 7
by the Receiving Party;

               (d) was disclosed to the Receiving Party other than under an obligation of confidentiality or
non-use, by a party other than the Disclosing Party who had no obligation to the Disclosing Party
not to disclose such information or Know-How to others; or

               (e) was independently discovered or developed by the Receiving Party or its Affiliates, as
evidenced by contemporaneous written records, without the use of or reference to, and by personnel
who had no knowledge of or access to, any Confidential Information of the Disclosing Party.

          7.2.2 Specific aspects or details of Confidential Information will not be deemed to be within
the public domain or in the possession of a person or entity merely because the Confidential
Information is embraced by more general information in the public domain or in the possession of
such person or entity. Further, any combination of Confidential Information will not be considered
in the public domain or in the possession of person or entity merely because individual elements of
such Confidential Information are in the public domain or in the possession of such person or
entity unless the combination and its principles are in the public domain or in the possession of
such person or entity.

     7.3 Disclosure and Use Restriction. Except as expressly provided herein, the Parties agree
that, during the Term and for [***] years thereafter (unless one or more of the exceptions
described in 7.2.1 apply), a Receiving Party and its Affiliates and sublicensees will keep
completely confidential and will not publish or otherwise disclose and will not use for any

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

32

 

purpose except for the purposes contemplated by this Agreement any Confidential Information of
the Disclosing Party, its Affiliates or sublicensees.

     7.4 Authorized Disclosure. A Receiving Party may disclose Confidential Information of a
Disclosing Party to the extent that such disclosure is:

          7.4.1 made in response to a valid order of a court of competent jurisdiction or other
governmental or regulatory body of competent jurisdiction; provided, however, that
the Receiving Party will first have given notice to the Disclosing Party and given the Disclosing
Party a reasonable opportunity to quash such order and to obtain a protective order requiring that
the Confidential Information and documents that are the subject of such order be held in confidence
by such court or governmental or regulatory body or, if disclosed, be used only for the purposes
for which the order was issued; and provided, further, that if a disclosure order
is not quashed or a protective order is not obtained, the Confidential Information disclosed in
response to such court or governmental order will be limited to that information which is legally
required to be disclosed in response to such court or governmental order;

          7.4.2 otherwise required by law or mandatory regulation; provided, however,
that the Disclosing Party will provide the Receiving Party with notice of such disclosure in
advance thereof to the extent practicable;

          7.4.3 made by the Receiving Party to the regulatory authorities as required in connection with
any application, filing, or similar requests for regulatory approvals; provided,
however, that reasonable measures will be taken to assure confidential treatment of such
information;

          7.4.4 made by the Receiving Party, in connection with the performance of this Agreement, to
Affiliates, permitted sublicensees, employees, consultants, representatives or agents, each of whom
prior to disclosure must be bound by obligations of confidentiality and non-use at least equivalent
in scope to those set forth in this Section 7;

          7.4.5 made by the Receiving Party to existing or potential acquirers or merger candidates,
potential collaborators (to the extent contemplated hereunder), investment bankers, existing or
potential investors, venture capital firms or other financial institutions or investors for
purposes of obtaining financing, each of whom prior to disclosure must be bound by obligations of
confidentiality and non-use at least equivalent in scope to those set forth in this Section 7; or

          7.4.6 made by Enzon (as a Receiving Party) to Micromet or made by Micromet (as a Receiving
Party) to Enzon, in each case otherwise in compliance with this Agreement and in performance of the
Micromet/Enzon Collaboration Agreement or any agreement related thereto.

     7.5 Use of Name. No Party will make public use of the other Party’s name except (i) in
connection with announcements and other permitted disclosures relating to this Agreement and the
activities contemplated hereby, (ii) as required by applicable law, and (iii) otherwise as agreed
in writing by such other Party.

     7.6 Press Releases.

33

 

          7.6.1 The Parties will make a joint press release regarding the execution of this Agreement,
the final form of which will be subject to approval of the Parties prior to its release to the
public. For subsequent press releases and other written public disclosures relating to this
Agreement or the Parties’ relationship hereunder (each, a “Proposed Disclosure”), each Party will
use reasonable efforts to submit to the other Party a draft of such Proposed Disclosure for review
and comment by the other Party at least [***] prior to the date on which such Party plans to
release such Proposed Disclosure, and in any event will submit such drafts at least [***] prior to
the release of such Proposed Disclosure, and will review and consider in good faith any comments
provided in response.

          7.6.2 If a Party is unable to comply with the foregoing [***] notice requirement because of a
legal obligation or stock exchange requirement to make more rapid disclosure, such Party will not
be in breach of this Agreement but will in that case give telephone notice to a senior executive of
the other Party and provide a draft disclosure with as much notice as possible prior to the release
of such Proposed Disclosure.

          7.6.3 A Party may publicly disclose without regard to the preceding requirements of this
Section 7.6 information that was previously disclosed in a Proposed Disclosure that was in
compliance with such requirements.

     7.7 Terms of Agreement to be Maintained in Confidence. Subject to the other provisions of
this Section 7 (including the exception for any public disclosures made in compliance with the
terms of Section 7.6), the Parties agree that the terms of this Agreement are confidential and will
not be disclosed by any Party to any Third Party (except to a Party’s professional advisor) without
advance written permission of the other Party; provided, however, that a Party may
make any filings of this Agreement required by law or regulation in any country so long as such
Party uses its reasonable efforts to obtain confidential treatment for portions of this Agreement
as available, consults with the other Party, and permits the other Party to participate, to the
extent practicable, in seeking a protective order or other confidential treatment; and
provided, further, that a Party may disclose the terms of this Agreement to a Third
Party (and its professional advisors) when such disclosure is reasonably necessary in connection
with (i) the grant of a license or sublicense of the licensed Patents to such Third Party, (ii) a
merger, acquisition, placement, investment, or other such transaction with such Third Party, or
(iii) the sale of securities to or other financing from such Third Party or a financing
underwritten by such Third Party, in which case disclosure may be made to any person or entity to
whom such Third Party sells such securities (and its professional advisors). Advance written
permission for disclosure will not be required when a Party is ordered to disclose information
concerning the Agreement by a competent tribunal or such disclosures are required by law,
regulation, or stock exchange rules, except that such Party will make all reasonable efforts to
limit any disclosure as may be required in the course of legal proceedings by entry of an
appropriate protective and confidentiality order, and will provide the other Party with as much
advance notice of such circumstances as is practicable.

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

34

 

8. Term and Termination

     8.1 Term. The term of this Agreement (the “Term”) will commence on the Effective Date and,
unless terminated pursuant to this Section 8, will expire upon the later of the (i) expiration of
the last-to-expire Valid Claim within the Consolidated Patent Portfolio, (ii) expiration of the
last-to-expire Valid Claim within the CAT Licensed Patents, Micromet Supplemental Patents or Enzon
Supplemental Patents or (iii) ten (10) years from first commercial sale of any Antibody Product
(including any SCA Product) which would but for the terms of a Product License Agreement infringe a
Valid Claim of a Patent of a Party or utilize the Know-How of a Party.

     8.2 Termination for Material Breach.

          8.2.1 Any material breach or failure by a Party to comply with any of its obligations
contained herein (including, without limitation any such breach or failure during an Insolvency
Event) will entitle the Party or Parties not in default to give to the Party in default written
notice specifying the nature of the default, requiring the defaulting Party to make good or
otherwise cure such default.

          8.2.2 Subject to Section 8.2.3 below, if, after a Party’s receipt of notice pursuant to
Section 8.2.1 above, such default is not cured within [***] days (or, if such default cannot be
cured within such [***] period, if the Party in default does not commence actions to cure such
default within such [***] period and thereafter diligently continue such actions and cure such
default within [***] days after the receipt of such notice, except in the case of a payment
default, as to which the defaulting Party will have only a [***] cure period), then the Party or
Parties not in default will be entitled, on written notice to the other Party and without prejudice
to any other rights conferred on it by this Agreement or available to it or them by law or in
equity, to terminate this Agreement immediately (solely as to such Party or Parties in default and
their rights and obligations hereunder).

          8.2.3 If a Party receiving a notice pursuant to Section 8.2.1 above, is also at the time of
receiving such notice subject to an Insolvency Event and such default is not cured within [***]
days (except in the case of payment default, as to which the defaulting party will only have a
[***] day cure period), then the Party not in default will be entitled, on written notice to the
other Party and without prejudice to any other rights conferred by this Agreement or available to
it or them by law or in equity, to terminate this Agreement immediately (solely as to such Party or
Parties in default and their rights and obligations hereunder).

     8.3 Relinquishment of License Rights. A Party may relinquish the license rights granted to it
under this Agreement by so providing notice to the other Parties hereto. For such time as there
are at least two parties to this Agreement, this Agreement will continue in full force and effect
(including as to the Party so relinquishing its license rights) except that, (i) all licenses
granted to the relinquishing Party will terminate; and (ii) the
relinquishing Party’s obligations to

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

35

 

pay the maintenance fees set forth in Section 4.2 hereof will terminate upon
the effective date of such relinquishment.

     8.4 Consequences of Expiration and Termination.

          8.4.1 Material Breach. Upon termination of this Agreement by a Party pursuant to Section 8.2
(solely as to such Party not in default and its obligations hereunder), (i) all licenses granted by
the terminating Party to the defaulting Party will terminate (except as provided in Sections 5.7.2
and 8.4.2); (ii) the licenses granted by the defaulting Party will survive (subject to continued
performance by the terminating Party of its payment obligations, if any); and (iii) the Parties
will amend and restate this Agreement to give effect to this Section 8.4.1 and the termination of
such Party’s obligations hereunder and to allow the other Parties to continue performance under
this Agreement, as applicable.

          8.4.2 Survival of Certain Sublicenses. Sublicenses granted by a defaulting Party to a Third
Party will survive termination of the defaulting Party’s license under Section 8.4.1(i);
provided, however, that (x) such Third Party is not the cause of the default, (y)
such Third Party is not in breach of, and continues to fully perform all obligations under, its
sublicense agreement any surviving provisions in this Agreement applicable to such sublicense, and
(z) the terminating Party and any remaining Party hereto continues to receive all license
maintenance payments set forth in Section 4.2.

          8.4.3 Obligations Continue. Expiration or termination of this Agreement for any reason will
not relieve the Parties of any obligation accruing prior to such expiration or termination. The
provisions of Sections 3.4, 3.5, 3.6, 4 (solely as to accrued and unpaid amounts), 5.7.2(a)(ii),
5.7.2(b)(ii), 6.5, 7, 8.4, 9, 10 and 11, together with any definitions used or schedules referenced
therein, will survive termination or expiration of this Agreement.

          8.4.4 Return of Confidential Information. Upon any expiration or termination of this
Agreement, each Party will, at the other Party’s option, promptly return or destroy any of such
other Party’s Confidential Information (including all Know-How) in its possession or control;
provided, however, that each Party may retain: (a) a single archival copy of the
Confidential Information of the other Party solely for the availing itself of the rights accorded
to it, or to perform its obligations, under the surviving provisions of this Agreement (including,
without limitation any and all license or sublicense rights expressly made to survive termination
or expiration hereof); and (b) any portion of the Confidential Information of the other Party which
a Party is required by applicable law to retain.

     8.5 Termination of Enzon Agreements or [***] Agreement.

          8.5.1 Upon termination of the Micromet/Enzon Marketing Agreement granting Micromet rights to
grant licenses to the Consolidated Patent Portfolio, the licenses granted to CAT in this Agreement
under the Consolidated Patent Portfolio will continue in full force and effect; provided,
however, that CAT’s acts or omissions under this Agreement did not cause such

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

36

 

termination; and provided, further, that CAT is not in breach of this
Agreement and continues fully to perform its obligations under this Agreement.

          8.5.2 Upon termination of the [***] Agreement, and upon request by Micromet or Enzon, CAT will
use commercially reasonable efforts to obtain a direct license for Micromet from the [***], its
successors or assigns to any CAT Licensed Patents licensed to CAT under such agreement upon the
terms set forth herein (including, without limitation, pursuant to Section 8.4 of the [***]
Agreement); provided, however, that CAT will have no such obligation to Micromet if
Micromet’s acts or omissions under this Agreement caused such termination of the [***] Agreement or
have no such obligation to Enzon if Enzon’s acts or omissions under this Agreement caused such
termination of the [***] Agreement

9. Indemnification and Insurance

     9.1 Indemnification by CAT. CAT will indemnify Micromet, Enzon, their Affiliates, and their
respective directors, officers, employees and agents, and defend and save each of them harmless,
from and against any and all losses, damages, liabilities, costs and expenses (including reasonable
attorneys’ fees and expenses)(collectively, “Losses”) in connection with any and all liability
suits, investigations, claims or demands by Third Parties (each, a “Third Party Claim”) to the
extent arising out of: (a) any theory of product liability (including, but not limited to, actions
in the form of tort, warranty or strict liability) concerning an Antibody Product that is Exploited
by CAT or its Affiliates pursuant to any right or license granted under this Agreement, or (b) any
failure by any sublicensee of CAT to comply with the obligations of Sections 2.1.4, 5.3, 5.5, 5.7.2
and 7 of this Agreement imposed on such sublicensee pursuant to Section 2.1 of this Agreement, in
each case except to the extent that such Losses arise out of or result from (i) the gross
negligence or reckless misconduct of a party seeking indemnification hereunder, or (ii) a material
breach by a party seeking indemnification hereunder of any provision of this Agreement.

     9.2 Indemnification by Micromet. Micromet will indemnify CAT, its Affiliates, and their
respective directors, officers, employees and agents, and defend and save each of them harmless,
from and against any and all Losses in connection with any and all Third Party Claim to the extent
arising out of: (a) any theory of product liability (including, but not limited to, actions in the
form of tort, warranty or strict liability) concerning an Antibody Product that is Exploited by
Micromet or its Affiliates pursuant to any right or license granted under this Agreement, or (b)
any failure by any sublicensee of Micromet to comply with the obligations of Sections 5.3, 5.6,
5.7.2 and 7 of this Agreement imposed on such sublicensee pursuant to Section 2.2 of this
Agreement, in each case except to the extent that such Losses arise out of or result from (i) the
gross negligence or reckless misconduct of a party seeking indemnification hereunder, or (ii) a
material breach by a party seeking indemnification hereunder of any provision of this Agreement.

     9.3 Indemnification by Enzon. Enzon will indemnify CAT, its Affiliates, and its respective
directors, officers, employees and agents, and defend and save each
of them harmless,

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

37

 

from and against any and all Losses in connection with any and all Third Party Claim
to the extent arising out of: (a) any theory of product liability (including, but not limited to,
actions in the form of tort, warranty or strict liability) concerning an Antibody Product that is
Exploited by Enzon or its Affiliates pursuant to any right or license granted under this Agreement,
or (b) any failure by any sublicensee of Enzon to comply with the obligations of Sections 5.3, 5.6,
5.7.2 and 7 of this Agreement imposed on such sublicensee pursuant to Section 2.2 of this
Agreement, in each case, except to the extent that such Losses arise out of or result from (i) the
gross negligence or reckless misconduct of a party seeking indemnification hereunder, or (ii) a
material breach by a party seeking indemnification hereunder of any provision of this Agreement.

     9.4 Indemnification Procedure.

          9.4.1 Notice of Claim. All indemnification claims in respect of a Party, its Affiliates or
their respective directors, officers, employees and agents (collectively, the “Indemnitees” and
each an “Indemnitee”) will be made solely by such Party to this Agreement (the “Indemnified
Party”). The Indemnified Party will give the indemnifying Party (the “Indemnifying Party”) prompt
written notice (an “Indemnification Claim Notice”) of any Losses or discovery of fact upon which
such Indemnified Party intends to base a request for indemnification under this Section 9, but in
no event will the Indemnifying Party be liable for any Losses that result from any delay in
providing such notice. Each Indemnification Claim Notice must contain a description of the claim
and the nature and amount of such Loss (to the extent that the nature and amount of such Loss are
known at such time). The Indemnified Party will furnish promptly to the Indemnifying Party copies
of all papers and official documents received in respect of any Losses.

          9.4.2 Prosecution of Claims. The obligations of an Indemnifying Party under this Section 9
will be governed by and be contingent upon the following additional terms and conditions:

               (a) Control of Defense.

                    (i) At its option, the Indemnifying Party may assume the defense of any Third Party Claim by
giving written notice to the Indemnified Party within thirty (30) days after the Indemnifying
Party’s receipt of an Indemnification Claim Notice.

                    (ii) Upon assuming the defense of a Third Party Claim, the Indemnifying Party may appoint as
lead counsel in the defense of the Third Party Claim any legal counsel selected by the Indemnifying
Party. In the event the Indemnifying Party assumes the defense of a Third Party Claim, the
Indemnified Party will immediately deliver to the Indemnifying Party all original notices and
documents (including court papers) received by any Indemnitee in connection with the Third Party
Claim. Should the Indemnifying Party assume the defense of a Third Party Claim, the Indemnifying
Party will not be liable to the Indemnified Party or any other Indemnitee for any legal expenses
subsequently incurred by such Indemnified Party or other Indemnitee in connection with the
analysis, defense or settlement of the Third Party Claim.

38

 

               (b) Right to Participate in Defense. Without limiting Section 9.4.2(a), any Indemnitee will
be entitled to participate in, but not control, the defense of such Third Party Claim and to employ
counsel of its choice for such purpose; provided, however, that such employment
will be at the Indemnitee’s own expense unless (i) the employment thereof has been specifically
authorized by the Indemnifying Party in writing, or (ii) the Indemnifying Party has failed to
assume the defense and employ counsel in accordance with Section 9.4.2(a) (in which case the
Indemnified Party will control the defense).

               (c) Settlement. With respect to any Losses relating solely to the payment of money damages in
connection with a Third Party Claim and that will not result in the Indemnitee’s becoming subject
to injunctive or other relief or otherwise adversely affect the business of the Indemnitee in any
manner, and as to which the Indemnifying Party will have acknowledged in writing the obligation to
indemnify the Indemnitee hereunder, the Indemnifying Party will have the sole right to consent to
the entry of any judgment, enter into any settlement or otherwise dispose of such Loss, on such
terms as the Indemnifying Party, in its sole discretion, will deem appropriate, and will transfer
to the Indemnified Party all amounts which said Indemnified Party will be liable to pay prior to
the time prior to the entry of judgment. With respect to all other Losses in connection with Third
Party Claims, where the Indemnifying Party has assumed the defense of the Third Party Claim in
accordance with Section 9.4.2(a), the Indemnifying Party will have authority to consent to the
entry of any judgment, enter into any settlement or otherwise dispose of such Loss provided it
obtains the prior written consent of the Indemnified Party (which consent will be at the
Indemnified Party’s sole and absolute discretion). The Indemnifying Party will not be liable for
any settlement or other disposition of a Loss by an Indemnitee that is reached without the written
consent of the Indemnifying Party. Regardless of whether the Indemnifying Party chooses to defend
or prosecute any Third Party Claim, no Indemnitee will admit any liability with respect to, or
settle, compromise or discharge, any Third Party Claim without the prior written consent of the
Indemnifying Party.

               (d) Cooperation. Regardless of whether the Indemnifying Party chooses to defend or prosecute
any Third Party Claim, the Indemnified Party will, and will cause each other Indemnitee to,
cooperate in the defense or prosecution thereof and will furnish such records, information and
testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings,
trials and appeals as may be reasonably requested in connection therewith. Such cooperation will
include access during normal business hours afforded to the Indemnifying Party to, and reasonable
retention by the Indemnified Party of, records and information that are reasonably relevant to such
Third Party Claim, and making Indemnitees and other employees and agents available on a mutually
convenient basis to provide additional information and explanation of any material provided
hereunder, and the Indemnifying Party will reimburse the Indemnified Party for all its reasonable
out-of-pocket expenses in connection therewith.

     9.5 Expenses. Except as provided above, the reasonable and verifiable costs and expenses,
including fees and disbursements of counsel, incurred by the Indemnified Party in connection with
any claim will be reimbursed on a calendar quarter basis by the Indemnifying Party, without
prejudice to the Indemnifying Party’s right to contest the Indemnified Party’s right to
indemnification and subject to refund in the event the Indemnifying Party is ultimately held not to
be obligated to indemnify the Indemnified Party.

39

 

     9.6 Insurance. During the Term, each Party will have and maintain such types and amounts of
liability insurance as is normal and customary in the industry generally for parties similarly
situated, and will upon request provide the other Party with a copy of its policies of insurance in
that regard, along with any amendments and revisions thereto.

10. Limitation of Liability

     EXCEPT AS PROHIBITED BY APPLICABLE LAW, IN NO EVENT WILL ANY PARTY BE LIABLE TO ANY OTHER
PARTY FOR LOST PROFITS, LOSS OF DATA, OR FOR ANY SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR
PUNITIVE DAMAGES, HOWEVER CAUSED, ON ANY THEORY OF LIABILITY AND WHETHER OR NOT SUCH PARTY HAS BEEN
ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, ARISING UNDER ANY CAUSE OF ACTION AND ARISING IN ANY
WAY OUT OF THIS AGREEMENT. THE FOREGOING LIMITATIONS WILL NOT APPLY TO DAMAGES ARISING FROM A
BREACH OF SECTION 7 ABOVE OR AN AWARD OF ENHANCED DAMAGES AVAILABLE UNDER THE PATENT LAWS FOR
WILLFUL PATENT INFRINGEMENT AND WILL NOT LIMIT ANY PARTY’S INDEMNITY OBLIGATIONS TO ANY OTHER PARTY
UNDER THIS AGREEMENT.

11. Miscellaneous

     11.1 Assignment. Without the prior written consent of each other Party hereto (which such
consent may be granted, withheld or conditioned at such other Party’s sole and absolute
discretion), no Party will sell, transfer, assign, delegate, pledge or otherwise dispose of,
whether voluntarily, involuntarily, by operation of law or otherwise, this Agreement or any of its
rights or duties hereunder; provided, however, that any Party may assign or
transfer this Agreement or any of its rights or obligations hereunder without the consent of the
other Parties:

               (a) to any Affiliate of such Party; provided, further, that

                    (i) such Affiliate may not otherwise sell, transfer, assign, delegate, pledge or otherwise
dispose of, whether voluntarily, involuntarily, by operation of law or otherwise (except pursuant
to any merger, consolidation or asset sale subject to Section 11.1(b) below), this Agreement or any
of its rights or duties hereunder without the prior written consent of the other Parties and such
consent may be granted, withheld or conditioned at either of the other Party’s sole and absolute
discretion; and

                    (ii) that if any such Affiliate is subsequently sold by or otherwise ceases to be an Affiliate
of the relevant Party (except pursuant to any merger, consolidation or asset sale subject to
Section 11.1(b) below) this Agreement must be assigned back to the relevant Party before such sale
or other event becomes effective; or

               (b) to any Third Party with which it merges or consolidates, or to which it transfers all or
substantially all of its assets to which this Agreement relates.

In each case described in this Section 11.1 the relevant Affiliate assignee, Third Party assignee
or surviving entity will assume in writing all of the assigning Party’s obligations under this
Agreement and the assigning Party will promptly provide notice to the other Parties of such

40

 

assignment. The assigning Party (except if it is not the surviving entity) will remain jointly and
severally liable under this Agreement with the relevant Affiliate assignee. Any purported
assignment or transfer in violation of this Section will be void ab initio and of no force or
effect.

     11.2 Severability. If any provision of this Agreement is held to be illegal, invalid or
unenforceable under any present or future law, then (a) such provision will be fully severable, (b)
this Agreement will be construed and enforced as if such illegal, invalid or unenforceable
provision had never comprised a part hereof, (c) the remaining provisions of this Agreement will
remain in full force and effect and will not be affected by the illegal, invalid or unenforceable
provision or by its severance from this Agreement, and (d) the Parties will use good faith efforts
to promptly replace such illegal, invalid or unenforceable provision with a valid and enforceable
provision having similar terms such that the objectives contemplated by the Parties when entering
this Agreement may be realized. To the fullest extent permitted by applicable law, each Party
hereby waives any provision of law that would render any provision prohibited or unenforceable in
any respect.

     11.3 Governing Law; Dispute Resolution.

          11.3.1 This Agreement, all disputes between the Parties related to or arising out of this
Agreement, the Parties’ relationship created hereby, and/or the negotiations for and entry into
this Agreement, including any dispute concerning its conclusion, binding effect, amendment,
coverage, or termination, will be governed by the laws of the State of New York, U.S.A., without
reference to any choice of law principles that would cause the application of the laws of a
different jurisdiction, and will (subject to Section 11.3.2 below) be subject to the non-exclusive
jurisdiction of the courts of competent jurisdiction located in Germany, England, and New York, New
York.

          11.3.2 The Parties will try to settle their differences amicably between themselves. In the
event of any controversy or claim arising out of or relating to any provision of this Agreement or
the performance or alleged non-performance of a Party of its obligations under this Agreement
(“Dispute”), a Party may notify the other Party in writing of such Dispute. If the Parties are
unable to resolve the Dispute within [***] of receipt of the written notice by the other Party,
such dispute will be referred to the [***] who will use their good faith efforts to resolve the
Dispute within [***] after it was referred to the [***]. If the [***] fail to resolve the Dispute,
each Party may pursue its rights and remedies as described in Section 11.3.1 above.
Notwithstanding the foregoing, no Dispute relating to Section 7 will be subject to this Section
11.3.2. In addition, nothing in this Section 11.3.2 will limit either Party’s right to seek
immediate injunctive or other equitable relief whenever the facts or circumstances would permit a
Party to seek such relief in a court of competent jurisdiction.

     11.4 Notices. All notices or other communications that are required or permitted hereunder
will be in writing and delivered personally, sent by facsimile (and promptly confirmed by personal
delivery or overnight courier as provided herein), or sent by internationally-recognized overnight
courier addressed as follows:

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

41

 

     If to Enzon, to:

           Enzon Pharmaceuticals, Inc.

           20 Kingsbridge Road

           Piscataway, New Jersey 08854-3969

          Attention: President

           Facsimile: +1 (732) 980-5911

          with a copy to:

           Kenyon & Kenyon

          One Broadway

           New York, NY 10004-1050

           Attention: Charles A. Weiss, Esq.

          Facsimile: +1 (212) 425-5288

     If to Micromet, to:

           Micromet AG

           Staffelseestrasse 2, 81477

          Munich, Germany

           Attention: Chief Business Officer

           Facsimile: +49 89 895-277 285

           with a copy to:

           Cooley Godward LLP

          One Freedom Square

          Reston Town Center

          11951 Freedom Drive

           Reston, Virginia 20190-5656

          Attention: Matthias Alder, Esq.

          Facsimile: +1 (703) 456-8100

     If to CAT, to:

          Cambridge Antibody Technology Ltd

           Milstein Building, Granta Park

           Cambridgeshire CB1 6GH

           England

           Attention: the Company Secretary

           Facsimile: +44 (0)1223 471472

or to such other address as the Party to whom notice is to be given may have furnished to the other
Party in writing in accordance herewith. Any such communication will be deemed to have been given
(i) when delivered, if personally delivered or sent by facsimile on a Business Day, and (ii) on the
second Business Day after dispatch, if sent by internationally-recognized

42

 

overnight courier. It is understood and agreed that this Section 11.4 is not intended to govern
the day-to-day business communications necessary between the Parties in performing their duties, in
due course, under the terms of this Agreement.

     11.5 Entire Agreement; Modifications.

          11.5.1 Entire Agreement.

               (a) Except as expressly provided otherwise in clauses (b) and (c) below of this Section
11.5.1, this Agreement, together with any schedules attached hereto (each of which is hereby
incorporated herein by reference), sets forth and constitutes the entire agreement and
understanding between the Parties with respect to the subject matter hereof and all prior
agreements, understanding, promises and representations, whether written or oral, with respect
thereto are hereby superceded and of no further force and effect, including without limitation, the
Original Creative BioMolecules License Agreement and the Original Enzon License Agreement.

               (b) In respect of the Original Creative BioMolecules License Agreement, the Parties agree and
acknowledge that: (i) as of the Effective Date, no amounts are due and payable under Sections
4.3.1 and Section 4.3.2 of the Original Creative BioMolecules License Agreement; (ii) Sections 1,
10.3 and 11 (together with all referenced Appendices) of the Original Creative BioMolecules
License Agreement will survive the termination of such agreement hereunder; (iii) Section 3.1 of
the Original Creative BioMolecules License Agreement will survive solely so that CAT may provide
the rights granted under each Existing Product Use Agreement (it being understood that such rights
will survive for each Existing Product Use Agreement solely for the term of such agreement);; (iv)
any and all notices required under the Original Creative BioMolecules License Agreement will be
made pursuant to the terms of Section 11.4 of this Agreement; and (v) to the extent any terms of
the Original Creative BioMolecules License Agreement are amended, modified or waived by the terms
of this Agreement, then the execution of this Agreement shall be deemed an amendment, modification
or waiver of the Original Creative BioMolecules License Agreement solely for such purpose.

               (c) In respect of the Original Enzon License Agreement, the Parties agree and acknowledge that
(i) as of the Effective Date, no amounts are due and payable under Sections 4.2.1 and Section 4.2.2
of the Original Enzon License Agreement; (ii) Sections 1, 10.3 and 11 (together with all
referenced Appendices) of the Original Enzon License Agreement will survive the termination of such
agreement hereunder; (iii) Section 3.1 of the Original Enzon License Agreement will survive solely
so that CAT may provide the rights granted under each Existing Product Use Agreement (it being
understood that such rights will survive for each Existing Product Use Agreement solely for the
term of such agreement);; (iv) any and all notices required under the Original Enzon License
Agreement will be made pursuant to the terms of Section 11.4 of this Agreement; and (v) to the
extent any terms of the Original Enzon License Agreement are amended, modified or waived by the
terms of this Agreement, then the execution of this Agreement shall be deemed an amendment,
modification or waiver of the Enzon License Agreement solely for such purpose.

43

 

               (d) The Parties agree and acknowledge that any Product License Agreement executed pursuant to
the terms of this Agreement will not be integrated or incorporated by reference in this Agreement,
but rather will be a separate and distinct obligation of the parties thereto. Each Party confirms
that it is not relying on any representations or warranties of the other Party except as
specifically set forth herein. For the avoidance of doubt, nothing in this Agreement is intended
to or shall be construed to provide that (i) a representation, covenant or obligation under this
Agreement shall be a representation, covenant or obligation under any other agreement or instrument
executed by the Parties, except as expressly provided otherwise herein, or (ii) a default under
this Agreement shall constitute a default under any other agreement or instrument executed by the
Parties, except as expressly provided otherwise herein.

          11.5.2 Amendment. No amendment or modification of this Agreement will be binding upon the
Parties unless made in writing and duly executed by authorized representatives of each Party
hereto.

     11.6 Relationship of the Parties. It is expressly agreed that the Parties’ relationship under
this Agreement is strictly one of licensor-licensee, and that this Agreement does not create or
constitute a partnership, joint venture, or agency. No Party will have the authority to make any
statements, representations or commitments of any kind, or to take any action, which will be
binding (or purport to be binding) on the other. All persons employed by a Party will be employees
of such Party and not of the other Party and all costs and obligations incurred by reason of any
such employment will be for the account and expense of such Party.

     11.7 Waiver. Any term or condition of this Agreement may be waived at any time by the Party
that is entitled to the benefit thereof, but no such waiver will be effective unless set forth in a
written instrument duly executed by or on behalf of the Party waiving such term or condition. The
waiver by any Party hereto of any right hereunder or of claims based on the failure to perform or a
breach by any other Party will not be deemed a waiver of any other right hereunder or of any other
breach or failure by said other Party or Parties whether of a similar nature or otherwise.

     11.8 Counterparts. This Agreement may be executed in three (3) or more counterparts, each of
which will be deemed an original, but all of which together will constitute one and the same
instrument.

     11.9 No Benefit to Third Parties. The representations, warranties, covenants and agreements
set forth in this Agreement are for the sole benefit of the Parties hereto and their successors and
permitted assigns, and they will not be construed as conferring any rights on any other parties.

     11.10 Further Assurance. Each Party will duly execute and deliver, or cause to be duly
executed and delivered, such further instruments and do and cause to be done such further acts and
things, including the filing of such assignments, agreements, documents and instruments, as may be
necessary or as the other Party or Parties may reasonably request in connection with this Agreement
or to carry out more effectively the provisions and purposes, or to better assure and confirm unto
such other Party or Parties its or their rights and remedies under this Agreement.

44

 

     11.11 English Language. This Agreement has been written and executed in the English language.
Any translation into any other language will not be an official version thereof, and in the event
of any conflict in interpretation between the English version and such translation, the English
version will control.

     11.12 Force Majeure. Neither Party will be deemed to be in breach of this Agreement as a
result of default, delay or failure to perform by such Party that results from any cause beyond the
reasonable control of such Party that could not reasonably be foreseen by such Party, including
without limitation, fire, earthquake, acts of God, acts of war, strikes, lockouts, or other labor
disputes, riots, civil disturbances, actions or inactions of governmental authorities (except
actions in response to a breach of applicable laws by such Party), or epidemics. This Section
11.12 will not operate to excuse payment by a Party of any amounts due to any other Party under
this Agreement. In the event of any such force majeure, the Party affected will promptly notify
the other Party, will use commercially reasonable efforts to overcome such force majeure, and will
keep the other Party informed with respect thereto. If the event of force majeure continues for a
period greater than [***] days, then the unaffected Party may terminate this Agreement immediately
by notice in writing to the affected Party.

     11.13 Construction. Except where the context otherwise requires, wherever used, the singular
will include the plural, the plural the singular, the use of any gender will be applicable to all
genders and the word “or” is used in the inclusive sense (and/or). The captions of this Agreement
are for convenience of reference only and in no way define, describe, extend or limit the scope or
intent of this Agreement or the intent of any provision contained in this Agreement. The term
“including” as used herein means including, without limiting the generality of any description
preceding such term. No rule of strict construction will be applied against any Party hereto.

[Remainder of this page is left blank intentionally. Signature page follows.]

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

45

 

     In Witness Whereof, the Parties have executed this Agreement by their respective
authorized representatives as of the date first written above.

	 	 	 	 	 
	Micromet AG 	 	 
	 
	 	 	 	 
	By:

	 	/s/ Christian Itin
 

Christian Itin, Ph.D
	 	 
	 

	 	Chief Business Officer	 	 
	 
	 	 	 	 
	By:

	 	/s/ G.K. Mirow
 

Name: G.K. Mirow
	 	 
	 

	 	Title: CFO	 	 
	 
	 	 	 	 
	Enzon Pharmaceuticals, Inc.	 	 
	 
	 	 	 	 
	By: 

Name:

	 	/s/ Arthur Higgins
 

Arthur Higgins
	 	 
	 
	Title:

	 	Chairman & CEO	 	 
	 
	 	 	 	 
	Cambridge Antibody Technology Limited	 	 
	 
	 	 	 	 
	By: 

Name:

	 	/s/ Diane Mellett
 

Diane Mellett
	 	 
	 
	Title:

	 	General Counsel	 	 

[Signature Page to the Research Cross-License Agreement]

 

 

SCHEDULE I

Consolidated Patent Portfolio

	 	 	 	 	 	 	 	 	 	 	 	 	 
	Application	 	Application	 	 	 	 	 	 	 	Patent	 	Date of
	Number	 	Filing Date	 	Country	 	Title of Application	 	Status	 	Number	 	Grant
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

 

 

	 	 	 	 	 	 	 	 	 	 	 	 	 
	Application	 	Application	 	 	 	 	 	 	 	Patent	 	Date of
	Number	 	Filing Date	 	Country	 	Title of Application	 	Status	 	Number	 	Grant
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

2

 

	 	 	 	 	 	 	 	 	 	 	 	 	 
	Application	 	Application	 	 	 	 	 	 	 	Patent	 	Date of
	Number	 	Filing Date	 	Country	 	Title of Application	 	Status	 	Number	 	Grant
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

3

 

	 	 	 	 	 	 	 	 	 	 	 	 	 
	Application	 	Application	 	 	 	 	 	 	 	Patent	 	Date of
	Number	 	Filing Date	 	Country	 	Title of Application	 	Status	 	Number	 	Grant
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 
	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]	 	 	 	 

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

4

 

Targeted Multifunctional Proteins

POLYPEPTIDE LINKERS FOR PRODUCTION OF BIOSYNTHETIC PROTEINS

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Patent /	 	 	 	 
	Country	 	Application #	 	Filed	 	Publication #	 	Inventors	 	Title
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	 	 	[***]
	 	[***]
	 	[***]	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

5

 

BIOSYNTHETIC ANTIBODY BINDING SITES/

GENETICALLY ENGINEERED ANTIBODY ANALOGUES AND FUSION PROTEINS THEREOF

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Patent /	 	 	 	 
	Country	 	Filed	 	Application #	 	Publication #	 	Inventors	 	Title
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

6

 

[***]

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Patent /	 	 	 	 
	Country	 	Filed	 	Application #	 	Publication #	 	Inventors	 	Title
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]

 

			
	**	 	The license rights granted under this Agreement do not apply to claims relating to those
antibodies of specific sequences binding to [***], which antibodies are described or disclosed in
the above-described Patents, and such claims are excluded from the definition of the Consolidated
Patent Portfolio.

[***]

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Patent /	 	 	 	 
	Country	 	Filed	 	Application #	 	Publication #	 	Inventors	 	Title
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	 	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

7

 

[***]

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Patent /	 	 	 	 
	Country	 	Filed	 	Application #	 	Publication #	 	Inventors	 	Title
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

8

 

SCHEDULE II

CAT Licensed Patents

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	[***]

 

			
	*	 	Patents in opposition proceedings.
	 
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

 

 

SCHEDULE III

CAT Field Limitations

The licenses granted by Micromet to CAT will not include any rights with respect to the following:

[***].

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

 

 

SCHEDULE IV

Excluded Field

“Excluded Field” means:

the discovery, isolation, characterization, research, development, and/or commercialization of an
Antibody useful for the diagnosis, treatment and/or prevention of one or more of the following
disease conditions wherein the primary scientific rationale or activity is [***]n:

	 	 	 
	i.

	 	[***]
	ii.

	 	[***];
	iii.

	 	[***],
	iv.

	 	[***]
	v.

	 	[***]; and/or
	vi.

	 	[***],

provided, however, that for the purpose of this Agreement the term “Excluded Field”
will not include the diagnosis, treatment and/or prevention of the above disease conditions caused
by [***].

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

 

 

SCHEDULE V

Gatekeeping Criteria

     For
each [***] submitted by a
[***] (which must be
accompanied by a [***], the [***]:

     1. the
[***]has either (a) [***] that would [***] in respect of
such [***] or (b) is [***]; or

     2. the
[***], at the date of submission of the [***] by a [***],
engaged in [***] concerning the [***]; or

     3. the
[***] has been, for at least [***], prior to the date of
[***] by a [***] (as can be measured by reliable and verifiable means),
engaged in [***] with respect to such a [***].

     For
the avoidance of doubt, the [***] will not subject any [***]
unless and until the [***] supplies the [***] which [***].

     Where the
[***] supplies the [***] with an
[***] and that
[***] is subjected to [***] described in [***],
then both Parties will be [***] in respect of such
an [***]. If either Party subsequently discovers that the
[***] had been [***] then the
[***] will submit a new [***] for the correctly identified [***],
with the effect that an additional [***]; provided,
however, that such [***] was attributable to the fault of the
Requesting Party. If a [***] will be [***] and the
[***] will be [***]. Any [***].

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

 

 

SCHEDULE VI

CAT Background Know-How

[***].

[***]:

[***]

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

 

 

SCHEDULE VII

Consolidated Know-How

[***].

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

 

 

SCHEDULE VIII

Excluded Technology

“Micromet-Enzon Excluded Technology” means:

	1.	 	“[***],” meaning the technology claimed in the following Patents to which CAT has sole right,
title and interest: (a) [***]; (b) [***];
	 
	2.	 	“[***],” meaning solely those Antibodies which bind to and [***] and in which an Antibody
binding region is involved in said [***];
	 
	3.	 	“Research Products,” meaning those certain research products for which CAT has granted
certain exclusive rights to a Third Party under the [***] License Agreement, as may then be in
effect; and
	 
	4.	 	“[***],” meaning any Antibody [***] for the purpose of simultaneously detecting and/or
measuring [***] whereby that product:

	 	(a)	 	contains or comprises:

(i) an [***] of [***] Antibodies of different [***] (excluding
Antibodies serving a purpose as controls), or

(ii) an [***] of [***] Antibodies of the same [***], provided that
such Antibody is used to [***] data points for the purpose of [***]
(excluding Antibodies serving a purpose as controls), and

	 	(b)	 	contains or comprises [***], and
	 
	 	(c)	 	is in a format where the [***], and
	 
	 	(d)	 	employs any type of [***], and
	 
	 	(e)	 	may be used [***] (as appropriate), and
	 
	 	(f)	 	is not, by way of example, (i) any type [***] assay.

“CAT Excluded Technology” means:

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

1

 

	1.	 	BiTE Products;
	 
	2.	 	Microarrays, as defined above in this Schedule; and
	 
	3.	 	any research and development activities employing any technology, other than Phage Display or
Ribosome Display, that changes the [***].

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

2

 

SCHEDULE IX

Form of Product License Agreement

(CAT as Licensor)

(separately
filed)

1

 

SCHEDULE X

Form of Product License Agreement

(Micromet as Licensor)

(separately
filed)

 

 

SCHEDULE XI

Currently Pending Conflict Cases within the Consolidated Patent Portfolio

Micromet Owned:

[***]

Micromet-licensed (from Enzon):

[***]

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

1

 

SCHEDULE XII

CAT Third Party Claims

[***]

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

 

 

SCHEDULE XIII

Existing Product Use Agreement

	 	 	 
	Licensee	 	Effective Date of Library License
	[***]

	 	[***]
	 
	 	 
	[***]

	 	[***]
	 
	 	 
	[***]

	 	[***]
	 
	 	 
	[***]

	 	[***]
	 
	 	 
	[***]

	 	[***]
	 
	 	 
	[***]

	 	[***]

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

 

 

Table Of Contents

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Page	 
	1.	 	DEFINITIONS	 	 	2	 
	 
	 	 	 	 	 	 	 	 
	2.	 	GRANT OF LICENSE	 	 	8	 
	 
	 	 	 	 	 	 	 	 
	 
	 	2.1	 	Licenses Grant By Micromet	 	 	8	 
	 
	 	 	 	 	 	 	 	 
	 
	 	2.2	 	Research License Grant By CAT	 	 	10	 
	 
	 	 	 	 	 	 	 	 
	 
	 	2.3	 	Know-How Transfer	 	 	13	 
	 
	 	 	 	 	 	 	 	 
	3.	 	TARGET SELECTION	 	 	14	 
	 
	 	 	 	 	 	 	 	 
	 
	 	3.1	 	Identification and Allocation of Targets	 	 	14	 
	 
	 	 	 	 	 	 	 	 
	 
	 	3.2	 	Notice and Selection Procedures	 	 	15	 
	 
	 	 	 	 	 	 	 	 
	 
	 	3.3	 	Product License Agreement	 	 	17	 
	 
	 	 	 	 	 	 	 	 
	 
	 	3.4	 	Records Retention	 	 	18	 
	 
	 	 	 	 	 	 	 	 
	 
	 	3.5	 	Financial Records, Audit	 	 	18	 
	 
	 	 	 	 	 	 	 	 
	 
	 	3.6	 	Confidentiality	 	 	18	 
	 
	 	 	 	 	 	 	 	 
	 
	 	3.7	 	Gatekeeping Disputes and Remedies	 	 	19	 
	 
	 	 	 	 	 	 	 	 
	4.	 	PAYMENTS; ANNUAL REPORT	 	 	20	 
	 
	 	 	 	 	 	 	 	 
	 
	 	4.1	 	Upfront License Fees	 	 	20	 
	 
	 	 	 	 	 	 	 	 
	 
	 	4.2	 	License Maintenance Fees	 	 	21	 
	 
	 	 	 	 	 	 	 	 
	 
	 	4.3	 	Payment	 	 	22	 
	 
	 	 	 	 	 	 	 	 
	 
	 	4.4	 	Annual Report	 	 	22	 
	 
	 	 	 	 	 	 	 	 
	 
	 	4.5	 	Withholdings	 	 	22	 
	 
	 	 	 	 	 	 	 	 
	5.	 	FILING, PROSECUTION, MAINTENANCE OF PATENT RIGHTS; IMPROVEMENTS	 	 	24	 
	 
	 	 	 	 	 	 	 	 
	 
	 	5.1	 	Responsibilities	 	 	24	 
	 
	 	 	 	 	 	 	 	 
	 
	 	5.2	 	Costs	 	 	24	 
	 
	 	 	 	 	 	 	 	 
	 
	 	5.3	 	Notice	 	 	24	 
	 
	 	 	 	 	 	 	 	 
	 
	 	5.4	 	Enforcement	 	 	24	 
	 
	 	 	 	 	 	 	 	 
	 
	 	5.5	 	Patent Challenges by CAT	 	 	25	 
	 
	 	 	 	 	 	 	 	 
	 
	 	5.6	 	Patent Challenges by Micromet or Enzon	 	 	25	 
	 
	 	 	 	 	 	 	 	 
	 
	 	5.7	 	Improvements	 	 	26	 
	 
	 	 	 	 	 	 	 	 
	6.	 	REPRESENTATION AND WARRANTIES; COVENANTS	 	 	28	 
	 
	 	 	 	 	 	 	 	 
	 
	 	6.1	 	Representations of Micromet	 	 	28	 

-i-

 

Table Of Contents

(CONTINUED)

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Page	 
	 
	 	6.2	 	Representations of CAT	 	 	29	 
	 
	 	 	 	 	 	 	 	 
	 
	 	6.3	 	Reciprocal Representations and Warranties	 	 	29	 
	 
	 	 	 	 	 	 	 	 
	 
	 	6.4	 	Additional Covenants	 	 	29	 
	 
	 	 	 	 	 	 	 	 
	 
	 	6.5	 	DISCLAIMER OF WARRANTY	 	 	30	 
	 
	 	 	 	 	 	 	 	 
	7.	 	CONFIDENTIALITY	 	 	30	 
	 
	 	 	 	 	 	 	 	 
	 
	 	7.1	 	Definition	 	 	30	 
	 
	 	 	 	 	 	 	 	 
	 
	 	7.2	 	Exclusions	 	 	30	 
	 
	 	 	 	 	 	 	 	 
	 
	 	7.3	 	Disclosure and Use Restriction	 	 	31	 
	 
	 	 	 	 	 	 	 	 
	 
	 	7.4	 	Authorized Disclosure	 	 	31	 
	 
	 	 	 	 	 	 	 	 
	 
	 	7.5	 	Use of Name	 	 	32	 
	 
	 	 	 	 	 	 	 	 
	 
	 	7.6	 	Press Releases	 	 	32	 
	 
	 	 	 	 	 	 	 	 
	 
	 	7.7	 	Terms of Agreement to be Maintained in Confidence	 	 	33	 
	 
	 	 	 	 	 	 	 	 
	8.	 	TERM AND TERMINATION	 	 	33	 
	 
	 	 	 	 	 	 	 	 
	 
	 	8.1	 	Term	 	 	33	 
	 
	 	 	 	 	 	 	 	 
	 
	 	8.2	 	Termination for Material Breach	 	 	33	 
	 
	 	 	 	 	 	 	 	 
	 
	 	8.3	 	Relinquishment of License Rights	 	 	34	 
	 
	 	 	 	 	 	 	 	 
	 
	 	8.4	 	Consequences of Expiration and Termination	 	 	34	 
	 
	 	 	 	 	 	 	 	 
	 
	 	8.5	 	Termination of Enzon Agreements or [***] Agreement	 	 	35	 
	 
	 	 	 	 	 	 	 	 
	9.	 	INDEMNIFICATION AND INSURANCE	 	 	35	 
	 
	 	 	 	 	 	 	 	 
	 
	 	9.1	 	Indemnification by CAT	 	 	35	 
	 
	 	 	 	 	 	 	 	 
	 
	 	9.2	 	Indemnification by Micromet	 	 	36	 
	 
	 	 	 	 	 	 	 	 
	 
	 	9.3	 	Indemnification by Enzon	 	 	36	 
	 
	 	 	 	 	 	 	 	 
	 
	 	9.4	 	Indemnification Procedure	 	 	36	 
	 
	 	 	 	 	 	 	 	 
	 
	 	9.5	 	Expenses	 	 	38	 
	 
	 	 	 	 	 	 	 	 
	 
	 	9.6	 	Insurance	 	 	38	 
	 
	 	 	 	 	 	 	 	 
	10.	 	LIMITATION OF LIABILITY	 	 	38	 
	 
	 	 	 	 	 	 	 	 
	11.	 	MISCELLANEOUS	 	 	38	 
	 
	 	 	 	 	 	 	 	 
	 
	 	11.1	 	Assignment	 	 	38	 
	 
	 	 	 	 	 	 	 	 
	 
	 	11.2	 	Severability	 	 	39	 
	 
	 	 	 	 	 	 	 	 
	 
	 	11.3	 	Governing Law; Dispute Resolution	 	 	39	 

 

	[***] 	 	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

-ii-

 

Table Of Contents

(CONTINUED)

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Page	 
	 
	 	11.4	 	Notices	 	 	40	 
	 
	 	 	 	 	 	 	 	 
	 
	 	11.5	 	Entire Agreement; Modifications	 	 	41	 
	 
	 	 	 	 	 	 	 	 
	 
	 	11.6	 	Relationship of the Parties	 	 	42	 
	 
	 	 	 	 	 	 	 	 
	 
	 	11.7	 	Waiver	 	 	42	 
	 
	 	 	 	 	 	 	 	 
	 
	 	11.8	 	Counterparts	 	 	43	 
	 
	 	 	 	 	 	 	 	 
	 
	 	11.9	 	No Benefit to Third Parties	 	 	43	 
	 
	 	 	 	 	 	 	 	 
	 
	 	11.10	 	Further Assurance	 	 	43	 
	 
	 	 	 	 	 	 	 	 
	 
	 	11.11	 	English Language	 	 	43	 
	 
	 	 	 	 	 	 	 	 
	 
	 	11.12	 	Force Majeure	 	 	43	 
	 
	 	 	 	 	 	 	 	 
	 
	 	11.13	 	Construction	 	 	43	 

-iii-

 

Exhibit 10.36

***Text Omitted and Filed Separately

Confidential Treatment Requested

Under 17 C.F.R. §§ 200.80(b)(4) and 240.24b-2

AMENDMENT

TO

RESEARCH CROSS-LICENSE AGREEMENT

     This Amendment (the “Amendment”) is made as of this 17th day of March, 2005 by and
among Micromet AG, located at Staffelseestrasse 2, D-81477, Munich, Germany (“Micromet”),
Enzon Pharmaceuticals, Inc., located at 685 Route 202/206, Bridgewater, New Jersey 08807,
USA (“Enzon”), and Cambridge Antibody Technology Limited, located at The Milstein
Building, Granta Park, Cambridgeshire CB1 6GH, England (“CAT”) (each of Micromet, Enzon, and CAT, a
“Party” and, collectively, the “Parties”).

Recitals

     A. The Parties have entered into that certain Research Cross-License Agreement, dated as of
September 3, 2003 (the “Agreement”), pursuant to which the Parties have granted certain
intellectual property licenses for the purposes described therein. Capitalized terms used herein
without definition shall have the meanings given to such terms in the Agreement.

     B. The Parties desire to amend the Agreement in order to: (i) include an additional licensed
patent of Enzon thereunder; (ii) reallocate the product options available to Micromet and Enzon
thereunder; (iii) confirm the Excluded Field has ceased to apply; and (iv) restructure timing of
the annual sublicense maintenance fee payable.

Agreement

     Now, Therefore, and in consideration of the mutual promises and covenants set forth
herein and for other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the Parties hereby agree as follows:

     1. Amendment to Section 1.14. The Parties hereby agree to amend Section 1.14 of the Agreement
by appending the following at the end of such Section:

Notwithstanding anything to the contrary in this Agreement, and subject to the
exclusions described in the preceding clauses (A) and (B), the “CAT Research Field”
with respect to the use or practice of inventions claimed in the PEC Patent will be
further restricted to the manufacture, use and sale of Single Chain Antibodies only
(not Antibody Products generally) for the prognosis, diagnosis, prophylaxis or
treatment of human diseases or conditions.

     2. Addition of Section 1.66. The Parties hereby agree to append the following at the end of
Section 1 as new Section 1.66:

1.

 

1.66 “PEC Patent” means [***].

     3. Amendment to Sections 2.1.3(b), 2.2.2(b) and 2.2.3(b). The Parties hereby agree to amend
Sections 2.1.3(b), 2.2.2(b), and 2.2.3(b) of the Agreement, in each case by replacing the words
“within [***] days of each anniversary” with the words “[***] of each calendar year in which an
anniversary occurs.”

     4. Amendment to Section 3.1.2. The Parties hereby agree to amend Section 3.1.2 of the
Agreement by replacing the words “[***] Nominated Targets” with the words “[***] Nominated Targets
(which number results from Micromet’s original allocation of [***], the re-allocation of altogether
[***] Nominated Targets pursuant to an amendment of this Agreement, and selection, as of November
3, 2003, of one Nominated Target).”

     5. Amendment to Section 3.1.3. The Parties hereby agree to amend Section 3.1.3 of the
Agreement by replacing the words “[***]” with the words “[***].”

     6. Amendment to Section 3.1.4. The Parties hereby agree to amend Section 3.1.4 of the
Agreement by replacing the words “[***]” with the words “[***].”

     7. Amendment to Schedule I. The Parties hereby agree to amend Schedule I of the Agreement by
appending the following at the end of such Schedule: “[***] The rights granted to such patent
under this Agreement are solely in the field of manufacture, use or sale of Single Chain
Antibodies.”

     8. Expiration of Excluded Field. The Parties acknowledge and agree that, effective as of 22
February, 2004, CAT has ceased to be bound by the Excluded Field restriction pursuant to its
agreement with [***] and, consequently, pursuant to the terms of Section 2.2.4 of the Agreement,
any restrictions set forth in the Agreement relating to the Excluded Field ceased to apply as of 22
February, 2004.

     9. Execution of Micromet or Enzon Product License Agreement. The Parties agree, prior to
executing any Product License Agreement (as defined in the Agreement) under which Micromet or Enzon
is to receive a license from CAT, to update the applicable form agreement attached to the Agreement
as Schedule IX to remove the restrictions relating to the Excluded Field described in the preceding
paragraph of this Amendment.

     10. Execution of CAT Product License Agreement. The Parties agree, prior to executing any
Product License Agreement (as defined in the Agreement) under which CAT is to receive a license
from Micromet, to update the applicable form agreement attached to the Agreement as Schedule X to
include a sublicense under [***] “in the field of manufacture, use or sale” of the applicable
Licensed Product.

     11. Warranty and Indemnity. Notwithstanding anything to the contrary in this Agreement, Enzon
warrants to CAT that (i) Enzon’s intent hereunder is to provide Micromet and CAT hereunder the same
rights under the PEC Patent as they would have received had the

 

			
	*** 	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

2.

 

license to the PEC Patent been
included under the Agreement as of 3 September 2003 as part of the Consolidated Patent Portfolio
(and as had always been intended by the parties at that time); and (ii) Enzon has not granted any
license to any party which would conflict with this provision or the Agreement.

     12. Counterparts. This Amendment may be executed in two or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same
instrument.

     13. Effectiveness. This Amendment shall become effective upon the execution hereof by both
Parties.

     14. Continuing Effect. Other than as set forth in this Amendment, all of the terms and
conditions of the Agreement shall continue in full force and effect.

     In Witness Whereof, the parties have executed this Amendment to Research
Cross-License Agreement as of the date first written above.

	 	 	 
	Micromet AG

	 	Enzon Pharmaceuticals, Inc.
	 
	 	 
	By: /s/ Christian Itin

	 	By: /s/ Jeffrey H. Buchalter
	 
	 	 
	Name: Christian Itin

	 	Name: Jeffrey H. Buchalter
	 
	 	 
	Title: CEO

	 	Title: Chairman, President & CEO

Cambridge Antibody Technology Lmited

By: /s/ Alasdair Moodie

Name: Alasdair Moodie

Title: Assistant General Counsel

3.exv10w37

 

Exhibit 10.37

***Text Omitted and Filed Separately

Confidential Treatment Requested

Under 17 C.F.R. §§ 200.80(b)(4) and 240.24b-2

Non-Exclusive Product License Agreement

     This Non-Exclusive Product License Agreement (“Agreement”) is made and entered into
effective as of September 3, 2003 (the “Effective Date”), by and between Cambridge Antibody
Technology Limited, having its principal offices at The Milstein Building, Granta
Park, Cambridgeshire CB1 6GH, England (“CAT”), and Micromet AG, having its
principal offices at Staffelseestrasse 2, 81477 Munich, Germany (“Micromet”). CAT and Micromet
each may be referred to herein individually as a “Party,” or collectively as the “Parties.”

     Whereas, CAT is the owner of (or licensee of) certain patents and know-how in the
field of Antibody Phage Display and is authorised to grant the licenses and other rights to
Licensee pursuant to the terms of this Agreement;

     Whereas, Micromet is developing the MT201 Product (defined below) and desires to
commercially develop the MT201 Product for the treatment of human diseases or conditions using the
CAT Licensed Patents (defined below) and pursuant to the terms and conditions set forth in this
Agreement and furthermore owns or controls certain patents that have claims relating to Phage
Display; and

     Whereas, CAT desires to grant a license to Micromet on a non-exclusive basis of the
right to use the CAT Licensed Patents for the purpose of researching, developing and
commercializing the MT201 Product and other products in respect of the EpCAM target.

     Now, Therefore, in consideration of the premises and the mutual covenants and
agreements herein contained, the Parties agree as follows:

1. Definitions

     When used in this Agreement, capitalized terms will have the meanings as defined below and
throughout the Agreement.

     1.1 “Affiliate” means a legal entity that, directly or indirectly, through one or
more intermediaries, controls, is controlled by, or is under common control with a Party. For
purposes of this definition only, “control” and, with correlative meanings, the terms “controlled
by” and “under common control with” means (a) the possession, directly or indirectly, of the power
to direct the management or policies of a legal entity, whether through the ownership of voting
securities or by contract relating to voting rights or corporate governance, or (b) the ownership,
directly or indirectly, of more than 50% of the voting securities or other ownership interest of a
legal entity; provided that, if local law restricts foreign ownership, control will be established
by direct or indirect ownership of the maximum ownership percentage that may, under such local law,
be owned by foreign interests.

 

 

     1.2 “Antibody” means a molecule or gene encoding such a molecule comprising or
containing more than one immunoglobulin variable domain or parts of such domain or any existing or
future fragments, variants, modifications or derivatives thereof.

     1.3  “Antibody Product” means any composition or formulation containing or comprising
one or more Antibodies in any format for the prognosis, diagnosis, prophylaxis or treatment of
human diseases or conditions or for use as a research reagent.

     1.4  “Antigen” means any structure, including an entire protein, post-translational
modifications, lipids, or glyco-lipids, for which Antibody variable domains have binding affinity.

     1.5  “BiTE Product” means any composition or formulation containing or comprising a
bi-specific Single Chain Antibody, wherein one arm of the Single Chain Antibody binds to T-cells.

     1.6  “Business Day” means any day (other than a Saturday or Sunday) upon which major
commercial banks are open for business in the cities of London and Munich.

     1.7  “CAT Background Know-How” means the Know-How Controlled by CAT relating to the
CAT Licensed Patents and described in Schedule II, which the Parties may amend from time to
time at their sole discretion in accordance with Section 2.5.

     1.8  “CAT Licensed Patents” means (a) those Patents identified in Schedule I,
and (b) any Patents that claim or cover any CAT Phage Display Improvements and that are selected by
Micromet for inclusion pursuant to Section 9.2.

     1.9  “CAT Phage Display Improvements” means any Improvement of a Phage Display
process or any other technology, process, or methodology (each as claimed in or covered by either
of the CAT Licensed Patents or CAT Background Know-How) that satisfies all of the following
criteria: (a) is first conceived or reduced to practice within [***] of the Effective Date;
provided, however, that upon the request of Micromet at any time during the [***]
period following the date that is [***] from the Effective Date and upon demonstration by Micromet
of good commercial, technical, or legal reasons for extension of the foregoing [***] period, the
Parties agree to negotiate in good faith the potential extension of such period for one (1)
additional[***] period, with the consent by CAT to such extension not to be withheld absent
demonstration of good commercial, technical, or legal reasons for opposing such extension; and (b)
is developed by or on behalf of CAT or its Affiliates; provided, however, that the
foregoing will exclude in respect of CAT only any such improvement, modification or adaptation to
the extent that CAT is not permitted to disclose, license or sublicense such improvement,
modification or adaptation as a result of an obligation of CAT to a Third Party.

     1.10  “Combination Product” means any product manufactured or sold by or on behalf of
Micromet in the Micromet Licensed Field which contains a Licensed Product and one or more other
[***].

     1.11  “Controlled” or “Controls” means, with respect to any Know-How, Patent, or
other intellectual property right, possession of the right, whether directly or indirectly, and
whether by ownership, license or otherwise, to assign, or grant a license, sublicense or other
right

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

2

 

to or under, such Know-How, Patent or right
as provided for herein without violating the
terms of any agreement or other arrangements with any Third Party.

     1.12  “Development” means any development work carried out on a Lead directed towards
eventual commercialization of such Lead as an Antibody Product.

     1.13  “Diagnostic Licensed Product” means any Licensed Product (including a
composition, formulation, device, assay or other product, but excluding Microarrays (as defined in
Schedule V)) (a) for sale as an in vitro or in vivo diagnostic for use in or in relation to
humans, or (b) for sale separately from but in support of a therapeutic product for use in or in
relation to humans.

     1.14  “Dossier” means a written summary setting forth a brief description of the
proposed use, application or clinical indication of a particular product composition or formulation
(including the MT201 Product) applicable to the EpCAM Target Program and its origin, amino acid
sequence, nucleotide sequence and Genbank or other accession number (if available);
provided, however, that the foregoing will exclude any information that is subject
to an obligation of confidentiality between Micromet and a Third Party.

     1.15  “EpCAM Target” means the whole or part of the human epithelial cell adhesion
molecule EpCAM identified by the SWISS-PROT entry name TTD1_HUMAN and accession number P16422 with
the amino acid sequence as set out in Schedule III which is specifically recognized by an
Antibody binding to the foregoing.

     1.16  “EpCAM Target Program” means (a) the discovery of Antibodies binding to the
EpCAM Target by practising inventions claimed in any CAT Licensed Patents or utilizing the CAT
Background Know-How; and (b) development of Antibody Products binding to the EpCAM Target by
practising inventions claimed in any CAT Licensed Patents or utilizing the CAT Background Know-How.

     1.17  “Excluded Field” means the field of research and development as set out in
Schedule IV.

     1.18  “Excluded Technology” means the applications and technologies as set out in
Schedule V.

     1.19  “Exploit” or “Exploitation” means to make, have made, import, export, use,
sell, offer for sale, or otherwise dispose of a product, including all discovery, research,
development, registration, modification, enhancement, improvement, manufacture, storage,
formulation, exportation, transportation, distribution, promotion and marketing activities related
thereto.

     1.20  “FDA” means the United States Food and Drug Administration, or any successor
agency thereto having the administrative authority to regulate the marketing of human
pharmaceutical products or biological therapeutic products, delivery systems and devices in the
United States of America.

     1.21  “Gatekeeping Procedure” means the process by which [***] whether, with
respect to a  [***], prior to a  [***], (a) such

 

	[***] 	 	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

3

 

[***] or which [***] or (b) [***].

     1.22  “Improvement” means any improvement, modification or adaptation of any
technology, process or methodology each as claimed in or covered by either of the CAT Licensed
Patents or CAT Background Know-How, as applicable, which may be developed by or on behalf of a
Party, its sublicensees or its Affiliates during the Term.

     1.23  “Insolvency Event” means, except for the event of a solvent reorganization or
amalgamation, (i) the filing by a Party in court or agency pursuant to any applicable statute or
regulation of any state or country, a petition in bankruptcy or insolvency or for reorganization or
for an arrangement or for the appointment of a receiver or trustee of a Party or of its assets, or
(ii) the filing by a Third Party against a Party of an involuntary petition in bankruptcy or
seeking reorganization, liquidation, dissolution, winding up arrangement, composition or
readjustment of such Party’s debts or any other relief under any bankruptcy, insolvency,
reorganization or other similar act or law of any jurisdiction now or hereafter in effect, or the
issuance of a warrant of attachment, execution or similar process against a Party, and, in each
case, only if the applicable petition, warrant of attachment, execution or similar process is not
dismissed within ninety (90) days after the filing thereof, or (iii) if any Party proposes or is a
Party to any dissolution or liquidation under applicable law, or makes an assignment for the
benefit of creditors.

     1.24  “Know-How” means all non-public inventions, data, information, methods,
procedures, processes and materials, including but not limited to, biological, chemical,
biochemical, toxicological, pharmacological, metabolic, formulation, clinical, analytical and
stability information and data (other than such Know-How which is or becomes the subject of a
patent or of a provisional or filed patent application or which otherwise becomes public).

     1.25  “Lead” means an Antibody that is selected from a pool of Antibodies against the
EpCAM Target and that has been generated by Phage Display, in relation to which a Party carries out
further development including, but not limited to, lead optimization.

     1.26  “Licensed Product” means (a) the MT201 Product and (b) any other product,
substance or formulation arising from the EpCAM Target Program, in each case, the Development,
manufacture, importation, use or sale of which (i) would, but for the provisions of this Agreement,
infringe one or more Valid Claims under the CAT Licensed Patents, or (ii) utilizes the CAT
Background Know-How.

     1.27  “MAA” means a marketing approval application filed with the European Medicines
Evaluation Agency or a Biologics License Application filed with the FDA, and any corresponding
applications in other countries or territories.

     1.28  “Major Market Country” means the [***].

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

4

 

     1.29  “Marketing Approval” means the approval of an MAA for a Licensed Product and
any pricing and reimbursement approvals to the extent the applicable Regulatory Authorities in a
country require a pricing or reimbursement approval prior to the marketing and sale of such
Licensed Product in such country.

     1.30  “Micromet Licensed Field” means the prognosis, diagnosis, prophylaxis or
treatment of human diseases or conditions by modulation of the EpCAM Target; provided,
however, that the foregoing will exclude the Excluded Field.

     1.31  “Micromet MT201 Patents” means the following Patents owned as of the Effective
Date by Micromet: [***].

     1.32  “Micromet Phage Display Improvement” means any Improvement of a Phage Display
process or any other technology, process, or methodology that is developed by or on behalf of
Micromet, its Affiliates or sublicensees and that satisfies all of the following criteria: (a) is
first reduced to practice, or described in a patent application, publication, or abstract within
[***] after the Effective Date; provided, however, that upon the request of CAT at
any time during the [***] period following the date that is [***] from the Effective Date and upon
demonstration by CAT of good commercial, technical, or legal reasons for extension of the foregoing
[***] period, the Parties agree to negotiate in good faith the potential extension of such period
for one (1) additional[***] period, with the consent by Micromet to such extension not to be
withheld absent demonstration of good commercial, technical, or legal reasons for opposing such
extension; (b) may not lawfully be Exploited without a license to one or more Valid Claims within
the CAT Licensed Patents; (c) is not a human therapeutic or diagnostic product, a manufacturing
method applicable to that product, or a method of using that product; (d) is not claimed in or
covered by any Patent Controlled by Micromet and is not an improvement, modification or adaptation
of any such invention; and (e) does not relate to any BiTE Product.

     1.33  “Micromet Research Field” means the identification or development of Antibody
Products for the prognosis, diagnosis, prophylaxis or treatment of human diseases or conditions by
modulation of the EpCAM Target; provided, however, that the foregoing will exclude
any research and development activities (a) in the Excluded Field, or (b) that involve
administration of any composition or formulation of Antibodies to humans.

     1.34  “[***] Agreement” means that certain license agreement by and between [***]
[***] and CAT dated as of [***], as may be then in effect, pursuant to which CAT is the exclusive
licensee of certain of the CAT Licensed Patents and certain other Know-How related thereto.

     1.35  “MT201 Product” means a human Antibody developed by Micromet binding to the
EpCAM Target, as described in further detail in the Dossier to be submitted by Micromet to CAT
pursuant to Section 3.1.2.

     1.36  “Net Sales” means the gross amount invoiced by Micromet, its Affiliate or its
sublicensee for sales of Licensed Products to any Third Party (and in all cases amounts actually

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

5

 

received to the extent not invoiced), less any (a) normal trade, cash and quantity discounts
actually allowed, including charge backs; (b) amounts allowed for returned or defective Licensed
Products; (c) insurance and transportation charges to the extent included in the invoiced amount;
and (d) custom duties, VAT, sales taxes or other governmental charges paid in connection with such
sales (but excluding what is commonly known as income taxes). Any of the deductions listed above
that involves a payment by Micromet, its Affiliate or sublicensee will be taken as a deduction in
the calendar quarter in which the payment is actually made by such entity; provided,
however, to the extent that the aggregate of such deductions in any calendar quarter for a
Licensed Product exceeds the gross amount invoiced by Micromet, its Affiliate or its sublicensee
for sales of such Licensed Product, then Micromet may carry forward any excess amounts and reduce
the gross amounts invoiced in connection with the applicable sale of Licensed Products in one or
more subsequent calendar quarter(s).

     Any amounts received on account of transfers of Licensed Products between Micromet, its
Affiliates or sublicensees of Licensed Products hereunder will be excluded from the calculation of
Net Sales, and Net Sales will be calculated based on the final sale of such Licensed Product by
Micromet, its Affiliates or sublicensees to any Third Party.

     In the event a Licensed Product is sold in the form of a Combination Product, Net Sales for
purposes of royalty payments on the Combination Product will be calculated by multiplying the Net
Sales of the Combination Product by the fraction A/(A+B), where A is the invoice price of the
Licensed
Product if sold separately (i.e., without the other active ingredients or components) by
Micromet, its Affiliate or sublicensee; and B is the aggregate invoice price of the other active
ingredients or components in the Combination Product, if sold separately by Micromet, its Affiliate
or sublicensee. In the event that no such separate sales are made by Micromet, its Affiliate or
sublicensee, then Net Sales for purposes of royalty payments on the Combination Product will be
calculated by multiplying the Net Sales of the Combination Product by the fraction C/(C+D) where C
is the fully allocated cost of the Licensed Product taken separately from the Combination Product
(i.e., not including the other active ingredients or components); and D is the aggregate fully
allocated cost of the other active ingredients or components; in each case, such costs being
determined using generally accepted accounting procedures consistently applied by Micromet, its
Affiliate or sublicensee, as applicable.

     1.37  “Patents” means (a) all patents and patent applications in any country or
supranational jurisdiction, and (b) any substitutions, divisions, continuations,
continuations-in-part, reissues, renewals, registrations, confirmations, re-examinations,
extensions, supplementary protection certificates and the like, and any provisional applications,
of any such patents or patent applications.

     1.38  “Phage Display” means the technology, process or methodology whereby Antibodies
are cloned, expressed, produced and screened on the surface of filamentous bacteriophage.

     1.39  “Primary Application” means a major application of a product containing an
Antibody binding to a target, as ascertained at the time of assessment of such Antibody as a
potential Licensed Product using objective and reasonable scientific and/or commercial criteria,
data and/or information. Primary Application does not mean any minor or incidental application.

6

 

     1.40  “Regulatory Authorities” means the European Medicines Evaluation Agency, the
FDA, any successor agencies thereto, and any equivalent health regulatory authorities in any
applicable country or territory.

     1.41  “Ribosome Display” means the technology, process or methodology whereby
Antibodies are cloned, expressed, produced and screened in vitro involving a step where an Antibody
or Antibodies are tested for binding to Antigen when said Antibody or Antibodies are attached to
its coding RNA and to ribosomes.

     1.42  “Single Chain Antibody” means an Antibody having binding affinity for an
Antigen whereby such Antibody comprises (i) a polypeptide segment having a light chain variable
region, (ii) a polypeptide having a heavy chain variable region, and (iii) at least one peptide
linker linking those polypeptides into a single chain polypeptide.

     1.43  “Term” has the meaning assigned to it in Section 10.1.

     1.44  “Therapeutic Licensed Product” means any Licensed Product sold for therapeutic
or prophylactic use in humans.

     1.45  “Third Party” means any party other than CAT, Micromet or their respective
Affiliates.

     1.46  “Valid Claim” means (i) any claim of an issued and unexpired patent within the
CAT Licensed Patents which has not been held unenforceable or invalid by a court or other
governmental agency of competent jurisdiction in a decision that is not appealed or cannot be
appealed, and which has not been disclaimed or admitted to be invalid or unenforceable through
reissue or otherwise, or (ii) a pending claim in a pending patent application within the CAT
Licensed Patents. Notwithstanding the foregoing clause (ii), in the event that a pending claim in
a pending patent application does not issue as a
valid and enforceable claim in an issued patent within [***] after the earliest date from
which such patent application claims priority, such a pending claim will not be a Valid Claim,
unless and until such pending claim subsequently issues as a valid and enforceable claim in an
issued patent, in which case such claim will be reinstated and be deemed to be a Valid Claim as of
the date of issuance of such patent.

2. Grant Of Licenses

     2.1 Research License. Subject to the terms and conditions of this Agreement, CAT
hereby grants to Micromet a nonexclusive, worldwide license under the CAT Licensed Patents and the
CAT Background Know-How to perform research and development activities in the Micromet Research
Field. Subject to the terms and conditions of this Agreement, Micromet will have the right to
grant a sublicense to any of its rights under the foregoing license to (i) its Affiliates and (ii)
any Third Party that enters into a research and/or collaboration agreement with Micromet in order
to perform research activities on behalf of Micromet in the Micromet Research Field;
provided, however, that any such sublicense will be consistent with the terms and
conditions of this Agreement, and will impose on the sublicensee the obligations of

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

7

 

Micromet and
grant CAT the rights contained in Sections 2.4, 5.5, 5.7, 7, 8 and 9 of this Agreement; and
provided, further, that Micromet has no right to grant to such Third Party a right
to grant further sublicenses, except to Affiliates of such Third Party. Micromet will provide CAT
with the identity of each Third Party licensee of Micromet that receives a sublicense of the rights
under this Section 2.1 within thirty (30) days of execution of the applicable agreement. Micromet
hereby covenants and agrees not to use or sublicense any of its rights under the foregoing license
except as expressly permitted in this Agreement.

     2.2 Commercialization License. Subject to the terms and conditions of this
Agreement, CAT hereby grants to Micromet a nonexclusive, worldwide, royalty-bearing license under
the CAT Licensed Patents and the CAT Background Know-How to Exploit Licensed Products in the
Micromet Licensed Field. Subject to the terms and conditions of this Agreement, Micromet may grant
and authorize the grant of further sublicenses under the foregoing license to any of its Affiliates
or to a Third Party; provided, however, that any such sublicense will be consistent
with the terms and conditions of this Agreement, and will impose on the sublicensee the obligations
of Micromet and grant CAT the rights contained in Sections 2.4, 5.5, 5.7, 7, 8 and 9 of this
Agreement. Micromet will provide CAT with the identity of each Third Party licensee of Micromet
that receives a sublicense of the rights under this Section 2.2 within thirty (30) days of
execution of the applicable agreement. The Parties understand and agree that the terms and
conditions of this Section 2.2 (including the right to sublicense and authorize further
sublicenses) will apply to any product, composition, or formulation upon the submission by Micromet
of a Dossier for such product pursuant to Section 3.1.1. Micromet hereby covenants and agrees not
to use or sublicense any of its rights under the foregoing license except as expressly permitted in
this Agreement.

     2.3 Reservation of Rights. Except for the rights specifically granted herein, CAT
reserves all rights to all CAT Licensed Patents and the CAT Background Know-How Controlled by it
and reserves the right to utilize or allow Third Parties to utilize the CAT Licensed Patents and
the CAT Background Know-How consistent with the terms of this Agreement. No implied licenses are
granted under this Agreement.

     2.4 Excluded Technology. Notwithstanding anything in this Agreement to the
contrary, CAT grants no rights to Micromet under this Agreement (a) to research, develop,
manufacture,
use, or sell Licensed Products using the Excluded Technology set forth in items [***] of
Schedule V, or (b) to Develop, manufacture, use, or sell any Licensed Product that is a
Research Product or Microarray, as those terms are defined in Schedule V. CAT will notify
Micromet promptly if:

          (a) CAT ceases to be bound by the Excluded Field restriction pursuant to its
agreement with [***]dated[***]; or

          (b) CAT no longer needs to exclude Research Products from the license granted
hereunder pursuant to its agreement with [***] dated [***](the “[***] License Agreement”), a copy
of which has been provided to Micromet by CAT as of the Effective Date.

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

8

 

CAT will promptly notify
Micromet of any modification or amendment to the [***] License Agreement and deliver to Micromet a
redacted copy of any such amended agreement.

     The restrictions set out in this Agreement relating to the Excluded Field or Research Products
set forth above (as the case may be) will, subject to any other restrictions on CAT and to the
provisions of this Agreement, cease to apply from the date of removal of such restriction pursuant
to the terms of the foregoing agreements.

     2.5 Know-How Transfer. Within ninety (90) days after the Effective Date, CAT will
disclose in writing and deliver to Micromet all CAT Background Know-How. CAT may during the Term
at its sole discretion propose to Micromet that additional CAT Background Know-How (developed by or
on behalf of CAT after the Effective Date) be disclosed to Micromet and added to Schedule
II. Micromet will be entitled to accept or reject such additional Know-How at its sole
discretion. If Micromet accepts such additional Know-How, then Schedule II of this
Agreement will be amended in accordance with Section 13.5.

3. Identification of Licensed Products and Reporting

     3.1 Identification of Licensed Products.

          3.1.1 General. Micromet will provide to CAT a Dossier in respect of each Licensed
Product conceived or developed within the EpCAM Target Program that Micromet desires to Exploit
under this Agreement. During the Term, Micromet will submit such a Dossier to CAT for a particular
product composition or formulation prior to the time Micromet begins administration to humans of
such composition or formulation in a human clinical trial with respect to such product composition
or formulation.

          3.1.2 MT201 Product. The Parties agree and acknowledge that MT201 Product is a
Licensed Product hereunder (and has already been administered to humans in a clinical trial) and
Micromet will submit a Dossier in respect of the MT201 Product within [***] following the Effective
Date.

          3.1.3 Confidentiality. CAT will treat all information contained in any Dossier (or
update thereto) provided to CAT under this Section 3.1 or Section 3.3 as Micromet’s Confidential
Information in accordance with the confidentiality provisions of Section 7.

     3.2 Abandonment of a Licensed Product. If at any time during the Term, Micromet
decides in its discretion that it no longer wishes to Exploit a Licensed Product itself or with or
through an Affiliate or Third Party (an “Abandoned Product”), Micromet will promptly notify CAT in
writing of such decision and any license granted by Section 2.2 of this Agreement will be deemed to
have been terminated solely with regard to such Abandoned Product from the date Micromet sets forth
in such notification. In the case of any Abandoned Product, the Parties will [***].

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

9

 

     3.3 Dossier Updates. Within [***] Business Days of each anniversary of the
Effective Date during the Term, Micromet will prepare and provide to CAT an update to any Dossier
submitted that summarizes the current status of the research and development regarding each
Licensed Product. Such update may include, by way of example, a brief description of any
collaborations, business transactions, changes of control, publications, conference presentations
and intellectual property or legal matters where such events are relevant to CAT as licensor or
Micromet as licensee under this Agreement, unless such update would constitute a breach by Micromet
of a non-disclosure obligation to a Third Party.

4. Gatekeeping and the Excluded Field

     4.1 EpCAM Target. The Parties hereby acknowledge and agree that the EpCAM Target
has been cleared through CAT’s Gatekeeping Procedure as of the Effective Date.

     4.2 Micromet Representations. Subject to Section 4.3 below, Micromet hereby
represents and warrants to CAT that as of the Effective Date: (a) it is not developing and does not
intend to develop a Licensed Product for a Primary Application in the Excluded Field; (b) its
primary purpose in using the CAT Licensed Patents under the licenses granted under this Agreement
is outside the Excluded Field; (c) it has provided CAT with the sequence of the EpCAM Target
detailed in Schedule III to allow CAT (i) to conduct an assessment, as of the Effective
Date, of [***] containing Antibodies to the EpCAM Target and the intended or actual use of such
Licensed Products, and (ii) to subject the EpCAM Target to such [***] or other customary or
scientifically established techniques as may be used to determine whether or not [***] of the
Licensed Products containing Antibodies to the EpCAM Target is [***]; and (d) it believes that the
Primary Application of the Licensed Products containing Antibodies to the EpCAM Target is outside
the Excluded Field.

     4.3 Limitation. Notwithstanding Section 4.2, if, following the Effective Date, it
is subsequently discovered by either Party that products containing Antibodies to the EpCAM Target
do have a Primary Application in the Excluded Field, the discovering Party will promptly notify the
other in writing of such discovery. Notwithstanding any such discovery or notice thereof, Micromet
will be entitled to continue with the research, development, use, or sale of any Antibody or
Licensed Product, including any application within the Excluded Field, under the terms and
conditions set forth herein, and such research, development, use or sale (together with any prior
research, development, use or sale) will not constitute a breach of Section 4.2 or any other
provision of this Agreement.

5. Payments

     5.1 Initial License Fee. On the Effective Date, Micromet will pay to CAT a
non-refundable, non-creditable license fee of US$[***].

     5.2 Therapeutic Licensed Product Milestone Payments and Royalty Rates. The
milestone payments and royalty rates set forth in this Section 5.2 will apply to each Therapeutic
Licensed Product.

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

10

 

     5.2.1 Milestones. Micromet will pay to CAT the following non-refundable,
non-creditable milestone payments for each Therapeutic Licensed Product Exploited by Micromet, its
Affiliates or sublicensees:

	 	 	 
	Milestone Event	 	Milestone Payment
	Acceptance of the filing of the first Marketing Approval
for such Therapeutic Licensed Product in the first Major
Market Country
	 	US$[***]
	Receipt of first Marketing Approval for such Therapeutic
Licensed Product in the first Major Market Country
	 	US$[***]

     5.2.2 Royalties.

          (a) Subject to the terms and conditions of this Agreement, Micromet will pay to CAT
a royalty payment equal to [***]% of Net Sales of each Therapeutic Licensed Product sold by
Micromet, its Affiliates or sublicensees throughout the world. The royalty payment obligation of
Micromet under this Section 5.2.2 will expire on a Therapeutic Licensed Product-by-Therapeutic
Licensed Product and country-by-country basis (in which such Therapeutic Licensed Product is sold)
upon the later of: (a) expiration of the last to expire Valid Claim of the CAT Licensed Patents
which, but for the license granted in this Agreement, would be infringed by the Development,
manufacture, importation, use or sale of such Therapeutic Licensed Product in such country; and (b)
ten (10) years from first commercial sale for use or consumption by the general public of such
Therapeutic Licensed Product by or on behalf of Micromet anywhere in the world. In the event that
the period described in clause (b) of the preceding sentence extends beyond the period described in
clause (a) of the preceding sentence with respect to a Therapeutic Licensed Product in a country (a
“Therapeutic Product Extended Period”), then the royalty rate of [***]% set out above will be
reduced to [***]% of Net Sales of such Therapeutic Licensed Product in such country during such
Therapeutic Product Extended Period.

          (b) Notwithstanding anything herein to the contrary, the Parties agree that no
royalties will be payable by Micromet for a particular country in respect of any Therapeutic
Licensed Product which does not utilize the CAT Background Know-How and which is first sold
commercially after the expiration of the last to expire Valid Claim of the CAT Licensed Patents in
such country, which, but for the license granted in this Agreement, would be infringed by the
Development, manufacture, importation, use or sale of such Therapeutic Licensed Product in such
country.

     5.3 Diagnostic Licensed Product Milestone Payments and Royalty Rates. The milestone
payments and royalty rates set forth in this Section 5.3 will apply to each Diagnostic Licensed
Product.

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

11

 

     5.3.1 Milestones. Micromet will pay to CAT the following non-refundable,
non-creditable milestone payments for each Diagnostic Licensed Product Exploited by Micromet, its
Affiliates or sublicensees:

	 	 	 
	Milestone Event	 	Milestone Payment
	Acceptance of the filing of the first Marketing Approval
for each such Diagnostic Licensed Product in the first
Major Market Country
	 	US$[***]
	Receipt of first Marketing Approval for each such
Diagnostic Licensed Product in the first Major Market
Country
	 	US$[***]

     5.3.2 Royalties.

          (a) Subject to the terms and conditions of this Agreement, Micromet will pay to CAT
a royalty payment equal to [***]% of Net Sales of each Diagnostic Licensed Product sold by
Micromet, its Affiliates or sublicensees throughout the world. The royalty payment obligation of
Micromet under this Section 5.3.2 will expire on a Diagnostic Licensed Product-by-Diagnostic
Licensed Product and country-by-country basis (in which such Diagnostic Licensed Product is sold)
upon the later of: (a) expiration of the last to expire Valid Claim of the CAT Licensed Patents
which, but for the license granted in this Agreement, would be infringed by the Development,
manufacture, importation, use or sale of such Diagnostic Licensed Product in such country; and (b)
ten (10) years from first commercial sale for use or consumption by the general public of such
Diagnostic Licensed Product by or on behalf of Micromet anywhere in the world. In the event that
the period described in clause (b) of the preceding sentence extends beyond the period described in
clause (a) of the preceding sentence with respect to a Diagnostic Licensed Product in a country (a
“Diagnostic Product Extended Period”), then the royalty rate of [***]% set out above will be
reduced to [***]% of Net Sales of such Diagnostic Licensed Product in such country during such
Diagnostic Product Extended Period.

          (b) Notwithstanding anything herein to the contrary, the Parties agree that no
royalties will be payable by Micromet for a particular country in respect of any Diagnostic
Licensed Product which does not utilize the CAT Background Know-How and which is first sold
commercially after the expiration of the last to expire Valid Claim of the CAT Licensed Patents in
such country, which, but for the license granted in this Agreement, would be infringed by the
Development, manufacture, importation, use or sale of such Diagnostic Licensed Product in such
country.

     5.3.3 Acceleration of Milestones. If the first commercial sale of a Diagnostic
Licensed Product by Micromet, its Affiliate or sublicensee is made in a Major Market Country where
no Marketing Approval has been granted for such Licensed Product, then both of the

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

12

 

milestone
payments set forth in Section 5.3.1 will be payable as if the relevant milestone events had
occurred as of the date of such first commercial sale.

     5.4 Payment.

          5.4.1 Payment of Milestones. Upon Micromet achieving a development milestone that
triggers a milestone payment obligation pursuant to Sections 5.2.1 or 5.3.1, Micromet will give
notice to CAT within [***] days of achieving each milestone, and will make the corresponding
milestone payment within [***] days of the achievement of the corresponding milestone event.

          5.4.2 Payment of Royalties. For any quarterly period for which royalties are
payable by Micromet to CAT under Sections 5.2.2 or 5.3.2, Micromet will provide notice to CAT
within [***] days after the end of each such calendar quarter and a written report with Micromet’s
good faith estimate of Net Sales accrued in the preceding calendar quarter and the royalties
payable thereon. Micromet will make royalty payments to CAT for Licensed Products or Diagnostic
Licensed Products sold during a calendar quarter within [***] of the last day of that calendar
quarter. Each royalty payment will be accompanied by a written report for that calendar quarter
showing the cumulative Net Sales of the applicable product sold by Micromet, its Affiliates and its
sublicensees on a country-by-country basis worldwide during the quarterly reporting period and the
corresponding royalties payable under this Agreement.

          5.4.3 Payment Method. All amounts due hereunder will be paid in US Dollars by wire
transfer in immediately available funds to Barclays Bank Plc, Benet Street Business Centre, P O Box
No 2, Cambridge, CB2 3PZ, England, Account Number [***]; Sort Code: [***], Swift Code: [***]
(payments may be routed through Barclays Bank Plc, New York, ABA Routing Code: [***]; Swift Code:
[***]) or such other bank account as CAT may from time to time notify Micromet. Any payments or
portions thereof due hereunder which are not paid on the date such payments are due will bear
interest from the due date until the date of payment at the rate which is the lower of (i)
[***]percentage points above the overnight London Interbank Offering Rate in effect on the due date
or (ii) the highest rate permitted by applicable law.

          5.4.4 Currency Conversion for Milestone Payments and Calculation of Net Sales. For
any currency conversion required in connection with any payment hereunder, or in determining the
amount of royalties due, such conversion will be made at the prevailing commercial rate of exchange
for purchasing the currency into which an amount is to be converted as publicly announced as the
spot rate quoted by Barclays Bank Plc (or its successor) in London on (i) the day which is fifteen
(15) Business Days following the date of the achievement of any milestone for which payment is due
pursuant to Sections 5.2.1 or 5.3.1 and (ii) the day which is the last Business Day of the
applicable quarterly period for any royalty payments made pursuant to Sections 5.2.2 or 5.3.2. For
purposes of determining the amount of royalties due, the amount of Net Sales in any foreign
currency will be computed by converting such amount into US Dollars as provided in this Section.
All payments due under this Agreement will be paid exclusive of value added tax.

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

13

 

          5.4.5 Credit for Royalties Paid on Uncollected Amounts. As set forth in this
Section 5.4.5, Micromet will be entitled to a credit on royalties paid by Micromet hereunder with
respect to any invoiced amounts that are included in Net Sales but are not collected by Micromet,
its Affiliate or sublicensee, as applicable (each such amount, an “Uncollected Amount”). Such
credit may be taken in the calendar quarter in which the applicable Uncollected Amount is no longer
recorded as a receivable or in one or more subsequent calendar quarter(s) to the extent that such
credit exceeds the amount payable by Micromet to CAT in any calendar quarter. The amount of such
credit will be equal to the difference between (x) the royalty actually paid by Micromet to CAT
hereunder for the Uncollected Amount, and (y) the royalty actually paid by CAT to [***] [***], its successors or assigns pursuant to the
[***] Agreement for the Uncollected Amount. Upon the request of Micromet in connection with this
Section 5.4.5, CAT will provide to Micromet payment records supporting payment to [***] by CAT in
respect of such Uncollected Amount. Micromet agrees that an Uncollected Amount will only be
recorded as not receivable once Micromet has used its reasonable endeavors to recover such amount
from the relevant Third Party in accordance with its usual practice for recovering unpaid debts.
To the extent that an Uncollected Amount recorded as not receivable is in fact subsequently
received by Micromet, Micromet will pay to CAT the corresponding amount of any credit previously
taken by Micromet in accordance with Section 5.4.2.

     5.5 Records; Audits. Micromet will at all times keep or cause or procure to be kept
and for at least [***] retain accurate data, accounts and supporting documentation of all Licensed
Products produced and/or sold, used or disposed of by or on behalf of Micromet and the Net Sales
thereof (collectively, “Records”) to the extent such Records are reasonably required for the
computation and verification of royalties and all other sums payable under this Agreement.
Micromet will give to or procure for CAT’s nominated representative, upon reasonable request in
writing and no more than [***], access to Micromet’s facilities during normal business hours to
inspect all Records kept in accordance with this Section 5.5 and to make copies or to take extracts
from these Records. However, CAT’s nominated representative will not disclose to CAT or any Third
Party any Confidential Information belonging to Micromet but will merely report on any under or
over payment discovered as a result of his inspection. CAT will bear all costs of such audit,
unless the audit reveals an underpayment of more than [***]% from payments otherwise due and
payable hereunder, in which case Micromet will bear the cost of the audit.

     5.6 Payment of Additional Amounts. If, based on the results of any audit,
additional payments are owed to CAT under this Agreement, Micromet will make such additional
payments promptly after the accounting firm’s written report is delivered to both Parties. If,
based on the results of any audit, payments made by Micromet pursuant to Sections 5.2 or 5.3
exceeded payments indicated by the audit as being due thereunder, such excess will be credited
against future amounts owed by Micromet under Sections 5.2 or 5.3.

     5.7 Confidentiality. CAT will treat all information provided to it pursuant to any
audit performed under Section 5.5 in accordance with the confidentiality provisions of Section 7
and will cause its accounting firm or other designated representative to enter into a reasonably

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

14

 

acceptable confidentiality agreement with Micromet obligating such firm or representative to
maintain all such financial information in confidence pursuant to such confidentiality agreement.

     5.8 Withholdings.

          5.8.1 Micromet will be entitled (if required to do so) to deduct tax from the
payments it makes to CAT under this Section 5 above (“Withholding Tax”) provided that:

               (a) Micromet will pay over such Withholding Tax to the relevant revenue authority
and will provide to CAT such documentary evidence as CAT may reasonably require regarding (i) the
amount so deducted, and (ii) evidence of payment to such authority; and

               (b) Micromet will provide to CAT such assistance as CAT may reasonably require
(including submission of documents to relevant revenue authorities) to obtain a repayment of the
Withholding Tax or (as the case may be) to obtain the benefit of such Withholding Tax whether by
credit against taxes or otherwise.

          5.8.2 If, pursuant to a relevant double taxation agreement, a Party has the right to
claim relief (whether in whole or in part) from any Withholding Tax, then:

               (a) Micromet will co-operate with CAT in seeking a written direction from the
relevant revenue authorities to the effect that either: (i) no Withholding Tax should be operated
in respect of payments under this Agreement, or (ii) the rate of Withholding Tax will be such lower
rate as specified by the relevant revenue authority, and Micromet will comply with any such
direction given; and

               (b) pending such written direction, Micromet will deduct Withholding Tax in
accordance with Section 5.8.1 above, but will, in addition to the sums otherwise payable under this
Agreement, pay to CAT such further sum as will ensure that, after operation of Withholding Tax on
all such sums, the net amount received by CAT equals the amount that CAT would have received had
the relevant revenue authority already issued the written direction described in Section
5.8.2(a)(i) above or, as the case may be, Section 5.8.2(a)(ii) above.

          5.8.3 If, as a result of any change in corporate status or location of CAT, or
permitted assignment of this Agreement by CAT, Withholding Tax becomes due on payments from
Micromet to CAT or its permitted assignee and CAT is not able to claim a credit or reimbursement
for such tax, in whole or in part, then any amount of Withholding Tax deducted by Micromet on
amounts payable by Micromet to CAT hereunder will be treated as if the amount of Withholding Tax
was paid directly to CAT, to the extent that a credit or reimbursement could not be claimed by CAT.

          5.8.4 If, as a result of any change in corporate status or location of Micromet, or
permitted assignment of this Agreement by Micromet, Withholding Tax becomes due on payments from
Micromet to CAT or its permitted assignee and CAT is not able to claim a credit or reimbursement
for such tax, in whole or in part, then Micromet will deduct Withholding Tax in accordance with
Section 5.8.1 above, but will, in addition to the sums otherwise payable under this Agreement, pay
to CAT such further sum as will ensure that, after operation of Withholding Tax on all such sums,
the net amount received by CAT equals the amount that CAT would have

15

 

received had the
non-creditable or non-deductible amount of such Withholding Tax not been deducted. To the extent
that any such amount deducted by Micromet in accordance with this Section 5.8.4 is in fact
subsequently able to be claimed by CAT as a credit or reimbursement for such tax otherwise
deducted, then CAT will pay to Micromet the corresponding amount of any such credit or
reimbursement for such tax otherwise eligible to be deducted by CAT.

6. Representation and Warranties; Covenants

     6.1 Representations of CAT. CAT represents to Micromet that as of the Effective
Date: (a) it Controls the CAT Licensed Patents and the CAT Background Know-How licensed under this
Agreement (subject to the exclusions in the Excluded Field and Excluded Technology); (b) the CAT
Licensed Patents includes all Patents relating to Phage Display that both (i) are owned by CAT or
are licensed from the [***] to CAT, and (ii) would be infringed by Micromet’s performance of
activities in the Micromet Research Field or the Development, manufacture, importation, use or sale of
Antibody Products resulting from such activities; provided, however, that it will
not be a breach of the foregoing representation if CAT has in good faith inadvertently omitted a
Patent from Schedule I and is not otherwise in breach of its covenant under Section 6.3
regarding such Patent; (c) except as disclosed in Schedules I and VI, it has not
received any written communication that expressly threatens interference actions or oppositions to
any Patents within the CAT Licensed Patents or other litigation before any patent office, court, or
any other governmental entity in any jurisdiction in regard to the CAT Licensed Patents; (d) except
as disclosed in Schedules I and VI, it has not been served with any complaint
alleging infringement of a Third Party’s patents arising from the practice of the claims in the
Patents within the CAT Licensed Patents; and (e) Schedule VI includes a complete list of
all pending claims of Third Parties (other than oppositions) in regard to the entitlement, validity
or enforceability of the CAT Licensed Patents.

     6.2 Reciprocal Representations and Warranties. Each Party represents and warrants to
the other Party that: (a) this Agreement is a legal and valid obligation binding upon its
execution and enforceable against it in accordance with its terms and conditions; and (b) the
execution, delivery and performance of this Agreement by such Party has been duly authorized by all
necessary corporate action, and the person executing this Agreement on behalf of such Party has
been duly authorized to do so by all requisite corporate actions.

     6.3 Additional Covenants. CAT hereby covenants and agrees that (a) it will maintain
throughout the Term all agreements with Third Parties granting CAT rights in and to the CAT
Licensed Patents and CAT Background Know-How that are necessary to grant Micromet the licenses
granted in Section 2 of this Agreement (including, without limitation, the [***] Agreement) and (b)
it will promptly upon discovery of any omission amend Schedule I as of the Effective Date
to include any Patent omitted from Schedule I.

     6.4 DISCLAIMER OF WARRANTY. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN THIS
AGREEMENT, EACH PARTY MAKES NO REPRESENTATIONS AND GRANTS NO WARRANTIES, EXPRESS OR IMPLIED,

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

16

 

EITHER
IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND CAT AND MICROMET EACH SPECIFICALLY
DISCLAIMS ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY
WARRANTY OF QUALITY, OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE NON-INFRINGEMENT OF
ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.

7. Confidentiality

     7.1 Definition. During the Term and subject to the terms and conditions of this
Agreement, a Party (the “Disclosing Party”) may communicate to the other Party (the “Receiving
Party”) confidential information in connection with this Agreement or the performance of its
obligations hereunder, including, without limitation, any Dossier or update thereto, any Know-How,
any information regarding CAT Phage Display Improvements or Micromet Phage Display Improvements,
any reports provided pursuant to this Agreement, any scientific and manufacturing information and
plans, marketing and business plans, and financial and personnel matters relating to a Party or its
present or future products, sales, suppliers, customers, employees, investors or business
(collectively, “Confidential Information”).

     7.2 Exclusions.

          7.2.1 Notwithstanding the foregoing, information of a Disclosing Party will not be
deemed Confidential Information with respect to a Receiving Party for purposes of this Agreement if
such information:

               (a) was already known to the Receiving Party or its Affiliates, other than under an
obligation of confidentiality or non-use, at the time of disclosure to the Receiving Party;

               (b) was generally available or known to parties reasonably skilled in the field to
which such information or Know-How pertains, or was otherwise part of the public domain, at the
time of its disclosure to the Receiving Party;

               (c) became generally available or known to parties reasonably skilled in the field
to which such information or Know-How pertains, or otherwise became part of the public domain,
after its disclosure to the Receiving Party through no fault of or breach of its obligations under
this Section 7 by the Receiving Party;

               (d) was disclosed to the Receiving Party other than under an obligation of
confidentiality or non-use, by a party other than the Disclosing Party who had no obligation to the
Disclosing Party not to disclose such information or Know-How to others; or

               (e) was independently discovered or developed by the Receiving Party or its
Affiliates, as evidenced by contemporaneous written records, without the use of or reference to,
and by personnel who had no knowledge of or access to, any Confidential Information of the
Disclosing Party.

17

 

          7.2.2 Specific aspects or details of Confidential Information will not be deemed to
be within the public domain or in the possession of a person or entity merely because the
Confidential Information is embraced by more general information in the public domain or in the
possession of such person or entity. Further, any combination of Confidential Information will not
be considered in the public domain or in the possession of a person or entity merely because
individual elements of such Confidential Information are in the public domain or in the possession
of such person or entity unless the combination and its principles are in the public domain or in
the possession of such person or entity.

     7.3 Disclosure and Use Restriction. Except as expressly provided herein, the
Parties agree that, during the Term and for [***] years thereafter (unless one or more of the
exceptions described in 7.2.1 apply), a Receiving Party and its Affiliates and sublicensees will
keep completely confidential and will not publish or otherwise disclose and will not use for any
purpose except for the purposes contemplated by this Agreement any Confidential Information of the
Disclosing Party, its Affiliates or sublicensees.

     7.4 Authorized Disclosure. A Receiving Party may disclose Confidential Information
of the Disclosing Party to the extent that such disclosure is:

          7.4.1 made in response to a valid order of a court of competent jurisdiction or
other governmental or regulatory body of competent jurisdiction; provided, however,
that the Receiving Party will first have given notice to the Disclosing Party and given the
Disclosing Party a reasonable opportunity to quash such order and to obtain a protective order
requiring that the Confidential Information and documents that are the subject of such order be
held in confidence by such court or governmental or regulatory body or, if disclosed, be used only for the purposes for which the
order was issued; and provided, further, that if a disclosure order is not quashed
or a protective order is not obtained, the Confidential Information disclosed in response to such
court or governmental order will be limited to that information which is legally required to be
disclosed in response to such court or governmental order;

          7.4.2 otherwise required by law or mandatory regulation; provided,
however, that the Disclosing Party will provide the Receiving Party with notice of such
disclosure in advance thereof to the extent practicable;

          7.4.3 made by the Receiving Party to the regulatory authorities as required in
connection with any application, filing, or similar requests for regulatory approvals;
provided, however, that reasonable measures will be taken to assure confidential
treatment of such information;

          7.4.4 made by the Receiving Party, in connection with the performance of this
Agreement, to Affiliates, permitted sublicensees, employees, consultants, representatives or
agents, each of whom prior to disclosure must be bound by obligations of confidentiality and
non-use at least equivalent in scope to those set forth in this Section 7;

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

18

 

          7.4.5 made by the Receiving Party to existing or potential acquirers or merger
candidates, potential collaborators (to the extent contemplated hereunder), investment bankers,
existing or potential investors, venture capital firms or other financial institutions or investors
for purposes of obtaining financing, each of whom prior to disclosure must be bound by obligations
of confidentiality and non-use at least equivalent in scope to those set forth in this Section 7;
or

          7.4.6 a disclosure of the terms of this Agreement and disclosed in accordance with
Section 7.6.

     7.5 Use of Name. Neither Party will make public use of the other Party’s name
except (i) in connection with announcements and other permitted disclosures relating to this
Agreement and the activities contemplated hereby, (ii) as required by applicable law, and (iii)
otherwise as agreed in writing by such other Party.

     7.6 Terms of Agreement to be Maintained in Confidence. Subject to the other
provisions of this Section 7 (including the exception for any public disclosures made in compliance
with the terms of this Section 7.6), the Parties agree that the terms of this Agreement are
confidential and will not be disclosed by either Party to any Third Party (except to a Party’s
professional advisor) without advance written permission of the other Party; provided,
however, that either Party may make any filings of this Agreement required by law or
regulation in any country so long as such Party uses its reasonable efforts to obtain confidential
treatment for portions of this Agreement as available, consults with the other Party, and permits
the other Party to participate, to the extent practicable, in seeking a protective order or other
confidential treatment; and provided, further, that either Party may disclose the
terms of this Agreement to a Third Party (and its professional advisors) when such disclosure is
reasonably necessary in connection with (i) the grant of a license or sublicense of the CAT
Licensed Patents to such Third Party, (ii) a merger, acquisition, placement, investment, or other
such transaction with such Third Party, or (iii) the sale of securities to or other financing from
such Third Party or a financing underwritten by such Third Party, in which case disclosure may be
made to any person or entity to whom such Third Party sells such securities (and its professional
advisors). Advance written permission for disclosure will not be required when a Party is ordered
to disclose information concerning the Agreement by a competent tribunal or such disclosures are
required by law, regulation, or stock exchange rules, except that such Party will make all
reasonable efforts to limit any disclosure as may be required in the course of legal
proceedings by entry of an appropriate protective and confidentiality order, and will provide
the other Party with as much advance notice of such circumstances as is practicable.

     7.7 Press Release.

          7.7.1 The Parties will make a joint press release regarding the execution of this
Agreement, the final form of which will be subject to approval of the Parties prior to its release
to the public. For subsequent press releases and other written public disclosures relating to this
Agreement or the Parties’ relationship hereunder (each, a “Proposed Disclosure”), each Party will
use reasonable efforts to submit to the other Party a draft of such Proposed Disclosure for

19

 

review
and comment by the other Party at least [***] prior to the date on which such Party plans to
release such Proposed Disclosure, and in any event will submit such drafts at least [***] prior to
the release of such Proposed Disclosure, and will review and consider in good faith any comments
provided in response.

          7.7.2 If a Party is unable to comply with the foregoing [***] notice
requirement because of a legal obligation or stock exchange requirement to make more rapid
disclosure, such Party will not be in breach of this Agreement but will in that case give telephone
notice to a senior executive of the other Party and provide a draft disclosure with as much notice
as possible prior to the release of such Proposed Disclosure.

          7.7.3 A Party may publicly disclose without regard to the preceding requirements of
this Section 7.7 information that was previously disclosed in a Proposed Disclosure that was in
compliance with such requirements.

8. Filing, Prosecution and Maintenance of Patent Rights 

     8.1 Prosecution and Maintenance. As between the Parties, CAT will be solely
responsible and bear all costs for the preparation, filing, prosecution and maintenance of the CAT
Licensed Patents in its discretion, subject to the terms and conditions of this Agreement.

     8.2 Costs. As between the Parties, CAT will be solely responsible and bear all
costs for (and enjoy all recovery from) any actions concerning the CAT Licensed Patents, including
but not limited to reexaminations, oppositions, interferences, and infringement actions, all in its
sole and absolute discretion.

     8.3 No Challenge. CAT will be permitted to terminate this Agreement if Micromet or
its Affiliates challenge, or intentionally direct or intentionally assist (other than under
compulsion of a legal process) a third party to challenge, the validity or enforceability of any of
the Patents within CAT Licensed Patents; provided, however, that the foregoing
termination right will not apply in the event that such challenge to a patent within the CAT
Licensed Patents is brought by Micromet or its Affiliates in response to a suit or proceeding on
such patent brought by CAT (or its Affiliates) against Micromet or its Affiliates. If a
sublicensee of Micromet or its Affiliates (or an Affiliate of such sublicensee) challenges the
validity or enforceability of or otherwise opposes any such Patent under which such sublicensee is
sublicensed, then Micromet upon notice by CAT will terminate such sublicense. Micromet and its
Affiliates will include provisions in all agreements that grant sublicense rights under the Patents
within CAT Licensed Patents that if the sublicensee or its Affiliates challenge the validity or
enforceability of or otherwise oppose any such Patents under which the sublicensee is sublicensed, Micromet may
terminate its sublicense agreement with such sublicensee.

     8.4 Notice. CAT will notify Micromet of any successful challenge to the CAT
Licensed Patents by any Third Party and will, upon request by Micromet, provide Micromet with
reasonable documentation regarding any such challenge. Micromet will notify CAT of any

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

20

 

infringement by a Third Party of any Patent in the CAT Licensed Patents of which Micromet becomes
aware and will provide CAT with the available evidence, if any, of such infringement.

     8.5 Enforcement. As between the Parties, CAT will have the exclusive right and sole
discretion during the Term to stop infringement of the CAT Licensed Patents, including by bringing
suit or other proceeding against the infringer in its own name. Upon request by CAT, Micromet will
provide reasonable assistance to CAT as a party to the lawsuit or other proceeding, at CAT’s
expense; provided, however, that CAT will retain control of the prosecution of such
suit or proceeding. CAT will bear all its costs incurred in connection with such lawsuit or other
proceeding, and, consequently, will be entitled to collect and retain for its own account such
damages and profits as may be accrued as a result of such lawsuit or other proceeding.

     8.6 Release. As of the Effective Date, each of CAT, and its Affiliates, assigns,
successors, and predecessors, and any directors and officers of the foregoing (each, a “CAT
Entity”), hereby releases and forever discharges Micromet, its Affiliates, assigns, successors, and
predecessors, and any directors and officers of the foregoing (each, a “Micromet Entity”), from any
and all actions, causes of action, claims or demands for damages, suits, debts, sums of money,
accounts, costs, expenses, compensation, consequential damages, covenants, interest, liens or any
other thing whatsoever, in law, equity or otherwise, whether now known or unknown or which have
ever existed, now exist or which may exist in the future (except to enforce the terms of this
Agreement), which any CAT Entity may have against any Micromet Entity arising out of, or relating
to, agreements, events or conduct related to any use by Micromet of the CAT Licensed Patents prior
to and including the Effective Date in relation to the EpCAM Target. For the avoidance of doubt
nothing in this Section 8.6 will prevent CAT from pursuing Micromet for any injunctive relief or
any loss, damage, claim or expense suffered or incurred by CAT as a result of any breach by
Micromet of the terms of this Agreement.

9. Improvements; Ownership

     9.1 Phage Display Improvements.

          9.1.1 Disclosure of Micromet Phage Display Improvements. Within [***] following
conception or discovery by or on behalf of Micromet, its Affiliates or sublicensees of any Micromet
Phage Display Improvements, Micromet will provide CAT with notice of such Micromet Phage Display
Improvements.

          9.1.2 Ownership. As between the Parties, and subject to the licenses granted in
Section 9.1.3, Micromet will retain all right, title and interest in and to any and all Micromet
Phage Display Improvements. Micromet will ensure that to the extent permitted by law, any Third
Party, including Micromet’s sublicensees, performing work related to Phage Display is under an
obligation: (a) to assign all inventions, Patents, and Know-How relating to any Micromet Phage
Display Improvements to Micromet, or where this obligation is not permitted, (b) to exclusively
license all such inventions, Patents, and Know-How to Micromet, with the

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

21

 

right to sublicense, or where neither of the
obligations described in the preceding clause (a) or (b) is permitted then, (c) to non-exclusively
license all such inventions, Patents, and Know-How to Micromet, with the right to sublicense.

          9.1.3 License to CAT. Subject to the terms and conditions of this Agreement,
Micromet hereby grants to CAT a perpetual, irrevocable, non-exclusive, worldwide, royalty-free,
fully paid license, with the right to grant and authorize the grant of sublicenses (in accordance
with the terms of Section 2.1 relating to sublicenses by Licensee, mutatis mutandis), under the
Micromet Phage Display Improvements and any intellectual property rights therein to use and
practice any Micromet Phage Display Improvements for the purpose of identifying, producing,
developing, making, importing and selling products (other than BiTE Products) containing or
comprising one or more Antibodies or for any other purpose. CAT hereby covenants and agrees not to
use or sublicense any of its rights under the foregoing license except as expressly permitted in
this Agreement. The license set forth in this Section 9.1.3 will survive expiration or termination
of this Agreement, except if this Agreement (or, after expiration or termination of this Agreement,
this Section 9.1.3) is terminated by Micromet for breach of the foregoing covenant by CAT, in which
case such license will terminate immediately and entirely.

     9.2 CAT Phage Display Improvements. Within [***] following conception or discovery
by or on behalf of CAT or its Affiliates of any CAT Phage Display Improvements, CAT will promptly
provide Micromet with written notice of such CAT Phage Display Improvements (to the extent that
such disclosure would not violate CAT’s non-disclosure obligations to one or more Third Parties).
If Micromet elects to include any Patents claiming or covering one or more of such CAT Phage
Display Improvements, then Micromet will provide CAT with written notice of such election and, upon
receipt by CAT of such notice, any such Patents will be deemed CAT Licensed Patents hereunder.
Subject to the licenses granted in Section 2, CAT will retain all right, title and interest in and
to any and all CAT Phage Display Improvements.

     9.3 Further Assurances. Each Party agrees to take all necessary and proper acts,
and will cause its employees, Affiliates, contractors, sublicensees, and consultants to take such
necessary and proper acts, to effectuate the ownership provisions set forth in this Section 9.

10. Term and Termination

     10.1 Term. This Agreement is effective as of the Effective Date and will expire
upon the last date upon which the royalties payable by Micromet to CAT under Section 5.2.2 or 5.3.2
expire unless terminated earlier as expressly provided otherwise in this Agreement (the “Term”).

     10.2 Termination for Material Breach.

          10.2.1 Any material breach or failure by a Party to comply with any of its
obligations contained herein (including, without limitation any such breach or failure during an
Insolvency Event) will entitle the Party not in default to give to the Party in default written
notice

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

22

 

specifying the nature of the default, requiring the defaulting Party to make good or
otherwise cure such default. The Parties agree and acknowledge that in no event will a material
breach or failure of any of Micromet’s obligations with regard to the research license granted in
Section 2.1 be deemed to be a material breach of any obligation with regard to any Licensed Product
nor otherwise permit termination by CAT of this Agreement, including without limitation, the license rights granted by Section 2.2 with respect to any
Licensed Product.

          10.2.2 Subject to Section 10.2.3 below if, after a Party’s receipt of notice
pursuant to Section 10.2.1 above, such default is not cured within [***] days (or, if such default
cannot be cured within such [***]-day period, if the Party in default does not commence actions to
cure such default within such [***]-day period and thereafter diligently continue such actions and
cure such default within [***] days after the receipt of such notice, except in the case of a
payment default, as to which the defaulting Party will have only a [***]-day cure period), then the
Party not in default will be entitled, on written notice to the other Party and without prejudice
to any other rights conferred on it by this Agreement or available to it or them by law or in
equity, to terminate this Agreement immediately.

          10.2.3 If a Party receiving a notice pursuant to Section 10.2.1 above, is also at
the time of receiving such notice subject to an Insolvency Event and such default is not cured
within [***] days (except in the case of payment default, as to which the defaulting party will
only have a [***] day cure period), then the Party not in default will be entitled, on written
notice to the other Party and without prejudice to any other rights conferred by this Agreement or
available to it or them by law or in equity, to terminate this Agreement immediately.

     10.3 Amendment or Termination of [***] Agreement.

          10.3.1 Upon any amendment of the [***] Agreement that materially reduces the
obligation of CAT to pay royalties to [***] in connection with a sale of “Products” (as defined
therein) by CAT or its sublicensee (without a corresponding material payment by CAT of cash or
in-kind consideration therefor), then CAT will promptly notify Micromet of such amendment and the
Parties will in good faith promptly amend the applicable provisions of this Agreement in order to
provide to Micromet, as best as practicable, the economic benefits (or reduction of obligations)
resulting from such amendment to the [***] Agreement.

          10.3.2 Upon termination of the [***] Agreement, and upon request by Micromet, CAT
will use commercially reasonable efforts to obtain a direct license for Micromet from [***], its
successors or assigns to any CAT Licensed Patents licensed to CAT under such agreement upon the
terms set forth herein (including, without limitation, pursuant to Section [***] of the [***]
Agreement); provided, however, that CAT will have no such obligation if Micromet’s
acts or omissions under this Agreement caused such termination of the [***] Agreement.

     10.4 Additional Termination Right Regarding the Research License. Subject to the
terms of this Section 10.4, at any time during the Term, CAT will be entitled to terminate the

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

23

 

license to Micromet under Section 2.1 solely in the event that (i) Micromet has ceased all research
and development activities in respect of the EpCAM Target Program for a continuous period of at
least [***] and (ii) Micromet has not [***]. CAT will provide to Micromet written notice at least
[***] in advance of any such proposed termination. If there is any dispute regarding whether the
terms and conditions of this Section 10.4 are satisfied, then CAT will not be entitled to terminate
the license grant under Section 2.1 pending final resolution of such dispute in accordance with
Section 13.3 of this Agreement.

     10.5 Consequences of Expiration and Termination.

          10.5.1 Material Breach. Upon termination of this Agreement by a Party pursuant to
Section 10.2, (i) all licenses granted by the terminating Party to the defaulting Party will
terminate (except as provided in Section 9.1.3 and Section 10.5.2); (ii) the licenses granted by
the defaulting Party will survive (subject to continued performance by the terminating Party of its
royalty obligations, if any); and (iii) the milestone and royalty obligations set forth in Section
5 with respect to the surviving licenses will continue.

          10.5.2 Survival of Certain Sublicenses. Sublicenses granted by a defaulting Party
to a Third Party will survive termination of the defaulting Party’s license under Section
10.5.1(i); provided, however, that (x) such Third Party is not the cause of the
default, (y) such Third Party is not in breach of, and continues to fully perform all obligations
under its sublicense agreement and any surviving provisions in this Agreement applicable to such
sublicensee, and (z) the terminating Party continues to receive from such Third Party all royalty
and milestone payments set forth in Section 5.

          10.5.3 Effect of Termination of Research License. Notwithstanding anything herein
to the contrary, termination by CAT of Micromet’s rights under Section 2.1 (as a result of
Micromet’s material breach of that Section or pursuant to Section 10.4 above) will, provided that
Micromet is complying with its other obligations under this Agreement, in no way terminate
Micromet’s rights under Section 2.2 with regard to any Licensed Product or relieve the Parties of
any other obligation under this Agreement.

          10.5.4 Return of Confidential Information. Upon any expiration or termination of
this Agreement, each Party will, at the other Party’s option, promptly return or destroy any of
such other Party’s Confidential Information (including all Know-How) in its possession or control;
provided, however, that each Party may retain: (a) a single archival copy of the
Confidential Information of the other Party solely for the availing itself of the rights accorded
to it, or to perform its obligations, under the surviving provisions of this Agreement (including,
without limitation any and all license or sublicense rights expressly made to survive termination
or expiration hereof); and (b) any portion of the Confidential Information of the other Party which
a Party is required by applicable law to retain.

     10.6 Survival. Expiration or termination of this Agreement for any reason will not
relieve the Parties of any obligation accruing prior to such expiration or termination, including

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

24

 

without limitation Micromet’s obligation to pay royalties under Section 5 above on the sale of
Licensed Products prior to the effective date of such expiration or termination. The provisions of
Sections 3.1.3, 5 (solely as to accrued and unpaid amounts and Sections 5.5 and 5.7), 6.4, 7, 8.6,
9.1.3, 10.5, 10.6, 11, 12 and 13, together with any definitions used or schedules referenced
therein, will survive termination or expiration of this Agreement.

11. Indemnification and Insurance

     11.1 Indemnification By Micromet. Micromet will indemnify CAT, its Affiliates, and
their respective directors, officers, employees and agents, and defend and save each of them
harmless, from and against any and all losses, damages, liabilities, costs and expenses (including
reasonable attorneys’ fees and expenses)(collectively, “Losses”) in connection with any and all
liability suits, investigations, claims or demands by Third Parties (each, a “Third Party Claim”)
to the extent arising out of: (a) any theory of product liability (including, but not limited to,
actions in the form of tort, warranty or strict liability) concerning a Licensed Product that is
Exploited by Micromet or its Affiliates pursuant to any right or license granted under this
Agreement, or (b) any failure by any sublicensee of
Micromet to comply with the obligations of Sections 2.4, 5.5, 5.7, 7, 8 and 9 of this
Agreement imposed on such sublicensee pursuant to Sections 2.1 and 2.2 of this Agreement, as
applicable; in each case, except to the extent that such Losses arise out of or result from (i) the
gross negligence or reckless misconduct of a party seeking indemnification hereunder, or (ii) a
material breach by a party seeking indemnification hereunder of any provision of this Agreement.

     11.2 Indemnification Procedure.

          11.2.1 Notice of Claim. All indemnification claims in respect of a Party, its
Affiliates or their respective directors, officers, employees and agents (collectively, the
“Indemnitees” and each an “Indemnitee”) will be made solely by such Party to this Agreement (the
“Indemnified Party”). The Indemnified Party will give the indemnifying Party (the “Indemnifying
Party”) prompt written notice (an “Indemnification Claim Notice”) of any Losses or discovery of
fact upon which such Indemnified Party intends to base a request for indemnification under this
Section 11, but in no event will the Indemnifying Party be liable for any Losses that result from
any delay in providing such notice. Each Indemnification Claim Notice must contain a description
of the claim and the nature and amount of such Loss (to the extent that the nature and amount of
such Loss are known at such time). The Indemnified Party will furnish promptly to the Indemnifying
Party copies of all papers and official documents received in respect of any Losses.

          11.2.2 Prosecution of Claims. The obligations of an Indemnifying Party under this
Section 11 will be governed by and be contingent upon the following additional terms and
conditions:

               (a) Control of Defense.

                    (i) At its option, the Indemnifying Party may assume the defense of any Third Party
Claim by giving written notice to the Indemnified Party within thirty (30) days after the
Indemnifying Party’s receipt of an Indemnification Claim Notice.

25

 

                    (ii) Upon assuming the defense of a Third Party Claim, the Indemnifying Party may
appoint as lead counsel in the defense of the Third Party Claim any legal counsel selected by the
Indemnifying Party. In the event the Indemnifying Party assumes the defense of a Third Party
Claim, the Indemnified Party will immediately deliver to the Indemnifying Party all original
notices and documents (including court papers) received by any Indemnitee in connection with the
Third Party Claim. Should the Indemnifying Party assume the defense of a Third Party Claim, the
Indemnifying Party will not be liable to the Indemnified Party or any other Indemnitee for any
legal expenses subsequently incurred by such Indemnified Party or other Indemnitee in connection
with the analysis, defense or settlement of the Third Party Claim.

               (b) Right to Participate in Defense. Without limiting Section 11.2.2(a), any
Indemnitee will be entitled to participate in, but not control, the defense of such Third Party
Claim and to employ counsel of its choice for such purpose; provided, however, that
such employment will be at the Indemnitee’s own expense unless (i) the employment thereof has been
specifically authorized by the Indemnifying Party in writing, or (ii) the Indemnifying Party has
failed to assume the defense and employ counsel in accordance with Section 11.2.2(a) (in which case
the Indemnified Party will control the defense).

               (c) Settlement. With respect to any Losses relating solely to the payment of money
damages in connection with a Third Party Claim and that will not result in the Indemnitee’s
becoming subject to injunctive or other relief or otherwise adversely affect the business of the
Indemnitee in any manner, and as to which the Indemnifying Party will have acknowledged in writing
the obligation
to indemnify the Indemnitee hereunder, the Indemnifying Party will have the sole right to
consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss,
on such terms as the Indemnifying Party, in its sole discretion, will deem appropriate, and will
transfer to the Indemnified Party all amounts which said Indemnified Party will be liable to pay
prior to the time prior to the entry of judgment. With respect to all other Losses in connection
with Third Party Claims, where the Indemnifying Party has assumed the defense of the Third Party
Claim in accordance with Section 11.2.2(a), the Indemnifying Party will have authority to consent
to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss provided
it obtains the prior written consent of the Indemnified Party (which consent will be at the
Indemnified Party’s sole and absolute discretion). The Indemnifying Party will not be liable for
any settlement or other disposition of a Loss by an Indemnitee that is reached without the written
consent of the Indemnifying Party. Regardless of whether the Indemnifying Party chooses to defend
or prosecute any Third Party Claim, no Indemnitee will admit any liability with respect to, or
settle, compromise or discharge, any Third Party Claim without the prior written consent of the
Indemnifying Party.

               (d) Cooperation. Regardless of whether the Indemnifying Party chooses to defend or
prosecute any Third Party Claim, the Indemnified Party will, and will cause each other Indemnitee
to, cooperate in the defense or prosecution thereof and will furnish such records, information and
testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings,
trials and appeals as may be reasonably requested in connection therewith. Such cooperation will
include access during normal business hours afforded to the Indemnifying Party to, and reasonable
retention by the Indemnified Party of, records and information that are reasonably relevant to such
Third Party Claim, and making Indemnitees and

26

 

other employees and agents available on a mutually
convenient basis to provide additional information and explanation of any material provided
hereunder, and the Indemnifying Party will reimburse the Indemnified Party for all its reasonable
out-of-pocket expenses in connection therewith.

     11.3 Expenses. Except as provided above, the reasonable and verifiable costs and
expenses, including fees and disbursements of counsel, incurred by the Indemnified Party in
connection with any claim will be reimbursed on a calendar quarter basis by the Indemnifying Party,
without prejudice to the Indemnifying Party’s right to contest the Indemnified Party’s right to
indemnification and subject to refund in the event the Indemnifying Party is ultimately held not to
be obligated to indemnify the Indemnified Party.

     11.4 Insurance. During the Term, each Party will have and maintain such types and
amounts of liability insurance as is normal and customary in the industry generally for parties
similarly situated, and will upon request provide the other Party with a copy of its policies of
insurance in that regard, along with any amendments and revisions thereto.

12. Limitation of Liability

     12.1 NOTHING IN THIS AGREEEMNT WILL RESTRICT OR LIMIT EITHER PARTY’S LIABILITY FOR
DEATH OR PERSONAL INJURY CAUSED BY SUCH PARTY’S NEGLIGENCE OR WILLFUL MISCONDUCT.

     12.2 SUBJECT TO SECTION 12.1 ABOVE, IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE
OTHER PARTY FOR LOST PROFITS, LOSS OF DATA, OR FOR ANY SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL
OR PUNITIVE DAMAGES, HOWEVER CAUSED, ON ANY THEORY OF LIABILITY AND WHETHER OR NOT SUCH PARTY HAS
BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, ARISING UNDER ANY CAUSE OF ACTION AND ARISING IN
ANY WAY OUT OF THIS AGREEMENT. THE FOREGOING
LIMITATIONS WILL NOT APPLY TO DAMAGES ARISING FROM A BREACH OF SECTION 7 ABOVE OR AN AWARD OF
ENHANCED DAMAGES AVAILABLE UNDER THE PATENT LAWS FOR WILLFUL PATENT INFRINGEMENT, AND WILL NOT
LIMIT EITHER PARTY’S INDEMNITY OBLIGATIONS TO THE OTHER PARTY UNDER THIS AGREEMENT.

13. Miscellaneous

     13.1 Assignment. Without the prior written consent of the other Party (which such
consent may be granted, withheld or conditioned at the other Party’s sole and absolute discretion),
neither Party will sell, transfer, assign, delegate, pledge or otherwise dispose of, whether
voluntarily, involuntarily, by operation of law or otherwise, this Agreement or any of its rights
or duties hereunder; provided, however, that either Party may assign or transfer
this Agreement or any of its rights or obligations hereunder without the consent of the other
Party:

               (a) to any Affiliate of such Party; provided, further, that

                    (i) such Affiliate may not otherwise sell, transfer, assign, delegate, pledge or
otherwise dispose of, whether voluntarily, involuntarily, by operation of law

27

 

or otherwise (except
pursuant to any merger, consolidation or asset sale subject to Section 13.1(b) below), this
Agreement or any of its rights or duties hereunder without the prior written consent of the other
Party and such consent may be granted, withheld or conditioned at the other Party’s sole and
absolute discretion; and

                    (ii) that if any such Affiliate is subsequently sold by or otherwise ceases to be an
Affiliate of the relevant Party (except pursuant to any merger, consolidation or asset sale subject
to Section 13.1(b) below) this Agreement must be assigned back to the relevant Party before such
sale or other event becomes effective; or

               (b) to any Third Party with which it merges or consolidates, or to which it
transfers all or substantially all of its assets to which this Agreement relates.

In each case described in this Section 13.1 the relevant Affiliate assignee, Third Party assignee
or surviving entity will assume in writing all of the assigning Party’s obligations under this
Agreement and the assigning Party will promptly provide notice to the other Party of such
assignment. The assigning Party (except if it is not the surviving entity) will remain jointly and
severally liable under this Agreement with the relevant Affiliate assignee. Any purported
assignment or transfer in violation of this Section will be void ab initio and of no force or
effect.

     13.2 Severability. If any provision of this Agreement is held to be illegal,
invalid or unenforceable under any present or future law, then (a) such provision will be fully
severable, (b) this Agreement will be construed and enforced as if such illegal, invalid or
unenforceable provision had never comprised a part hereof, (c) the remaining provisions of this
Agreement will remain in full force and effect and will not be affected by the illegal, invalid or
unenforceable provision or by its severance from this Agreement, and (d) the Parties will use good
faith efforts to promptly replace such illegal, invalid or unenforceable provision with a valid and
enforceable provision having similar terms such that the objectives contemplated by the Parties
when entering this Agreement may be realized. To the fullest extent permitted by applicable law,
each Party hereby waives any provision of law that would render any provision prohibited or
unenforceable in any respect.

     13.3 Governing Law; Dispute Resolution.

          13.3.1 This Agreement, all disputes between the Parties related to or arising out of
this Agreement, the Parties’ relationship created hereby, and/or the negotiations for and entry
into this Agreement, including any dispute concerning its conclusion, binding effect, amendment,
coverage, or termination, will be governed by the laws of England and Wales without reference to
any choice of law principles that would cause the application of the laws of a different
jurisdiction, and will (subject to Section 13.3.2 below) be subject to the non-exclusive
jurisdiction of the courts of competent jurisdiction located in England and Germany.

          13.3.2 The Parties will try to settle their differences amicably between themselves.
In the event of any controversy or claim arising out of or relating to any provision of this
Agreement or the performance or alleged non-performance of a Party of its obligations under this
Agreement (“Dispute”), a Party may notify the other Party in writing of such Dispute.

28

 

If the
Parties are unable to resolve the Dispute within [***] of receipt of the written notice by the
other Party, such dispute will be referred to [***] who will use their good faith efforts to
resolve the Dispute within [***] after it was referred to [***]. If [***] fail to resolve the
Dispute, each Party may pursue its rights and remedies as described in Section 13.3.1 above.
Notwithstanding the foregoing, no Dispute relating to Section 7 will be subject to this Section
13.3.2. In addition, nothing in this Section 13.3.2 will limit either Party’s right to seek
immediate injunctive or other equitable relief whenever the facts or circumstances would permit a
Party to seek such relief in a court of competent jurisdiction.

     13.4 Notices. All notices or other communications that are required or permitted
hereunder will be in writing and delivered personally, sent by facsimile (and promptly confirmed by
personal delivery or overnight courier as provided herein), or sent by internationally-recognized
overnight courier addressed as follows:

     If to CAT, to:

Cambridge Antibody Technology Ltd

Milstein Building, Granta Park

Cambridgeshire CB1 6GH

England

Attention: the Company Secretary

Facsimile: +44 (0)1223 471472

     If to Micromet, to:

Micromet AG

Staffelseestrasse 2

D-81477Munich, Germany

Attention: Chief Business Officer

Facsimile: +49 89 895-277-285

with a copy to:

Cooley Godward LLP

One Freedom Square

Reston Town Center

11951 Freedom Drive

Reston, Virginia 20190-5656

Attention: Matthias Alder, Esq.

Facsimile: +1 (703) 456-8100

or to such other address as the Party to whom notice is to be given may have furnished to the other
Party in writing in accordance herewith. Any such communication will be deemed to have been given
(i) when delivered, if personally delivered or sent by facsimile on a Business Day,

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

29

 

and (ii) on the
second Business Day after dispatch, if sent by internationally-recognized overnight courier. It is
understood and agreed that this Section 13.4 is not intended to govern the day-to-day business
communications necessary between the Parties in performing their duties, in due course, under the
terms of this Agreement.

     13.5 Entire Agreement; Modifications. This Agreement, together with any schedules
attached hereto (each of which is hereby incorporated herein by reference), sets forth and
constitutes the entire agreement and understanding between the Parties with respect to the subject
matter hereof and all prior agreements, understanding, promises and representations, whether
written or oral, with respect thereto are hereby superceded and of no further force and effect.
Each Party confirms that it is not relying on any representations or warranties of the other Party
except as specifically set forth herein. For the avoidance of doubt, nothing in this Agreement is
intended to or shall be construed to provide that (a) a representation, covenant or obligation
under this Agreement shall be a representation, covenant or obligation under any other agreement or
instrument executed by the Parties, except as expressly provided otherwise herein, or (b) a default
under this Agreement shall constitute a default under any other agreement or instrument executed by
the Parties, except as expressly provided otherwise herein. No amendment or modification of this
Agreement will be binding upon the Parties unless made in writing and duly executed by authorized
representatives of both Parties.

     13.6 Relationship of the Parties. It is expressly agreed that the Parties’
relationship under this Agreement is strictly one of licensor-licensee, and that this Agreement
does not create or constitute a partnership, joint venture, or agency. Neither Party will have the
authority to make any statements, representations or commitments of any kind, or to take any
action, which will be binding (or purport to be binding) on the other. All persons employed by a
Party will be employees of such Party and not of the other Party and all costs and obligations
incurred by reason of any such employment will be for the account and expense of such Party.

     13.7 Waiver. Any term or condition of this Agreement may be waived at any time by
the Party that is entitled to the benefit thereof, but no such waiver will be effective unless set
forth in a written instrument duly executed by or on behalf of the Party waiving such term or
condition. The waiver by either Party of any right hereunder or of claims based on the failure to
perform or a breach by the other Party will not be deemed a waiver of any other right hereunder or
of any other breach or failure by said other Party whether of a similar nature or otherwise.

     13.8 Counterparts. This Agreement may be executed in two (2) or more counterparts,
each of which will be deemed an original, but all of which together will constitute one and the
same instrument.

     13.9 No Benefit to Third Parties. The representations, warranties, covenants and
agreements set forth in this Agreement are for the sole benefit of the Parties hereto and their
successors and permitted assigns, and they will not be construed as conferring any rights on any
other parties.

     13.10 Further Assurance. Each Party will duly execute and deliver, or cause to be
duly executed and delivered, such further instruments and do and cause to be done such further acts
and things, including the filing of such assignments, agreements, documents and

30

 

instruments, as may
be necessary or
as the other Party may reasonably request in connection with this Agreement or to carry out
more effectively the provisions and purposes, or to better assure and confirm unto such other Party
its rights and remedies under this Agreement.

     13.11 English Language. This Agreement has been written and executed in the English
language. Any translation into any other language will not be an official version thereof, and in
the event of any conflict in interpretation between the English version and such translation, the
English version will control.

     13.12 Force Majeure. Neither Party will be deemed to be in breach of this Agreement
as a result of default, delay or failure to perform by such Party that results from any cause
beyond the reasonable control of such Party that could not reasonably be foreseen by such Party,
including without limitation, fire, earthquake, acts of God, acts of war, strikes, lockouts, or
other labor disputes, riots, civil disturbances, actions or inactions of governmental authorities
(except actions in response to a breach of applicable laws by such Party), or epidemics. This
Section 13.12 will not operate to excuse payment by a Party of any amounts due to any other Party
under this Agreement. In the event of any such force majeure, the Party affected will promptly
notify the other Party, will use commercially reasonable efforts to overcome such force majeure,
and will keep the other Party informed with respect thereto. If the event of force majeure
continues for a period greater than one hundred and eighty (180) days, then the unaffected Party
may terminate this Agreement immediately by notice in writing to the affected Party.

     13.13 Construction. Except where the context otherwise requires, wherever used, the
singular will include the plural, the plural the singular, the use of any gender will be applicable
to all genders and the word “or” is used in the inclusive sense (and/or). The captions of this
Agreement are for convenience of reference only and in no way define, describe, extend or limit the
scope or intent of this Agreement or the intent of any provision contained in this Agreement. The
term “including” as used herein means including, without limiting the generality of any description
preceding such term. No rule of strict construction will be applied against either Party.

     [Remainder of this page is left blank intentionally. Signature page follows.]

31

 

     In Witness Whereof, the Parties have executed this Agreement by their respective
authorized representatives as of the date first written above.

	 	 	 	 	 	 	 
	Cambridge Antibody Technology Limited	 	 
	 
	 	 	 	 	 	 
	By:	 	/s/ Diane Mellett	 	 
	 	 	 	 	 
	Name:	 	Diane Mellett	 	 
	 	 	 	 	 
	Title:	 	General Counsel	 	 
	 	 	 	 	 
	 
	 	 	 	 	 	 
	Micromet AG 	 	 
	 
	 	 	 	 	 	 
	By:	 	/s/ Christian Itin	 	 
	 	 	 	 	 
	 	 	Christian Itin, Ph.D	 	 
	 	 	Chief Business Officer	 	 
	 
	 	 	 	 	 	 
	By:	 	/s/ Gregor K. Mirow	 	 
	 	 	 	 	 
	 

	 	Name:

Title:
	 	Gregor K. Mirow
 

CFO
 

	 	  

[Signature Page to the MT-201 Non-Exclusive Product License Agreement]

 

 

Schedule I

CAT Licensed Patents

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	[***]	 	[***]	 	[***]	 	[***]
	PUBLISHED PCT
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	US
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	EUROPE
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	AUSTRALIA
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	JAPAN
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	CANADA
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	SOUTH KOREA
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

 

			
	*	 	Patents in opposition proceedings.
	 
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

 

 

Schedule II

CAT Background Know-How

     [***]:[***]

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

 

 

Schedule III

EpCAM Target

     The EpCAM Target sequences are:

[***]

     EpCAM nucleotide sequence

[***]

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

 

 

Schedule IV

Excluded Field

“Excluded Field” means:

the discovery, isolation, characterization, research, development, and/or commercialization of an
Antibody useful for the diagnosis, treatment and/or prevention of one or more of the following
disease conditions wherein the primary scientific rationale or activity is [***]:

	 	i.	 	[***]);
	 
	 	ii.	 	[***];
	 
	 	iii.	 	[***],
	 
	 	iv.	 	[***];
	 
	 	v.	 	[***]; and/or
	 
	 	vi.	 	[***],

provided, however, that for the purpose of this Agreement the term “Excluded Field”
will not include the diagnosis, treatment and/or prevention of the above disease conditions caused
by [***].

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

 

 

Schedule V

Excluded Technologies

“Excluded Technology” means:

	1.	 	“[***],” meaning the technology claimed in the following [***] to which CAT has sole
right, title and interest: [***]”

	2.	 	“[***],” meaning the technology claimed in the following Patents to which CAT has sole
right, title and interest: [***];

	3.	 	“[***],” meaning solely Antibodies which [***] and in which [***];

	4.	 	“Research Products,” meaning those certain research products for which CAT has granted
certain exclusive rights to a Third Party under the [***] License Agreement, as may then
be in effect.

	5.	 	“[***],” meaning any Antibody [***] for the purpose of simultaneously detecting and/or
measuring Antigens whereby such product:

	 	(a)	 	Contains or comprises:

	 	(i)	 	an [***] of [***] Antibodies of different [***]
[***] (excluding Antibodies serving a purpose as controls), or
	 
	 	(ii)	 	an [***] of [***] Antibodies of the same [***]
[***], provided that such Antibody is used to [***] [***] [***] data
points for the purpose of [***] (excluding Antibodies serving a purpose
as controls), and

	 	(b)	 	contains or comprises an array of Antibodies [***], and
	 
	 	(c)	 	is in a format where the [***], and
	 
	 	(d)	 	employs any type of [***], and
	 
	 	(e)	 	may be used [***] or [***] (as appropriate), and
	 
	 	(f)	 	is not, by way of example, (i) any type of [***] technology; (ii) any type of
[***] technology; (iii) any type of [***] assay.

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

 

 

Schedule VI

CAT Third Party Claims

[***]

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

 

 

Table of Contents

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	Page	 
	1.	 	DEFINITIONS	 	 	1	 
	2.	 	GRANT OF LICENSES	 	 	7	 
	 
	 	2.1	 	Research License	 	 	7	 
	 
	 	2.2	 	Commercialization License	 	 	8	 
	 
	 	2.3	 	Reservation of Rights	 	 	8	 
	 
	 	2.4	 	Excluded Technology	 	 	8	 
	 
	 	2.5	 	Know-How Transfer	 	 	9	 
	3.	 	IDENTIFICATION OF LICENSED PRODUCTS AND REPORTING	 	 	9	 
	 
	 	3.1	 	Identification of Licensed Products	 	 	9	 
	 
	 	3.2	 	Abandonment of a Licensed Product	 	 	9	 
	 
	 	3.3	 	Dossier Updates	 	 	9	 
	4.	 	GATEKEEPING AND THE EXCLUDED FIELD	 	 	10	 
	 
	 	4.1	 	EpCAM Target	 	 	10	 
	 
	 	4.2	 	Micromet Representations	 	 	10	 
	 
	 	4.3	 	Limitation	 	 	10	 
	5.	 	PAYMENTS	 	 	10	 
	 
	 	5.1	 	Initial License Fee	 	 	10	 
	 
	 	5.2	 	Therapeutic Licensed Product Milestone Payments and Royalty Rates	 	 	10	 
	 
	 	5.3	 	Diagnostic Licensed Product Milestone Payments and Royalty Rates	 	 	11	 
	 
	 	5.4	 	Payment	 	 	12	 
	 
	 	5.5	 	Records; Audits	 	 	14	 
	 
	 	5.6	 	Payment of Additional Amounts	 	 	14	 
	 
	 	5.7	 	Confidentiality	 	 	14	 
	 
	 	5.8	 	Withholdings	 	 	14	 
	6.	 	REPRESENTATION AND WARRANTIES; COVENANTS	 	 	15	 
	 
	 	6.1	 	Representations of CAT	 	 	16	 
	 
	 	6.2	 	Reciprocal Representations and Warranties	 	 	16	 
	 
	 	6.3	 	Additional Covenants	 	 	16	 
	 
	 	6.4	 	DISCLAIMER OF WARRANTY	 	 	16	 
	7.	 	CONFIDENTIALITY	 	 	16	 

-i- 

 

 

Table of Contents

(continued)

	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	Page	 
	 
	 	7.1	 	Definition	 	 	16	 
	 
	 	7.2	 	Exclusions	 	 	17	 
	 
	 	7.3	 	Disclosure and Use Restriction	 	 	17	 
	 
	 	7.4	 	Authorized Disclosure	 	 	18	 
	 
	 	7.5	 	Use of Name	 	 	18	 
	 
	 	7.6	 	Terms of Agreement to be Maintained in Confidence	 	 	18	 
	 
	 	7.7	 	Press Release	 	 	19	 
	8.	 	FILING, PROSECUTION AND MAINTENANCE OF PATENT RIGHTS	 	 	19	 
	 
	 	8.1	 	Prosecution and Maintenance	 	 	20	 
	 
	 	8.2	 	Costs	 	 	20	 
	 
	 	8.3	 	No Challenge	 	 	20	 
	 
	 	8.4	 	Notice	 	 	20	 
	 
	 	8.5	 	Enforcement	 	 	20	 
	 
	 	8.6	 	Release	 	 	20	 
	9.	 	IMPROVEMENTS; OWNERSHIP	 	 	21	 
	 
	 	9.1	 	Phage Display Improvements	 	 	21	 
	 
	 	9.2	 	CAT Phage Display Improvements	 	 	21	 
	 
	 	9.3	 	Further Assurances	 	 	22	 
	10.	 	TERM AND TERMINATION	 	 	22	 
	 
	 	10.1	 	Term	 	 	22	 
	 
	 	10.2	 	Termination for Material Breach	 	 	22	 
	 
	 	10.3	 	Amendment or Termination of [***] Agreement	 	 	23	 
	 
	 	10.4	 	Additional Termination Right Regarding the Research License	 	 	23	 
	 
	 	10.5	 	Consequences of Expiration and Termination	 	 	23	 
	 
	 	10.6	 	Survival	 	 	24	 
	11.	 	INDEMNIFICATION AND INSURANCE	 	 	24	 
	 
	 	11.1	 	Indemnification By Micromet	 	 	24	 
	 
	 	11.2	 	Indemnification Procedure	 	 	24	 
	 
	 	11.3	 	Expenses	 	 	26	 
	 
	 	11.4	 	Insurance	 	 	26	 

-ii-

 

	[***] 	 	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

 

 

Table of Contents

(continued)

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	Page	 
	12.	 	LIMITATION OF LIABILITY	 	 	26	 
	13.	 	MISCELLANEOUS	 	 	27	 
	 
	 	13.1	 	Assignment	 	 	27	 
	 
	 	13.2	 	Severability	 	 	27	 
	 
	 	13.3	 	Governing Law; Dispute Resolution	 	 	28	 
	 
	 	13.4	 	Notices	 	 	28	 
	 
	 	13.5	 	Entire Agreement; Modifications	 	 	29	 
	 
	 	13.6	 	Relationship of the Parties	 	 	29	 
	 
	 	13.7	 	Waiver	 	 	29	 
	 
	 	13.8	 	Counterparts	 	 	30	 
	 
	 	13.9	 	No Benefit to Third Parties	 	 	30	 
	 
	 	13.10	 	Further Assurance	 	 	30	 
	 
	 	13.11	 	English Language	 	 	30	 
	 
	 	13.12	 	Force Majeure	 	 	30	 
	 
	 	13.13	 	Construction	 	 	30	 

-iii-

 

 

Exhibit 10.37

***Text Omitted and Filed Separately

Confidential Treatment Requested

Under 17 C.F.R. §§ 200.80(b)(4) and 240.24b-2

AMENDMENT

TO

NON-EXCLUSIVE PRODUCT LICENSE AGREEMENT

     This Amendment (the “Amendment”) is made as of this 17th day of March, 2005 by and
between Micromet AG, located at Staffelseestrasse 2, D-81477, Munich, Germany (“Micromet”)
and Cambridge Antibody Technology Limited, located at The Milstein Building, Granta Park,
Cambridgeshire CB 1 6GH, England (“CAT”) (each of Micromet, and CAT, a “Party” and, collectively,
the “Parties”).

Recitals

     A. The Parties have entered into that certain Non-Exclusive Product License Agreement, dated
as of September 3, 2003 (the “Agreement”), pursuant to which the Parties have granted certain
intellectual property licenses for the MT201 Product and other products in respect of the EpCAM
target and for the purposes described therein. Capitalized terms used herein without definition
shall have the meanings given to such terms in the Agreement.

     B. The Parties desire to amend the Agreement to delete the Excluded Field.

Agreement

     Now, Therefore, for and in consideration of the mutual promises and covenants set
forth herein and for other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the Parties hereby agree as follows:

     1. Expiration of Excluded Field. The Parties acknowledge and agree that, effective as of 22
February, 2004, CAT has ceased to be bound by the Excluded Field restriction pursuant to its
agreement with [***] dated [***] and, consequently, pursuant to the terms of Section 2.4
of the Agreement, any restrictions set forth in the Agreement relating to the Excluded Field have
ceased to apply as of 22 February 2004.

     2. Counterparts. This Amendment may be executed in two or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same
instrument.

     3. Effectiveness. This Amendment shall become effective upon the execution hereof by both
Parties.

     4. Continuing Effect. Other than as set forth in this Amendment, all of the terms and
conditions of the Agreement shall continue in full force and effect.

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

1.

 

     In Witness Whereof, the parties have executed this Amendment to the Non-Exclusive
Product License Agreement as of the date first written above.

	 	 	 	 	 	 	 	 	 	 	 
	Micromet AG	 	Cambridge Antibody Technology Limited	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Christian Itin
 

	 	 	 	By:
	 	/s/ Alasdair Moodie
 

	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Name:

	 	Christian Itin
 

	 	 	 	Name:
	 	Alasdair Moodie
 

	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Title:

	 	CEO
 

	 	 	 	Title:
	 	Assistant General Counsel
 

	 	 
	 
	 	 	 	 	 	 	 	 	 	 

2.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}]]